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1 General Introduction 

1.1 Immune diagnosis of paraneoplastic 
neurological disease 
J. [[,B. Moll and Ch.J. ["cht 
Department of NeurD-onco!ogg 
D,: Daniel den Hoed Cancer Center Gnd 
Department of Nellrolog)~ 
University Hospital Dijkzig/, 
Rotterdam, The Netherlands 
Abstract 
In recent years a continuous stream of new information on clinical, pathological and 
immunological aspects of paraneoplastic neurological syndromes has been published. In this 
survey, we will discuss current opinions on the value of anti-neuronal antibody detection for 
establishing a diagnosis of one of the paraneoplastic syndromes of the central nervous 
system. 
Acknoll'/edgellle/Jt 
H'e thank Dr. Jerome B. Posner for his valuable commellts. 
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Introduction 
Paraneoplastic neurological syndromes (PNS) of the central nervous system consist of a 
variety of clinical neurological disorders that include encephalomyelitis, paraneoplastic 
cerebellar degeneration (PCD), subacute sensory neuronopathy (SNNP), retinal 
paraneopiastic syndrome, stiff-man syndrome and motor neuron disease. 
For the clinician, it is often difficult to arrive at a correct diagnosis and to identify the 
underlying hunor. In two-third of cases a paraneoplastic neurological syndrome precedes the 
discovery of underlying cancer. Neurological signs and ancillary investigations are usually 
aspecific and the hlmor is frequently of small volume. However, demonstration of specific 
anti-neuronal antibodies has created new possibilities for establishing a reliable diagnosis of 
PNS. 
In 1965, \Vilkinson and Zeromski identified a specific anti-neuronal antibody in serum of 
patients who suffered from sensory neuronopathy and small cell lung cancer l , but it took 
almost twenty years before the diagnostic value of these antibodies became clear.-4. Since, a 
number of well-characterized autoantibodies against neuronal antigens have been recognized 
in association with specific neurological syndromes and certain types of cancer5•l2 • 
The involved antigens have for the larger part been identified and cDNAs have been cloned 
from neural and tumor expression libraries13-17• Recombinant proteins are now available for 
diagnostic assays and the precise nature of the target antigens is currently subject of study. 
Nevertheless, questions remain because autoantibodies against central nervous system (eNS) 
antigens have been identified in a variety of other clinical situations and occasionally in 
normal controls. These uncertainties include the exact diagnostic value of the antibodies, the 
minimum titer-height in serum and the nature of reactive antigens. 
These points need further clarification in order to provide the clinician with practical 
guidelines that enable appropriate interpretation of the detection of anti-neuronal antibodies. 
Posner and coworkers defined the tequirements for recognition of anti-neuronal antibodies 
that are clinically vahlable18• 
1. The antibody must be present in more than one patient, with a similar neuro-
logical disorder and corresponding tumor, and the presence of both false-
negative and false-positive autoantibodies should be rare. 
2. The concentration of antibodies in serum must be relatively high. 
3. A higher titer in cerebrospinal fluid (CSF) than in serum would suggest 
intrathecal synthesis and would provide evidence for a neurologically relevant 
antibody. 
4. The antibodies should react with a symptomatic part of the nervous system 
and the nature of the antigen must be identified by both indirect immunofluo-
rescence and \Vestern blots on neuronal proteins. 
Using these criteria, several antibodies have been identified that appear to mark specific 
paraneoplastic syndromes each of which is related to a narrow range of tumors (table 1). 
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Based on these requirements, we will review the most common PNS-associatcd anti-
neuronal antibodies, including the anti-Hu, anti-Purkinje cell, anti-yo, anti-Ri, anti-128 kD 
and anti-CAR antibodies. For each of these antibodies the associated clinical syndrome, the 
underlying malignancy and the nature of the reactive antigen will be discussed. Lambert-
Eaton myasthenic syndrome will not be mentioned here, although it is clearly paraneoplastic 
and antibody-mediated. Other paraneoplastic disorders of muscle and peripheral nerve are 
usually not antibody-related and will also not be discussed. At the end, the clinical conse-
quences of the detection of anti-neuronal antibodies in patients suspected of PNS will be 
summarized as guidelines. 
Para neoplastic Encephalo-Myelitis/Sensory-Neuronopathy: 
Anti-Hu Antibody 
In patients with paraneopiastic encephalomyelitis (PEM) more than one part of the CNS can 
be involved leading to a combination of cerebral, cerebellar, brain stcm or spinal cord signs. 
In many cases, one affectcd part of the CNS causes the majority of neurological signs like 
limbic encephalitis, brain-stem encephalitis or cerebeHar syndrome. Besides, a paraneoplastic 
or subacute paraneoplastic sensory neuronopathy (PSN) can be the only clinical phenomenon 
or it can accompany the encephalomyelitis. Both PEM and PSN arc regarded as different 
clinical representations of the same disease entity, that is also designated as the anti-Hu 
syndrome if associated with the presence of anti-Hu antibodies I2,18,19, 
The most frequently associated tumor is a small-cell lung cancer (SCLC) that occurs in 
about three-quarter of patients with PEMlPSNI2. Next frequent comes non-small ccll cancer 
of the lung although other tumors may be encountered including gynaecological tumors, 
neuroblastoma and Hodgkin's disease. 
Antibodies 
The first antibody reported was found in serum of four patients with SNNP and SCLC, 
although others could initially not repeat these findings l .". In 1985, Graus et al. detected by 
indirect immunofluorescence an antibody that predominantly reacted with nuclei of neurons 
in serum of two patients with small-cell lung cancer2. This antibody was neither found in 
normal subjects nor in neurological patients with or without cancer. By means of \Vestern 
blotting on nuclear extracts of rat and human brain it was shown that this antibody reacted 
with a 35-38 kilo Dalton protein. The antibody was designated anti-Hu, after the initials of 
the patient in whom it was first discovered21 • Others called this antibody anti-neuronal 
nuclear antibody or ItANNA_It122,23. 
In about 80% of patients who harbour anti-Hu antibodies, SCLC can be identified12. Other 
tumors include non-small cell lung cancer, breast carcinoma, seminoma, chondro-myxosar-
coma, prostate carcinoma, neuroblastoma and adenocarcinoma of the colon. In 13% of a 
series of 71 anti-Hu positive patients no tumor was found. In anti-Hu positive patients with 
PNS and SCLC, 95% of patients have tumor activity limited to the chest12. 
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Table 1 Overview of the different PNS and associated antibodies with clinical and immunological features 
Antibody Paraneoplastic Neurological Most frequently I mmunoh istochem i siry Western blot 
Syndrome Associated 
Cancers 
Anti-Hut Encephalomyelitis, Small cell lung, Strong staining of all 38·40 kD reactive 
ANNA-I Sensory-Neuronoputhy non- small cell neuronal nuclei and triplet band on extracts 
lung weaker staining of of crude or isolated 
cytoplasm eNS neurons/nuclei 
and SCLC, 
Recombinant protein of 
43 kD (HuD) 
Purkinje cell 
antibodies: 
Anti-Yol Acute to suhacute pan- Ovarian, breast, Purkinje cell 34 and 62 kD band 
APeA-11 cerebellar syndrome, uterus cytoplasm and a-.;ons, from Purkinje cell 
PCA-I dysarthria and upbeat coarse granular extracts and breast and 
nystagmus staining ovary tumors of pa-
tients, reactive with 
recombinant CDR 34 
and CDR 62 proteins 
APCA-2f More slowly developing M. Hodgkin Purkinje cell No reactive protein 
PCA-2 cerebellar syndrome, less cytoplasm, fine bands detected as yet 
frequent dysarthria and granular staining 
nystagmus 
Anti-Rif Opsoclonus-Myoclonus Breast, small cell All nuclei of eNS 55 kD and 80 kD neu-
ANNA-2 lung ronal nuclear protein, 
55kD recombinant 
protein 
Anti-CAR Visual loss, retinal Small cell lung, Retinal neurons, rods 23 kD and 48 kD pro-
degeneration breast, non-small and cones tein of retinal extracts, 
cell lung 26 (23)kD recombinant 
protein 
Anti-128kD Stiff-man syndrome Breast Synapsis of CNS 128 kD protein on 
neurons neuronal extracts 
n.k. = not known 
Neurologically asymptomatic patients with SCLC can harbour low titers of anti-Hu anti-
bodies and in these patients smaller hlmors are present as compared to SCLC without anti-
Hu antibodies24• This antibody is found almost exclusively in patients with a smoking 
history, PEMlPSN has also been associated with other tumors in which no anti-Bu antibody 
could be identified, including breast, ovarian, uterus, stomach, oesophagal cancer, testicular 
carcinoma, synovioma, Hodgkin's lymphoma and non-small cell lung cancer. Five patients 
have been described who suffer from PEMlPSN with SCLC and who carry no anti-Hu 
antibody. 1\vo of these cases with SNNP showed relatively mild symptoms compared to 
anti-Hu positive patientsl2,1S, 
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Table I Overview of the different PNS and associated antibodies with clinical and immunological features 
(continued) 
Antigen 
Neuron specific 
RNNDNA binding 
protein, rolc in RNA 
processing of neurons 
DNA binding, gene tran-
scription regulators, carry 
leucine-zipper and zinc-
finger motifs 
n.k. 
RNA-binding, role in 
post migratory maturation 
of neurons 
Visinin like, calmodulin 
family, calcium binding 
domains 
Amphiphysine, synaptic 
vesicle protein, function 
unknown 
False positivity 
Estimated 
Diagnostic 
Sensitivity 
30·40% 
40% 
n.k. 
n.k. 
n.k. 
n.k. 
Estimated Total no. of Total no. of References 
Diagnostic patients false positive 
Specificity patients. 
95-100% >150 13 5,10,12 
70·100% >100 7 8,9,35,3738,89 
100% 35 0 3,35,40 
90-100% 23 48,63,66,90 
80·100% 6 70·72,91·93 
100% 5 0 94-96 
Two studies have indicated a low specificity of anti-Hu for PEMJPSN. In one series anti-
neuronal antibodies were observed in 43% of SCLC patients without any correlation to the 
neurological symptoms25• In another study, anti-Hu antibodies were observed in high titers 
(i.e, > I :800) in 27 of 81 patients with SCLC without clear relationship to the neurological 
disorder. Of the 27 antibody positive patients only two suffered from PNS26• However, in 
both these series anti-Hu detection was based only on immunohistochemistry or indirect 
immunofluorescence and was not confirmed by Western blots. Under these circumstances an 
overreporting of the presence of paraneoplastic antibodies will easily occur as many different 
autoantibodies can bind to either neuronal nuclei or its cytoplasm. Dalmau et al. reported 
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anti-Blt antibodies in low titers in 15% of all patients with SCLC by using the combination 
of immunohistochemistry and \Vestern blotting on SCLC protein extracts, indeed indicating 
that detection of these antibodies is not only limited to neurologically symptomatic 
patients27, 
Using both teclmiques together, a total of 13 patients have been reported carrying positive 
anti-Hu titers with concomitant neurological disease and no tumorl2, These observations may 
thus be interpreted as false-positive as they carry no firm relation with cancer. Another 
possible explanation is suggested by the remarkable finding that two patients with anti-Hu 
positive PNS and SCLC showed spontaneous regression of their tmllorl2,2U7. This fascinating 
observation may indicate that anti-neuronal antibodies in patients without cancer might be 
related to the presence of an undetectable tumor-load or even to regression of tumor. 
Another reason for false-positivity is cross-reactivity with other autoantibodies. One such 
reactivity has been suggested in a subset of patients with primary Sjogren's syndrome who 
seemingly contained anti-Hu antibodies that however did not react with the HuD fusion 
protein28,29. These observations provide one answer for the variance in diagnostic signifi-
cance of these antibodies and simultaneously emphasize the necessity for improving labora-
tory techniques. Most investigators would agree that the finding of anti-Hu antibodies 
indicates specificity approaching 100% for the diagnosis of PNS and the associated 
neoplasm being SCLC in over 80% of cases, if detected in titers of above 1:500 - 1 :5000. 
The sensitivity is ~ 40%5.10.12 if both immunohistochemistry and \\'estern blotting are 
utilized. 
Antigen 
Grau's established that anti-Hu antibodies react with a 38-40 kD protein band on \\'estern 
blot of protein extracts of cerebral cortex21 • Further experiments have revealed that the 
antigen consists of a triple band that can be identified using whole cerebral or cerebellar 
protein extracts. Most anti-Hu positive cases show the strongest reactivity with the lower 
part of this triplet. Incidentally anti-Hu sera show a stronger reaction with the upper part 
[unpublished data]. So far, these small differences seem to bear no clinical significance. 
The Hu antigen is expressed by all neuronal nuclei of the eNS, by dorsal root ganglion cells 
and less strongly in the cytoplasm of these cell groups". 
A eDNA has been isolated from a cerebellar and a SCLC expression library that produced a 
recombinant protein of 43 kD, designated as HuD and reactive with all anti-Hu positive sera 
n. The gene coding for the Hu antigen has been mapped to the human chromosome Ip3430. 
By amino acid sequencing and assessment of gene homology, the presence of three RNA 
binding sites were recognized on the protein showing a strong homology to the Drosophila 
proteins Elav and Sex-lethal, that playa role in the early maturation of neurons and sex 
determination of Drosopl!ila. HuD is uniquely expressed by neuronal cells and certain tumor 
cells and may be involved in neuron-specific RNA processing13• 
All SCLC cell lines that have been studied did express Hu. However, there is no satisfactory 
explanation for the fact that there is only a small minority of patients with SCLC that 
develops anti-lin antibodies and PEMlPSN. One may speculate that this could be related to a 
genetically determined specific immunological make-up as indicated by the presence of 
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systemic autoantibodies in up to 52% of all PNS patients as compared to 15% in control 
subjects (chapter 3), Another explanation for the rarity of PNS may bc a mutation of the Hu 
protein causing subtle changes in its amino~acid sequence that would make the antigen more 
immunogenic l2, 
Para neoplastic Cerebellar Degeneration: 
Anti-Purkinje cell Antibodies 
Paraneoplastic cerebellar_degeneration (PCD) is a rare complication of a variety of cancers, 
particularly ovarian and breast cancer, small cell lung cancer and Hodgkin's disease, 
although other malignancies may be involved3,8,31-33, Clinically, the disorder is characterized 
by subacute development of pan-ccrebellar dysfunction and pathologically by selective loss 
of Purkinje cells without inflammatory infiltrates, At the other hand, one can estimate that at 
least 50% of middle-aged patients who suddenly develop a pan-cerebellar disorder would go 
on to carry a tumor within a few years3--1, 
Antibodies 
The first report on antibodies against cytoplasm of Purkinje cells (PCab) was from a patient 
with cerebellar degeneration and Hodgkin's disease31 , A second patient with similar anti~ 
bodies was described in 1981 3, In 1983, an antibody specifically staining the cytoplasm of 
Purkinje cells and deep cerebellar nuclei was independently found by Greenlee and by 
Jaeckle and coworkers in patients with a gynaecological tumor and PCD but not in control 
series"', On Western blot the autoantibody reacted with a 34-38 kD and 62-64 kD protein 
using protein extracts of isolated ~urkinje cells36, The antibody was identified in 18 out of 
42 in one series and in 7 out of 21 in another series of patients with PCD using protein 
extracts of gradient isolated Purkinje cells9,37, This antibody has been designated anti-yo or 
PCA-1. 
In a recent study by Peterson and others 55 patients were reported with anti~Yo positive 
PCD, Ovarian cancer was found in 26, breast cancer in 13 and seven patients had other 
malignancies (fallopian tube, endometrial, mesovarium and adenocarcinoma of the lung)38, 
Anti-yo antibodies were not seen in 13 patients with PCD and Hodgkin's disease, nor in 45 
patients with breast cancer, 24 with ovarian cancer with or without a non~paraneoplastic 
cerebellar syndrome nor in 325 patients with non-paraneoplastic cerebellar syndromes and 
neither in 50 normal subjects3S, 
In a review on 62 patients with PCD and breast cancer, PCab's were found in 30 patients, 
but not all were verified by immunoblot for harbouring definitely anti-Yo antibodies, Nine 
patients were Peab negative and the others were not tested, In 77% of patients the cerebellar 
degeneration antedated the discovery of their breast cancer with a median of 16 months 
(range 2-41 months)", 
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One can estimate that a total of about 40% of patients with peD would harbour autoanti-
bodies against Purkinje cells, and consequently 60% of patients with clinically proven peD 
are Peab-negative. 
The specificity for anti-Yo detection in patients with cerebellar syndrome ranges from 70% 
to nearly 100% for establishing a diagnosis of peD. Patients with anti-Yo antibody positive 
PCD differ from patients with anti-Yo negative PCD both clinically and in gender". In anti-
Yo negative peD, dysarthria and nystagmus appear far less frequent and are absent in 50% 
of cases. The neurological disorder is less severe, develops more slowly and usually follows 
rather than precedes a diagnosis of cancer. The majority of anti-Yo negative peD patients 
are males predominantly suffering from lung cancer or from Hodgkin's disease3s• 
The PCab's found in PCD associated with Hodgkin's disease react with a different antigen 
and is designated PCA-2'. It yields a more fine-speckled cytoplasmic staining of cerebellar 
Purkinje cells on immunohistochemistry and does not produce a reactive band on \Vestern 
blots.lI .n . In one series of clinically proven PCD and Hodgkin's disease, only six out of 21 
patients had PCab antibodies". Until 1992 a total of 43 patients with Hodgkin's disease and 
PCD haye been reported. Of 31 patients tested for PCab's only 10 were positiYe. One 
explanation for the infrequent occurrence of this antibody may be the labile nature of the 
involved antigen that would be deformed using conventional tissue processing. 
False positivity 
Only incidental cases of false positive anti-Yo antibodies have been reported in patients with 
PCD and no tumor, or in patients with tumor and no PCD. One series identified 13 patients 
with PCah positive PCD and no cancer despite intensive searching22• PCah antibodies with 
ovarian cancer and no PCD have been reported in three patients1. Recently, PCab's were 
identified in two patients with chronic sensory neuronopathy without cancer. However, it is 
doubtful if this observation really represents anti-Yo since the antibody did not solely react 
with Purkinje cell cytoplasm but also with cytoplasm of other neurons41 • 
In summary, a total of 7 patients with anti-yo positive PCD without tumor have been 
reported. Like for the Hu syndrome, one possible explanation for false positivity of anti-Yo 
might be that the tumor-load is minor or that the tumor would have regressed spontaneously 
by effective antibody-mediated immune surveillance. If true, such observations are intriguing 
as they provide clues for further research on the immunotherapy of cancer. 
Antigens 
Immuno-electrorunicroscopy studies have revealed that the anti-Yo antibody binds to clusters 
of ribosomes, to the granular endoplasmic reticulum and to Golgi complex vesicles of 
Purkinje cells32.42• Tluee antigens reactive with anti-Yo antibodies have been cloned. The 
minor 34 kD antigen is designated CDR34 (cerebellar degeneration related) and the gene has 
been mapped to the upper boundary of the FRAX marker on the human X-cluomosome 
(Xq24-q27)"·4J. The major 62 kD protein gene is designated CDR62 and has been mapped to 
the autosome 16 (l6p12-p13.1Y'·". CDR proteins are uniquely expressed in Purkinje cells 
and some neuroectodermal cell lineages. Unlike Bu, which is expressed in all SCLC, the 
CDRs are only expressed in tumors of patients with anti-yo positive PCD. 
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A cDNA encoding a 52 kD protein has been cloned and shows extensive homology to the 
other CDR62 protein. This protein was not only detected in cerebellum and brainstem but 
also in the intestinesl6. Both CDR proteins have a leucine-zipper motif and a highly 
repetitive sequence of a hexapeptide. Using deletion fragments of the recombinant 52 kD 
protein, the major epitope of anti-Yo was localized at the site of the leucine-zipper motif at 
the amino-acid residues 94-133 16. 
One has suggested that these proteins are DNA-binding proteins and may have a prominent 
role in regulating gene transcription, if coupled to an as yet unknown partner protein. 
Binding of anti-Yo antibodies after uptake in Purkinje cells to these proteins may interfere 
with gene transcription by inhibiting the binding of the partner protein I6,.t2. 
Paraneoplastic Opsoclonus-Myoclonus Syndrome: 
Anti-Ri Antibody 
Opsoclonus is a disorder of saccadic eye movements consisting of involuntary arhythmic and 
multidirectional conjugated saccades. The opsoclonus is often associated with tnmcal ataxia, 
dysarthria, myoclonus, vertigo or encephalopathy and may accompany PCDIS. Probably a 
lesion of the pontine paramedian reticular formation is the site of the lesion responsible for 
the opsoclonlls45. ' 
Opsoclonus-myoclonus syndrome (OMS) occurs primarily in children as a self-limiting 
disorder and can be the result of a viral infection of the brainstem. In about 2% of children 
suffering from neuroblastoma, the disorder occurs as a paraneoplastic syndrome, and 50% of 
children who present with OMS would harbour a neuroblastoma46,41. 
In adults the OMS occurs less frequently as a paraneoplastic disorder. In a review on 58 
cases, there were only 11 believed to be of paraneopiastic origin48 • The two most commonly 
associated tumors are lung and breast cancer, although many other tumors can he involved49. 
Paraneoplastic OMS differs from other paraneoplastic syndromes in that remissions occur 
following anti-tumor therapy, after administration of thiamine, clonazepam or 
spontaneously50.51. 
Antibodies 
Children with neuroblastoma and OMS have an excellent prognosis for long-time survival as 
compared to neuroblastoma patients without OMS. This would suggest a possible immune 
surveillance although no specific anti-neuronal antibodies have been detected to date 52+55. 
Antibodies of different specificities have been observed in total of 9 infants with OMS 
without neuroblastoma and were partially directed against neurofilamentolls structures, 
although the meaning of these observations is still uncertainS6-S8 • 
In adults, some studies have failed to demonstrate antibodies in paraneoplastic OMS, 
including patients with SCLC~9.S9. In cases with antibodies against Purkinje ceUs, the occur-
rence of OMS is likely to be an accompanying symptom of more widespread PCD and 
would represent a different entity of disease compared to a distinct paraneoplastic OMS with 
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neuroblastoma or with other tumors48,60.6J. In association with breast carcinoma, a specific 
anti-neuronal nuclear antibody in patients with parancoplastic OMS has been identified by 
the Posner group. Tllis antibody was designated anti-Ri and resembles immunohistochemi-
cally Ihe Hu antibody by reacling wilh virtually all neuronal nuclei of Ihe eNS. Weslern 
blotting however would clearly distinguish it from anti-Hu antibodies by reacting with two 
separale bands of 53-61 kD and 75-84 kD". This antibody is also referred 10 as "ANNA-
21m. 
These findings have been confirmed in one series in which anti-Ri antibodies were recog-
nized in serum and CSF of eight women with severe ataxia of which six had opsoclonus. 
Breast carcinoma was found in five patients, adenocarcinoma in one and carcinoma of the 
fallopian tube in another patient; in one subject no cancer could be found, As of now a total 
of 21 anti-Ri seropositive cases with paraneoplastic OMS have been reported, Of these, 
cancer was diagnosed in 19 patients (16 with breast, 2 with gynaecological cancer, I with 
lung cancer) and no cancer could be identified in two patients59,6J-66, Anti-Ri was neither 
detected in one series of 23 patients with OMS and other types of cancer, nor in one series 
of 87 patients with breast cancer and no OMS6J , 
False positivity 
Two anti-Ri positive cases were identified in OMS without cancer6J,66, There is one descrip-
tion of an anti-Ri positive patient with breast cancer and gait ataxia, vertigo, eye-movement 
disturbances and without tme opsoclonus6S, A recent observation on antibodies against a 58-
59 kD neuronal protein in a patient with ovarian cancer and a patient with small cell lung 
cancer and paraneoplastic OMS would suggest that apart from anti-Ri, different antibodies 
may occasionally be associated with paraneoplastic OMS67, 
Antigen 
The gene that encodes a protein recognized by anti-Ri sera has been cloned and has been 
called Nova, This highly conserved protein seems to play a role in the post-migratory 
maturation of neurons and is homologous to other RNA-binding proteins68, In mice, its 
expression is restricted to the brain stem and spinal cord l4 , 
Other paraneoplastic syndromes 
Reti11al Paraneoplastic Syndrome: Anti-Retinal Antibodies 
Although distinctly uncommon, visual loss due to retinal degeneration has been associated 
with the presence of cancer, If present it is usually seen with SCLC but occasionally with 
breast, uterus, non-small cell lung carcinoma or melanoma, The retinal paraneoplastic 
syndrome was first described in 1979 by Sawyer et al. in three patients with visual loss, 
associated with SCLC in two, and endometrial sarcoma in one patient69, 
Antibodies against a 23-26 kD CAR (Cancer Associated Retinopathy, Recoverin70) retinal 
protein have been found in patients with retinal paraneoplastic syndrome and SCLCJ1,71, 
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\Vhen anti-CAR antibodies are found in high titers in patients with unexplained visual loss, a 
search for an underlying malignancy is warranted, This is specially true when one realizes 
that in patients with retinal paraneoplastic syndrome, improvement of visual perception has 
been reported following either immuno-suppressant or anti-tumor therapy72-H, 
Stiff-mall SYlldrome: Allti-GAD alld Allti-128kD alltibodies 
Stiff-man syndrome is a rare and severe disease of the central nervous system characterized 
by progrcssivc rigidity and painful spasms of the body musculature that was first described 
in 195675, In about two-thirds of patients, the syndrome is associated with diabetes mellitus 
and these patients harbour antibodies against pancreatic islet-cells and GAD (glutamic acid 
decarboxylase), A distinct group is formed by paraneoplastic stiff-man syndrome76, Breast 
cancer is often the underlying malignancy and an antibody recognizing a 128 kD protein 
(amphiphysin) has becn isolated". 
Paraneoplastic }viotor Neuroll Disease 
It is uncertain whether motor neuron disease may occur as a paraneoplastic disorder in 
association with a solid tumor, apart from cases when it is the predominant or presenting 
symptom of encephalomyelitis associated with the anti-Hu syndrome (about 14-20% of 
PEMlPSN cases)12. 
A separate form exists as a subacute motor neuronopathy in association with haemato-
oncological disorders, like Hodgkin's and non-Hodgkin's lymphoma or leukemia78-8l , In a 
survey on 422 patients with motor neuron disease, eight patients had lymphoma82• Younger 
and colleagues have suggested that in these patients sometimes the presence of upper motor 
neuron signs would establish a diagnosis of paraneopiastic amyotrophic lateral sclerosis, In 
three of the seven patients examined, the lymphoma was accompanied by a paraprotein. 
Guidelines for the clinical usefulness of anti-neuronal antibody 
detection 
Encephalomyelitis / sensOlY nelll"Ollopalhy 
In clinical practice, patients with an acute or subacute developing encephalomyelitis or 
sensory neuronopathy should be examined on the presence of anti-Hu antibody. If this 
antibody is found, a search for an underlying tumor should primarily be directed towards 
detection of small cell lung cancer. If the initial search is negative, the tumor may become 
manifest in the months after the onset of neurological symptoms, One would preferably 
screen sera for anti-Hu by using indirect immunohistochemical assays on rat and human 
cerebellar cortex. Positive immunohistochemical reactivity must subsequently be confirmed 
by \Vestern blot using human proteins as substrate and preferably by use of the recombinant 
protein as well. ImmunohistochemicaHy determined titers of anti-Hu antibodies of 1 :500 or 
higher can safely be interpreted as positive and would yield a diagnostic specificity of 98%. 
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Cerebellar syndrome 
Patients with clinical suspicion on paraneoplastic cerebellar syndrome should be screened on 
the presence of anti-Purkinje cell antibodies. Anti-Purkinje cell antibodies consist of a 
variety of antibodies reactive with different antigens. These can be used as diagnostic 
markers for diagnosing a paraneoplastic origin of the cerebellar syndrome and if positive 
would prompt a search for an underlying tumor. It is important to differentiate between anti-
Yo antibodies versus nOll-Yo peab's that can be associated with Hodgkin's disease. Patients 
with peD and positive anti-Yo antibodies determined by immunohistochemistry and 
"'estern blot on extracts of isolated Purkinje cells or recombinant Yo-antigens constitute a 
distinct group. Apart from rare exceptions, they carry gynaecological cancer and a focused 
search for an often occult tumor seems warranted. Presently, the major role for the identifi-
cation of anti-Yo antibody is an early tumor diagnosis that would enable initiating treatment 
and hopefully leads to arresting the neurological progression. 
When other Peab's are detected in a patient suspected of peD the search for cancer should 
focus on gynaecological tumors, breast carcinoma, Hodgkin's disease or lung cancer. 
Detection of antibodies is performed by immunohistochemical detection and \Vestern blot 
analysis using both human and rat tissue as substrate or recombinant Yo-protein. Immuno-
histochemically determined titers of Peab above 1 :500 can be regarded as positive, yielding 
specificities approaching 100%. 
Opsoclonlls Myoclollus Syndrome 
Detection of anti-Ri antibodies seems useful in adults with OMS either with or without other 
accompanying neurological symptoms. Anti-Ri antibodies are inllllunohistochemically 
difficult to differentiate from anti-Hu antibodies and reliable identification should be based 
on results from Western blotting on both cortical protein extracts and the recombinant 
protein. The specificity of anti-Ri detection for a diagnosis of paraneoplastic OMS is nearly 
100%. The detection of anti-Ri antibodies should prompt a careful search for an underlying 
tumor, especially breast cancer. Occasionally no tumor can be found, although the presence 
of an occult tumor cannot be ruled out and this makes close follow-up advisable. 
The finding of anti-Yo or other Peab's antibodies associated with paraneopiastic OMS 
indicates that this syndrome can be part of a more widespread peD and under these circum-
stances a tumor search should also be directed to other gynaecological malignancies than 
breast cancer. 
The significance of other anti-neuronal specific antibodies in patients with clinically 
sllspected paraneoplastic OMS remains uncertain as yet. The sensitivity of the presence of 
these antibodies is low, as in many cases of OMS and cancer no antibodies can be found. 
Conclusion 
Except for motor neuron disease, the paraneoplastic disorders described here meet the 
requirements for possessing relevant antibodies. In each syndrome, autoantibodies should be 
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found in more than one patient at high titer. Each antibody thus designates a group of 
patients having a similar neurological disorder associated with specifically associated 
cancers. Usually the antibody reacts with a symptomatic part of the nervous system tissue, 
although a more widespread reactivity with clinically unaffected areas of eNS can be 
present. False positive antibodies are rare and tlus observation makes the detection of these 
antibodies of significant clinical value, not only for establishing a diagnosis of PNS, but also 
by indicating the presence and type of underlying neoplasm. 
Nevertheless, there remains a substantial group of patients who are suspected of PNS and 
harbour no specific antibodies. Based on recent findings in patients with probable PNS, it 
seems likely that future studies may reveal the recognition of other specific antibodies that 
meet the criteria mentioned above6-l,83.88. Obviously, the clinician should remain alert, 
particularly when no specific antibodies are found and the possibility of a non-paraneoplastic 
cause should be kept high on the differential diagnostic list. \Ve believe that this story is not 
complete and that over the next few years a number of other autoantibodies that are specifi-
cally associated with PNS will be identified. 
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1.2 Aim of the thesis 
Introduction 
Although the first report on the detection of an anti-neuronal antibody in paraneoplastic 
neurological disease dates from 1965, it was only in the mid-eigthies that the presence of 
anti-neuronal antibodies in serum was used as a diagnostic marker for-PNS I -4. 
In 1989 we introduced the assay to determine pmaneoplastic antibodies as a diagnostic assay 
available to neurologists and other physicians in The Netherlands. At that time the classi-
fication of paraneopiastic syndromes (PNS) of the central nervous system was mainly based 
on clinical criteria. Although it was noticed that in more than 50% of cases the neurological 
symptoms precede the finding of underlying neoplasm, establishing a definite diagnosis of 
PNS during life was difficult5• Findings based on ancillary investigations were not specific 
and the diagnosis was based on clinical symptoms and on exclusion of other causes5• 
The indirect immunofluorescence assay (II F) and the Western blotting technique to identify 
anti-neuronal antibodies were developed at the Departments of Pathology and Neuro-
oncology of the. Daniel den Hoed Cancer Center. This enabled us to provide a reference 
laboratory in The Netherlands for the detection of these antibodies in patients suspected of 
paraneoplastic neurological disorders. The above mentioned developments and the availabili-
ty of patient sera created the base for the work described in this thesis. 
The overall aim of the study describell ill this thesis was the development of methods for 
the identification of allti-neuronal specific antibodies alld their alltigens, to establish a 
diagnosis of paraneoplastic neurological disorders ami the allalysis of the relation of these 
a1ltibodies with the clinical syndrome alld the underlying malignancy. 
Diagnostic value 
\Vhen setting up an assay with the purpose of it being of clinical diagnostic use, the first 
question that rises is that of sensitivity and specificity of that assay. The aim of the first 
study, described in cflapter 2, was to establisfl tfle sellsitivity alld specificity of tfle allti-
neurollal antibodies (at that time anti~HII and anti-Yo) for makillg the lliagllosis of PNS, 
IVflell detected by IIF. Although it was known at that time, that the anti-Hu and anti-yo 
antibodies were specifically related to paraneoplastic encephalomyelitis/sensory neuronopa-
Ihy(PEMlPSN) and paraneoplastic cerebellar degeneration (peD), respectively, and not 
found in control groupS2.3.6, no systematical study has been described reporting on the 
diagnostic value of the detection of these antibodies. 
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Genetic predisposition 
Several observations suggest that a paraneopiastic neurological syndrome may in fact 
constitute a model of a human disease in which an immune response is directed against both 
the nervous system and the tumor.1-1O• Antibodies primarily directed against a tumor antigen 
and cross~reacting with similar neuronal antigens provide the conunon link. However, little 
information is avaiJable on the immunological mechanisms underlying this model. \Vhether 
the antibodies playa pathogenic role in causing neurological damage and tumor control or 
that their presence is merely an epiphenomenon remain to be established. Another crucial 
question is why only a few of all cancer patients develop this immune response and why 
other patients with the same hlmors do not. This question is intriguing, if one realizes that 
the antibodies are directed against antigens which are expressed by each small cell lung 
cancer (SCLC)7,8, 
The aim of the study described in chapter 3 ,vas /0 provMe dala slIpportillg the hypothesis 
Iltal tlte rare occurrellce of PNS may possibly be eJ.:plailleri by a gelletic predispositioll of 
PNS patiellts to develop autoimmu1Ie disease. \Ve describe 23 patients with paraneoplastic 
disease of the nervous system that are examined for the presence of systemic autoantibodies, 
including antibodies against DNA, Ro(SS-A), La(SS-B), mitochondria and IgG (rheumatoid 
factor). The presence of these autoantibodies may indicate a genetic susceptibility to develop 
autoimmune phenomena and may explain its relatively rare occurrence. 
Clinical heterogeneity and IgG subclasses 
Paraneoplastic encephalomyelitis/sensory neuronopathy (PEMlPSN) is a rare neurological 
syndrome, occurring in less than 1 % of patients with SCLC II . It is therefore not surprising 
that mainly case reports or small series have been published on this subject. As recently as 
1989 the largest series published on PEMlPSN still consisted of 18 patients""l2·", The 
patients reported presented with a wide variety of clinical signs indicating the presence of 
limbic encephalitis, sensory neuronopathy, motor neuron dysfunction, cerebellar ataxia or 
brainstem dysfunction. The finding of the anti-Hu antibody in these patients in association 
with the presence of SCLC, suggests that these clinical signs are all manifestations of the 
same pathogenic process. It is, however, unknown why the Hu-syndrome shows major 
differences in clinical symptoms. The pathological findings also differ greatly in the site of 
inflammation and IgG depositions in the central nervous system1S•16• It has been suggested 
that the clinical variety of the Hu-syndrome may be explained by different properties of anti-
Hu antibodies like fine specificity of the antibody against different antigens of the Hu family 
(HuD, HuC, Hel-NI), antibody titer17, complement binding capacity, accessibility of the 
central nervous system for antibodies or by differences in intrathecal anti-Hu synthesis1S,16.18. 
Western blot analysis shows that anti-Hu of some patients primarily recognizes the upper or 
the lower band of the Hu protein complex (unpublished data), Another possibility is that the 
variety of anti-Hu IgG subclasses are responsible for the clinical heterogeneity. In an earlier 
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study involving a small number of patients, however, no correlation was found between IgG 
subclass and clinical presentation l6• Until now there seems no satisfactory explanation for the 
variation in clinical symptoms or involved areas of the central nervous system in PEMlPSN. 
We studied series of 29 patients with the Btl-syndrome in relation with the anti-Bu IgG 
subclasses and tried to e.\plaill tlte variety in clillical course of tlte allti-HII associated 
PEMIPSN (c!tapler 4). 
Novel antibodies 
Because of the low incidence of PNS in patients with cancer, it is unlikely that the oncolo-
gist will see one patient with a paraneoplastic syndrome every year. If a patient with cancer 
complains of neurological symptoms, the likelihood of such a patient to have a 
paraneoplastic neurological syndrome is low, and non-paraneoplastic causes should primarily 
be sought. On the other hand, if a patient without cancer develops neurological symptoms 
and the cause of the neurological disability is not immediately obvious, the likelihood that 
such a patient has cancer is considerable l9• This is especially true when the patient presents 
with one of the classic paraneoplastic syndromes. Although the likelihood in such patients of 
having cancer has not weB been established, Posner gives an estimation of these changes to 
occur (table I). The specificity of the antibodies for a diagnosis of PNS is high, but their 
sensitivity is relatively low12.1O. Many patients clinically suspected of a PNS (probably> 
50%) remain in whom no antibodies can be found ll •14• At the other hand, many studies, 
mostly case-reports, indicate that other anti-neuronal antibodies against until as yet uncharac-
terized antigens may be present in some nsero-negative" PNS patients21 •23 • Other studies 
have not been able to detect other antibody reactivities in PEMlPSN patients with SCLC". 
These differences may be explained by heterogeneity in patient groups or in detection tech-
niques. Not all antibodies can be detected by routine immunohistochemical or Western blot 
assays. Methods of fixation can modify the antigenic epitopes and interfere with antibody 
detection25 • Recently guidelines for the detection of clinically relevant antibodies associated 
with PNS have been published"'''. It is possible that other antibodies, although not fulfilling 
these guidelines are present in sera of patients with PNS. For Hu it has been shown that the 
antigen can occasionally be expressed by other tumors and corresponding antibodies can be 
found in serum28• Given the low sensitivity so far and isolated reports on incompletely 
characterized antibodies, it seems relevant to try to idelltify lIew allti~lIeurollal reactivity ill 
relatioll to the lIeurological symptoms alld thus illcrease tlte overall sellsitivity of the 
deleclioll of allli-llet/rollal alllibodies for Ifte diagllosis of PNS (cftaplers 5, 6 alld 7). 
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Thble 1 Estimated likelihood of a given neurological disorder to be a paraneoplastic 
syndrome 
Syndrome 
Lambert-Eaton myasthenic syndrome 
Subacute cerebellar degeneration 
Opsoclonus/myoclonus (children) 
Sensory neuronopathy 
OpsocJonus/myoclOiluS syndrome 
Myasthenia gravis 
Sensorimotor peripheral neuropathy 
Encephalomyelitis 
Dennatomyositis 
% Paraneoplastic 
60 
50 
50 
20 
20 
15 
10 
10 
10 
Source: J.B. Posner. Neurologic complications of cancer Contemporary neurology series, \'01.45, p357. EA. 
Davis Company, Philadelphia. 1995. 
Guidelines 
Since the discovery of the anti-Hu, -Yo and -ill antibodies. identification of the paraneoplas-
tic anti-neuronal antibodies rests on indirect immunofluorescence and \Vestern blot analy-
SiS26, However, not all laboratories use \\'estern blot analysis to identify the molecular 
weight of detected antigens25,29.30. A major problem in comparing results of different 
investigators has been that individual laboratories employ different techniques for the 
detection of these antibodies. Material from several animal species is used, methods of 
preparing substrates for Western blot are not always clearly described and concentrations of 
semm and end~point staining are not similar. Sometimes this results in substantial diffe-
rences in sensitivity and specificity of the techniques used for paraneoplastic antibody detec-
tion30, Some early and recent publications on incompletely characterized novel anti-neuronal 
antibodies21 -23 have complicated the situation, and seem to make it difficult for the clinician 
to interpret the significance of these antibodies. 
Approach to consensus 
In view of these uncertainties and controversies between research groups on the teclmiques 
and on the terminology of anti-neuronal antibodies, a workshop on this topic was organized 
during an international symposium on Paraneoplastic Neurological Disease, held on 22-23 
October 1994 in Rotterdam, The Netherlands. The primary aim of this workshop was to 
/ortlllilate a report containing generally accepted gllidelilles to make laboratory testing of 
allti~lIellrOJtal antibody detectioll more ulliform alld easily illterpretable alld besides, to 
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clarify the terminology. The resulting consensus described in chapter 8 reports on the work 
from 11 international research groups that formed the consensus group to discuss and define 
the terminology, the methodology and interpretation of the finding of paraneoplastic anti-
neuronal antibodies. 
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Abstract 
The diagnostic value of the presence of anti~neuronal antibodies in serum was examined in 
21 patients suspected of paraneopiastic disorders of the nervous system (group 1) and was 
compared to three control groups; group 2: 25 patients with a neurological disease, without 
cancer and not signs of paraneoplastic disorder; group 3: 27 patients with neurological 
disease and cancer and no signs of a paraneoplastic disorder; group 4: 94 patients with 
cancer and without neurological disease. In group 1, anti-neuronal nuclear antibodies were 
detected in eight patients (38%), in titres from 1:1000 to 1:32000. A small cell lung cancer 
was present in six patients, ovarian cancer in one patient and in one patient no tumour could 
be detected. The neurological symptoms preceded a diagnosis of cancer in five out of eight 
patients. Anti-neuronal antibodies were found in the serum of two out of 94 patients (2%) 
from control group 3 but not in scnllll from any of the other control groups. These data 
indicate a moderate sensitivity of 38%, but a high specificity of 98.6% (95% confidence 
interval 95.5-99.8%) for the presence of anti-neuronal nuclear antibodies if a paraneoplastic 
nervous system disorder is suspected. 
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Introduction 
Paraneoplastic disorders of the nervous system can be divided mainly into limbic encephali-
tis, brainstem encephalitis, subacute cerebellar degeneration and a sensory or motor neurone-
pathy. In more than 50% of cases, they precede the finding of the underlying neoplasm I, 
Diagnosis during life can be difficult because clinical symptoms and findings on ancillary 
investigations arc not specific. In recent years, several anti-neuronal autoantibodies have 
been identified in the serum of patients with a paraneoplastic disorder of the nervous 
systcm2•4• The antinuclear nucleoprotein antibody (anti-Hu) is mainly associated with small 
cell lung carcinoma (SCLC) and binds to nuclei of neurons2•S, The anti-Purkinje cell 
antibody (PCA) binds to the cytoplasm of Purkinje cells and has primarily been identified in 
patients with breast and ovarian cancer3,6. Apart from its interest in aetiology of 
paraneoplastic neurologic syndromes, the finding of these autoantibodies ,can be used for 
diagnostic purposes. \Ve investigated the diagnostic value of the presence of anti-neuronal 
antibodies in patients with neurological signs suspected of paraneopiastic origin and 
compared it with three control groups. 
Patients and Methods 
Indirect immunofluorescence technique 
The presence of anti-neuronal autoantibodies was investigated by the indirect immunoflu-
orescence method (IIF). Snap frozen tissue blocks of human neuronal tissue (obtained at 
necropsy within six hours after death, from individuals without neurological disease) and 
with fresh neuronal tissue obtained from healthy \Vistar rats, were used as test tissue. 
Unfixed frozen sections of human and rat cortex, cerebellum, spinal cord and vagal and 
optic nerve were incubated with serum diluted with phosphate-buffered saline (PBS, pH 7.2) 
I :50 up to I :6400, for one hour at room temperature. After rinsing three times in PBS for 
five minutes the sections were incubated with anti-human Ig and IgG (Fab)2, IgM (Fab)2 
and IgA (Fab)2 monoclonal antibodies conjugated with fluorescein isothiocyanate (FITC) for 
30 minutes (DAKO, Glostrup, Denmark). The dilution for the second antibody was I: I 00 
for Ig, IgG (Fab)2 and 1:50 for IgM (Fab)2. Sections were rinsed three times in PBS for five 
minutes, overlaid with a coverglass using a 10% glycine/PBS solution as mounting fluid, 
and evaluated under a Leitz fluorescence microscope with a FITC outfit. 
As negative controls, sections were also incubated with PBS alone. To differentiate anti-
neuronal antibodies from non-neuronal specific anti-nuclear antibodies, sera were also tested 
against frozen sections of llormal human and rat liver. Stained sections were reviewed by the 
investigator and technician without previous knowledge of the patient's clinical status. Sera 
were considered positive for anti-neuronal antibodies only when distinct fluorescence 
staining was present in a titre of I :500 or higher. Antibody-positive sera were also incubated 
with frozen sections of normal human and rat cerebral cortex, cerebellum, spinal cord, 
optical and vagal nerve. 
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Table 1 Patients and controls 
Groups of patients 
Neurological disease with sllspicion of 
paraneoplastic neurologic disease 
organic brain syndrome 
cerebellar ataxia 
sensory neuronopathy 
myelopathy 
brainstem encephalitis 
2 Neurological disease without cancer and no 
suspicion of paraneoplastic neurologic disease 
3 Cancer with neurological disease but no 
suspicion of paraneoplastic neurologic disease 
4 Cancer without neurological disease 
small cell lung cancer 
breast cancer 
ovarian cancer 
No. 
21 
5 
6 
5 
4 
I 
25 
27 
94 
38 
9 
47 
37 
Four different categories of patients were distinguished: Group I: patients with or without a 
verified cancer, in whom a reasonable or strong suspicion of a paraneoplastic neurological 
disorder was presented. Three case reports from this group have been described in detaW; 
Group 2: control group of 25 patients with neurological disease not related to a paraneo-
plastic neurological disorder and without cancer; Group 3: control group of 27 patients with 
neurological disease not related to a parancoplastic neurological disorder and with cancer; 
Group 4: control group of 94 patients with cancer and no known neurological disease. 
Control sera of group 4 were collected over a period of five years and stored at -70°C. All 
patients in this group were prospectively studied and followed as part of ongoing chemo-
therapy trials. All sera of groups 1, 2, 3 and 4 were negative for anti-nuclear antibodies 
(ANF), when tested on normal human and rat liver or muscle tissue. In peripheral nerve or 
non-neuronal tissue, no reactivity could be observed using the same sera. No differences 
were seen in staining patterns on human or rat tissue. 
Results 
The number of patients in each group and a listing of the neurological diagnoses are 
summarized in table 1. The individual clinical and IIF data in patients with positive titres 
can be found in table 2. Anti-neuronal antibodies were detected in eight out of 21 patients 
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from group I (38%); in six patients with SCLC, in one patient with ovarian carcinoma and 
in one patient no tumour could be found. A bright speckled fluorescence of nuclei of 
cerebellar granular and Purkinje cells and cortical neurons with sparing of the nucleolus was 
observed in six patients (fig I and fig 2). This anti~ncllronal nuclear antibody was of the IgG 
type (titres from I: 1000 to I: 32 000), except one patient with an IgM antibody (titre 
I: 1000). Neurological symptoms preceded the diagnosis of a neoplasm in five out or the 
eight positive patients from group I with a median time interval of four months. An organic 
brain syndrome, compatible with a diagnosis of limbic encephalitis was seen in three patients 
with SCLC. 
Extensive investigations including CT scan of the brain, bacterial and viral cultures of the 
cerebrospinal fluid (CSF) were negative. Causes for metabolic encephalopathies could be 
excluded and there were no indications of toxic exposure or drug abuse. Psychiatric 
evaluation did not reveal a cause for the mental abnormalities. A subacute cerebellar 
degeneration consisting of a truncal and appendicular ataxia together with dysarthria was 
seen in two patients with SCLC. A sensory neuronopathy in association with abnormal 
plantar reflexes was found in one patient with SCLC and in one patient in whom no tumour 
could be detected. A brain stem encephalitis consisting of a peripheral facial palsy, vestibu-
lar vertigo, glossopharyngeal and vagal nerve dysfunction, dysarthria and pyramidal signs 
was observed in a patient with ovarian carcinoma. 
In the controls, only two patients of group 3 had increased titres of anti-neuronal nuclear 
antibodies, and both had a SCLC. One of these had recurrent headache with equivocal signs 
of pyramidal tract lesion, but no other neurological signs. The other patient had brain metas-
Table2 Clinical and IIF data of patients with anti-neuronal nuclear antibodies 
Tumor Onset (months) Main clinical feature 
Group I 
I SCLC -0.5 Organic brain syndrome 
2 SCLC -2.5 Organic brain syndrome 
3 SCLC -24 Ataxia, dysarthria 
4 SCLC -2 Ataxia, dysarthria, sensory neuronopathy 
5 SCLC +4 Organic brain syndrome 
6 Ovarian cancer +9 Brain stem encephalitis 
7 No tumour -6 Sensory neuronopathy 
8 SCLC Sensory Ileuronopathy 
Group 3 
9 SCLC Brain metastasis 
10 SCLC Pyramidal tract lesion 
Onset: time of onset of symptoms before detection of tumour, SCLC: small cell lung cancer 
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tases, treated by radiotherapy and was neurologically asymptomatic at the time serum was 
taken, \Vhen we consider group 2, 3 and 4 as one control group, the presence of anti-
neuronal nuclear antibodies in patients suspected of a paraneoplastic neurolological disorder 
(group 1) indicate a sensitivity of 38% and a specificity of 98.6% (95% confidence interval 
95.5-99.8%), (table 3). 
Discllssion 
Anti-neuronal IgG antibodies in serum of patients with a paraneoplastic disorder of the 
nervous system have been identified, and can mainly be divided in anti-neuronal nuclear or 
cytoplasmic antibodies2.4, Antibodies binding to neuronal nuclei have been observed in 
Purkinje, granular, basket and molecular cells of the cerebellum as well as to nuclei of 
neurons in the cerebral cortex, brain stem, spinal cord and dorsal root ganglion25, These anti-
neuronal nuclear antibodies have primarily been recognised as binding to neuronal nucleo-
protein antigens with a molecular weight of 35-40 Kd and have been designated as anti-
HU2,5, The majority of anti-Hu antibodies are associated with SCLC2-5, \Ve found anti-
neuronal nuclear antibodies in three patients with an organic brain syndrome and these were 
compatible with a diagnosis of limbic encephalitis, in two patients with cerebeJIar ataxia and 
in one patient with a sensory neuronopathy, all with SCLC. An isolated IgM antibody in a 
patient with SCLC and suspected of limbic encephalitis is a new observation, 
Table 2 Clinical and I1F data of patients with anti-neuronall1l1clear antibodies (continued) 
Antibody specificity 
Titre Class CN PC GC BC SC MLC AHC 
Group 1 
1:1600 IgG + + 
1:1000 IgM + + + + + + 
1:4000 IgG + + + + + + 
1:32000 IgG + + 
1:2000 IgG + + + + 
1:6400 IgG + + + + + + 
1:1600 IgG 
1:25000 IgG + + 
Group 3 
1:800 IgG + + 
1:6400 IgG + + + + + 
CN: Cerebral cortical neuron, pc: Purkinje cell, GC: Granular cell, BC: Basket cell, SC: Stellate cell, MLC: 
Molecular layer cell, AHC: Anterior hom cell. 
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L,ble3 Diagnostic value of anti-neuronal antibodies for the presence of a PNS* 
No. of positive tests No. of negative tests Sensitivity Specificity 
in control patients in control patients 
Anti-neuronal nuclear 
antibodies 
Anderson et al.5 1988 14/87 303/303 14.5% 100% 
This series 8/21 1441146 38% 98% 
Anti-neuronal 
cytoplasmic antibodies 
laeckle et aI.' 1985 6112 1671167 50% 100% 
Anderson et al.6 1988 18/42 317/319 43% 99% 
Smith et al.s 1988 6/26 1251125 23% 100% 
• In this table only series in which a titre of 1:500 or higher was considered to be positive have been included. 
An anti-neuronal nuclear antibody in a patient with brainstem encephalitis and ovarian 
cancer has also not been reported before. The cause of this variation in clinical syndromes is 
unknown, hut it may relate to differences in binding to one group of neurons or another. 
In contrast, anti-neuronal cytoplasmic antibodies have primarily been associated with 
binding to Purkinje cells together with the occurrence of cerebellar ataxia and have been 
designated as PCA (anti-Purkinje cell antibodies)',4", The clinical picture is usually designa-
ted as a paraneoplastic subacute cerebellar degeneration and has been encountered in 
gynaecological cancer, mainly ovarian, in breast and small cell lung cancer or in 
lymphoma3.4.6. In more than 50% of cases the paraneoplastic neurological disorder precedes 
the finding of a malignancy 1 , which we also observed here. Until recently a final diagnosis 
of paraneoplastic disorder of the NS could only be confirmed at necropsy since the results of 
ancillary investigations arc ofM!l negative or aspecific. Viral and post-viral inflammatory 
disease, Sjogren's syndrome or an idiopathic syndrome may give rise to similar clinical 
pictures8,9. The detection therefore of anti-neuronal autoantibodies in serum of patients 
suspected of a paraneoplastic NS syndrome could be of great help"', For this purpose 
information is needed about the sensitivity and specificity of the presence of these autoanti-
bodies, 
For anti-Hu antibodies, Anderson et al. found a specificity of almost 100% in a series of 18 
patients with paraneoplastic NS disorder together with various control groups up to a total of 
303 patients with or without cancer or neurological abnormalities5. They found false positive 
antibodies in two patients with a possible paraneoplastic neurological syndrome, but without 
the presence of a malignancy5, We found positive autoantibodies in two control patients of 
group 3, Two of these had a small cell lung cancer of the lung and positive titres of anti-
neuronal nuclear antibodies, Neither of them had signs which are usually compatible with a 
paraneoplastic disorder of the NS, \Vhen we restrict ourselves to patients with positive titres 
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of anti-neuronal nuclear antibodies in serum, we found a specificity of 98% for the associa-
tion of these antibodies with a suspected paraneoplastic disorder of the NS. 
The presence of PCA has also been shown to be highly specific for a diagnosis of a para-
neoplastic cerebellar degeneration6,JO. In contrast to its specificity, the diagnostic sensitivity 
for the presence of either anti-Hu or PeA-antibodies was rather low in the few reported 
series, but this may be partly due to differences in opinion on a sufficiently high titer in 
serumll ,12. A cut-off point of a titre of 1 :500 or higher prevents a false positive interpretation 
of non-specific background stain5,6"o. Despite this precaution, the sensitivity may further 
differ from one series to another as the degree of clinical suspicion and the interpretation of 
subtle neurological findings is open to variation, Nevertheless, its high specificity makes the 
indirect immunofluorescence test a clinical useful screening test for the detection of anti-
neuronal antibodies in serum of patients suspected of paraneopiastic disorder of the NS. 
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Abstract 
Sera from 23 patients with paraneoplastic disease of the central nervous system (PNS) were 
examined for the presence of anti-neuronal (anti-Hu, anti-yo or anti-Ri) and systemic 
autoantibodies, including antibodies against DNA, centromeres, nRNp, Srn antigen, Sci-70, 
Ro(SS-A), La(SS-B), mitochondria, thyroid antigens, parietal cells, brush border antigen and 
rheumatoid factor. As controls, 33 patients with small cell lung cancer, 33 with ovarian 
cancer and 7 with breast cancer were examined. Systemic autoantibodies were found in 52% 
patients with paraneoplastic neurological syndromes compared to only 25% in control series 
of patients with solid tumors (p~O.OI3). 
We conclude that this high percentage of systemic autoantibodies in PNS indicates a genetic 
susceptibility to develop autoinunune phenomena. One assumes that another prerequisite to 
develop paraneoplastic neurological disease is the oCCurrence of cross-reactivity against 
antigens expressed in both tumor and nervous tissue. Both conditions are probably necessary 
to develop PNS and may explain its relatively rare occurrence. 
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Introduction 
Anti-neuronal antibodies can be found in serum and cerebro-spinal fluid (CSF) of patients 
with paraneopiastic syndromes of the central nervous systemH , The etiology of PNS is 
unknown but may be explained by an autoimmune reaction directed against certain specific 
antigens or epitopes shared by the underlying neoplasm and the nervous system4.8, Until 
now, three types of antibody reactivity have been demonstrated in association with PNS and 
their underlying tumors. These include the anti-Hu, anti-yo and anti-Ri antibody which are 
connected to small cell lung cancer, ovarian cancer and breast cancer, respectivcly9.1I. 
Other anti-neuronal autoantibody reactivities have been identified in individuals or small 
groups of patients with PNS, but their precise characteristics and clinical value remain yet to 
be determined12•15 • 
An unresolved question is why a small percentage «1%) of patients with cancer do develop 
this type of immune response and associated neurological disease. This problem is particu~ 
lady intriguing if one realizes that the Hu antigen is expressed by all small cell lung cancers, 
and not only in patients suffering from PNSll ,16. One answer could be that these patients 
have a genetic susceptibility to develop autoimmune reactivities. \Ve examined wether in 
sera of patients with PNS, besides anti-neuronal autoantibodies, also systemic (non-neuronal) 
autoantibodies could be identified. 
Patients and Methods 
Sera of23 consecutive patients (mean age: 59.7 ±13.8 years, malelfemale ratio 14/9) with a 
clinical diagnosis of PNS and positive test for anti-neuronal antibodies (15 anti-Hu and 6 
anti-Yo and 2 anti-Ri; titers> I: 1000) were tested for both organ and non-organ specific 
autoantibodies associated with other autoimmune disorders. Sera were tested for IgG antibo-
dies against nuclear antigens including: native n-DNA, centromeres and the ENA group 
(nRNp, Sm antigen, Scl-70, Ro(SS-A), La(SS-B)). Other non-nuclear antibodies were tested 
against: mitochondria, smooth muscle, thyreoglobulin, thyroid microsomal antigen, gastric 
parietal celis, brush-border antigen and rheumatoid factor. 
Serological determinations were performed without prior knowledge of clinical data. All 
tests were performed on one serum sample per patient. Samples were stored at -80 °c prior 
to testing. 
Indirect immunofluorescence tests (IIF) were performed on all sera using various substrates 
as antigenic source including rat liver, culture preparations of Hep-2 cells (Inova, St. Diego, 
USA), Crithidia luciliae (DNA), rat kidney (mitochondria and brush border antigen), thyroid 
(thyroglobulin and microsomal fraction), stomach (parietal cells and smooth muscle)I1·". 
Antibodies to Sm, nRNP and ScI 70 were determined by immuno-precipitation reaction in 
agar gel20•21 • Presence ofanti-Ro/SS-A and anti-LaiSS-B antibodies were tested by an ELISA 
method using affinity purified antigens". Rheumatoid factor (lgM and IgA) was determined 
by an ELISA". Antibodies to ganglioside GMI were determined using an ELISA". Anti-
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neuronal antibody detection was performed using the indirect immunofluorescence assay and 
Western blotting techniques essentially as described by Grausll and slightly modified as 
described before25 • 
Briefly, Hu fusion proteins (obtained from H. Furneaux, Memorial Sloan-Kettering Hospital, 
New York) and protein samples of both rat and human cerebral and cerebellar neurons, liver 
and spleen were separated by electrophoresis on a 10% polyacrylamide gel. Gels were 
loaded with 20 pmg of protein per lane. After electrophoretically being transferred to 
Hybond nitrocellulose membrane (Amersham, Buckinghamshire, United Kingdom), separate 
lanes were incubated with patient's and control sennll in a 1 :2000 dilution. After washing, 
lanes were incubated with alkaline phosphatase labeled anti-human IgO. To visualize 
reactive hands membranes were developed in 5-bromo-4-chloro-3-indolyl phosphate and 
nitroblue tetrazolium (Bio-Rad, Hercules, California). 
In order to prove or exclude the presence of cross-reactivity of the anti-Bu with other 
antigens, sera were also pre-absorbed to the Hu fusion-proteins before testing. Sera from 
healthy controls and 33 patients with small cell lung cancer, 33 with ovarian ca9cer and 7 
with breast cancer were used. Also reference values of our laboratory in which these tests 
were performed, including prevalence of autoantibodies in the normal population were llsed 
as controls. 
Results 
Of 23 sera from patients with PNS, 12 (52%) contained non-neuronal specific antibodies 
against one or more of the tested antigens, compared to 18 of the 73 (25%) control sera from 
patients with cancer only (p~O.013; see tables I and 2;). In 6 patients (25%) two or nlore 
antibodies could be identified. Anti-nuclear antibodies (ANA, centromeres, nRNP, Sm and 
La(SS-B) antibodies) were seen in 12 patients (52%). Antibodies against the ENA group 
were seen in 5 patients (22 %): two against La(SS-B), one against nRNP alone and two 
against both Sm antigen and nRNP. Antibodies against centromeres were seen in sera of two 
patients. In two sera anti-mitochondrial activity was observed and three sera showed 
antibodies against brush-border antigen. Three patients showed antibodies against smooth 
muscle antigen and two against parietal cells. No antibodies could be found to thyroid 
antigens, rheumatoid factor or Scl-70. Patients had no clinical signs of any other auto-
immune disease than the paraneoplastic neurological syndrome. 
Frequency of individual autoantibodies are listed in comparison with antibody frequency in 
the normal and diseased population (table 2). Pre-absorption to the Hu fusion proteins did 
not change the results of the systemic autibody testing. 
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Table 1 Systemic autoantibodies in patients with paraneoplastic neurological syndromes 
ANSA 
Pat.no. Age PNS Type Ig class I titer Tumor ANA DNA Cent 
31 CS PCA IgO >1:1600 M. Hodgkin 
2 61 CS PCA IgO >1:1600 Ovarian ++ 
3 78 CS PCA IgO >1:1600 Renal cell 
4 78 CS PCA IgO >1:1600 M. Hodgkin 
5 37 CS PCA IgO >1:1600 Ovarian 
6 39 CS PCA IgO 1:1600 M. Hodgkin 
7 72 SNNP Hu IgO >1:1600 SCLC S40 
8 70 CS Hu IgO 1:1600 SCLC 
9 65 SNNP Hu IgO 1:500 SCLC 
10 60 SNNP Hu IgO 1:1600 SCLC S40 
II 68 SNNP Hu IgO 1:1600 SCLC 
12 46 CS Hu IgO 1:800 Breast HI60 
13 81 CS Hu IgO >1:1600 SCLC 
14 83 CS Hu IgO/IgM >1:1600 SCLC 
15 59 SNNP Uu IgO/IgM 1:32 (CSF) SCLC HI60 ++ 
16 59 LE Hu IgO >1:1600 SCLC SI60 
17 45 ANP Hu IgO >1:1600 SCLC 
18 60 SNNP Hu IgO 1:1600 SCLC S80 
19 61 SNNP Hu IgO 1:1600 SCLC 
20 56 SNNP Hu IgO 1:1600 SCLC S80 
21 48 SNNP Hu IgO >1:800 SCLC 
22 58 CS Ri IgO >1:1600 Breast 
23 58 SNNP Ri IgO 1:800 SCLC S80 
PNS = Paraneoplastic neurological syndrome PCA = Anti-Purkunje cell antibody 
CS = Cerebcllarsyndrome CSF = Cerebrospinal fluid 
SNNP = Sensory neuropathy SCLC = Small lung cell cancer 
LE = Limbic encephalitis ANA = Anti-nuclear antibodies 
ANP = Autonomic neuropathy DNA = Anti-DNA antibodies 
ANSA = Anti-neural specific antibodies Cent = Anti-centromere antibodies 
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Table 1 Systemic autoantibodies in patients with paraneoplastic neurological syndromes 
(continued) 
ENA 
Pat.no. RNP SI11 SS-A SS-B 
2 ++ ++ 
3 ++ ++ 
4 
5 ++ 
6 
7 
8 
9 
10 
II 
12 
13 
14 ++ 
15 
16 
17 
18 ++ 
19 
20 
21 
22 
23 
S = Speckled anti-nuclear antibodies 
II = Homogenou~ anti-nuclear antibodies 
ENA = Extractable nuclear antibodies 
RNP = Anti-ribonucleo protein antibodies 
Sm = Anti-Sm antibodies 
AMA = Anti-mitochondrial antibodies 
Sci AMA ASMC ASPA BB 
++ ++ 
++ ++ 
++ ++ 
++ 
++ 
++ 
++ 
ASMC = Anti-smooth muscle antibodies 
ASPA = Anti-parietal cell antibodies 
BB = Anti-Brush border antibodies 
RF = Rheumatic factor 
++ = positive 
RF 
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Table 2 Total number and prevalence (%) of systemic autoantibodies in paraneoplastic 
neurological syndromes and cancer- and !lonnal cOl1trol5* 
ENA 
No. of 
patients ANA DNA Cent RNP Sm SS-A 
PNS 23 8 (34) 0(0) 2 (9) 3 (13) 2 (9) 0(0) 
Subgroups 
I. AntiwHu positive IS 7 (46) 0(0) (7) 0 (0) 0 (0) 0(0) 
2. PCA positive 6 0 (0) 0(0) 0 (0) 3 (50) 2 (33) 0(0) 
3. Anti-Ri positive 2 I (50) 0(0) I (50) 0 (0) 0 (0) 0(0) 
Solid tumors 73 II (15) I (I) 0 (0) 0 (0) 0 (0) 0(0) 
SUbglVlIpS 
I. Small cell lung carcinoma 33 7 (21) I (3) 0 (0) 0 (0) 0 (0) 0(0) 
2. Ovarian carcinoma 33 5 (IS) 0(0) 0 (0) 0 (0) 0 (0) 0(0) 
3. Breast carcinoma 7 I (14) 0(0) 0 (0) 0 (0) 0 (0) 0(0) 
NOl'mal individuals 107 7 (7) I (I) I (I) I (I) I (I) I (I) 
* For legend see table I; Numbers indicate absolute value and percentage of total is given between brackets. 
Discussion 
\Ve studied the presence of a spectrum of systemic autoantibodies in 23 patients with anti-
neuronal antibody proven PNS. The overall frequency of systemic autoantibodies was 
significantly higher than in the control population (52% vs < 25%, table 2), 
Since the discovery of anti-neuronal specific antibodies in pati~nts with sensory neurono-
pathy and small cell lung cancer by Wilkinson et a1. in 19652, more data have become 
available indicating that PNS may be caused by an autoimmune mechanismS,7. 
Paraneoplastic neurological syndromes partially fulfil Witebsky's criteria to characterize an 
autoimmune disease26• These criteria include the demonstration of relevant antibodies or cell-
mediated immunity and the isolation of responsible antigens capable to induce an immune 
response in animals with corresponding pathological changes following either active or 
passive immunization. 
Autoantibodies have been detected in both serum and cerebrospinal fluid of PNS patients, 
indicating intrathecal antibody production27, These antibodies can bind to neurons in brain 
regions affected by PNS',', In vitro experiments have pointed to a cytolytic effect of these 
antibodies against neuronal and tumor cell-lines28• 
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Table 2 Total number and prevalence (%) of systemic autoantibodies in paraneoplastic 
neurological syndromes and callcer- and nonnal controls* (continued) 
ENA Total p-value 
SS-B Sci AMA ASMC ASPA BB RF II II 
2 (9) 0(0) 2 (9) 3 (13) 2 (9) 3 (13) o (0) 17(74) 12 (S2) <0.00 I <0.00 I 
2 (13) 0(0) 2 (13) 2 (13) o (0) I (7) o (0) 10(67) S (33) 0.010 0.081 
0 (0) 0(0) o (0) o (0) 2 (33) 2 (33) o (0) S (83) S (83) O.OOS 0.001 
0 (0) 0(0) o (0) 0 (0) o (0) 0 (0) o (0) 2 (100) 2(100) 0.023 0.003 
0 (0) 0(0) (I) I (I) 2 (3) o (0) 6 (8) 18 (2S) 10 (14) 
0 (0) 0(0) I (3) (3) (3) 0 (0) 2 (6) 9 (27) 4 (12) 
0 (0) 0(0) o (0) 0 (0) 2 (6) 0 (0) 4 (12) 8 (24) 6 (18) 
0 (0) 0(0) o (0) o (0) 0 (0) o (0) o (0) (14) o (0) 
I (I) 0 (0) o (0) o (0) 7 (7) o (0) S (S) 16 (IS) 14 (13) <0.001 <0.001 
#=Total number and percentage 0 of patients having one or more autoantibodies; I=including ANA; 
II=exciuding ANA, 
Antigens have been isolated and cloned from both neural and tumor tissue, and expression 
ofthe Hu antigen can be found in nearly each small cell lung cancer, irrespective whether 
patients suffer from associated PNS or nOe,S,2,}, However, neither by passive or active 
immunization, one has as yet been able to reproduce the disease in experimental animals28, 
Inspite of the rapid progress in detecting and isolating the involved antibodies with their 
corresponding antigens, the question remains why only a relatively small number of patients 
with cancer develop PNS. 
Our data show that PNS patients, besides anti-neuronal antibodies, frequently harbor 
systemic autoantibodies that are usually associated with autoimmune diseases and of which 
some only rarely occur in the normal population. 
Humans frequently develop autoantibodies without actual disease and this autoantibody 
formation appears to be related to both age and sex, the highest prevalence being observed in 
older females and the lowest in younger males30, 
Autoimmune disorders develop predominantly in women and it is no exception that more 
than one autoimmune disorder occurs in the same individual. The overlaps are generally 
seen within the same category of disease, but a higher incidence of organ-unrelated 
antibodies can be found in patients with an autoimmune disease30• One obvious explanation 
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for tlus aggregation of autoimmune responses may be a genetically determined predisposi-
tion of the individual for autoimmune reactivity30. 
One alternative explanation for the rarity of PNS may be the presence of a mutated antigen 
expressed by only a few small cell lung cancers. Dalmau et al. established a deleted region 
in the eDNA coding for Hu in SCLC of one PNS patiene'. One argument against this theory 
holds that it seems less likely that antibodies raised against a mutated altered protein, would 
recognize the unmutated antigen as expressed by the central nervous system. 
The finding of systemic antibodies in our patients cannot exclude a possible mutation of the 
Hu antigen as the underlying cause for the induction of PNS, but would make it a less 
probable explanation. 
\Ve conclude that the detection of a high percentage of autoantibodies usually associated 
with a spectrum of systemic autoimmune diseases provides indirect evidence for a genetic 
susceptibility in patients with PNS for autoinunune reactivity. Another prerequisite may be a 
cross-reactivity against identical antigens or epitopes by both tumor and nervous tissue. Both 
conditions are probably indispensable to develop PNS and may also explain the relative 
rarity of PNS in patients with cancer. As mainly small cell lung cancer shares certain anti-
gens with neurons, this would explain the particular association of PNS with this type of 
cancer. 
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Abstract 
It is unknown whether the wide clinical variety of the anti-Hu syndrome relates to differences 
in anti-Hu IgG subclasses. Therefore we examined the correlation between the anti-Hu IgG 
subclass (IgGI_4) and clinical data in a group of 29 anti-Hu positive patients with 
paraneoplastic encephalomyelitis/sensory neuronopathy (PEMlPSN). The clinical course and 
onset of anti-Hu positive patients with PEMIPSN was divided according to: (I) presenting 
symptoms, (2) spectrum of neurological disease, (3) onset of disease, (4) time from neurolog-
ical to tumor diagnosis. and (5) type of underlying tumor. Anti-Hu reactivity was determined 
by both the indirect immunofluorescence assay and immunoblot using the recombinant HuD 
protein. The anti-Hu IgG subclasses were tested by indirect immunohistochemistry, using 
HRP-IabeHed mouse anti-human IgG I -4 on sections of rat cerebellum. Seventeen patients 
(59%) presented with sensory, 3 (10%) with cerebellar, 4 (14%) with motor, 4 (14%) with 
mental and 1 (4%) with autonomic symptoms. Seven patients (24%) showed signs and 
symptoms of unifocal involvement. Fourteen patients had involvement of two areas. In seven 
patients three areas were involved. In eighteen patients (62%) the onset of neurological 
symptoms was subacute, in six acute and in five a more chronic course of disease was seen. 
Fourteen patients (48%) had a SCLC, 5 patients (17%) had a probable SCLC, 4 patients had a 
nOIl-SCLC and three patients had a breast cancer. In 4 patients (14%) no tumor was found 
after follow-up between 20 to 78 months. Seven patients had only IgG I antibodies, 12 IgGJ in 
combination with IgG2 and 6 with IgG). IgG4 was seen in four patients. Two patients showed 
only IgG2 • Pearson's correlation analysis indicated that a unifocal involvement is associated 
with absence of IgGJ antibodies (p~O.OI). This may imply that patients with IgG J anti-Hu 
antibodies may have more often multi focal involvement of the central nervous system. 
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Introduction 
PEMlPSN is an infrequent neurological syndrome, that occurs in less than 1 % of patients 
with small cell lung cancer (SCLC)'. Most patients with PEMlPSN and SCLC develop an 
immune response against the 35-40 kD neuronal protein (Hu antigen) which is expressed on 
neuronal cells and SCLC cells2,3. In 80% of patients neurological symptoms antedate the 
tumor diagnosis and the detection of the anti-Hu antibodies may lead to an early diagnosis of 
a still unidentified SCLC. Thus, anti-Hu antibodies, when found in high titer in serum and 
cerebrospinal fluid (CSF) of patients with PEM/PSN, may serve as a diagnostic marker for 
SCLC'·6 
The detection of the anti-Hu antibody in patients with a variety of clinical signs as limbic 
encephalitis, sensory neuronopathy, motor neuron dysfunction, cerebellar ataxia or brainstem 
dysfunction suggests that these may all be different manifestations of one pathogenic 
process. However, the role of the anti-Hu antibody in causing clinical manifestations of 
PEMIPNS is unclear. Both in vivo and in vitro studies could not demonstrate a direct 
pathogenic role for the anti-Bu antibody 1.10. It is unknown why patients show major 
differences in clinical symptoms or histopathological findings regarding site of inflammation 
and IgG depositions in the central nervous system (CNS). 
One large study showed that 59% of the patients with PEMlPSN presented with sensory 
symptoms, 14% with motor weakness, 21% with cerebral symptoms, 13% with cerebellar 
dysfunction, 11 % with brainstcm dysfunction and 10% with orthostatic hypertension caused 
by autonomic nerve dysfunction II. Other clinical studies involved only small numbers of 
patients 2,12. Until now no satisfactory explanation is known for the variation in clinical 
presentation and involved areas of the CNS in PEMlPSN. 
The clinical variety of the Bu-syndrome may be caused by modulation of the immune 
response at the level of the blood brain barrier or differences in intrathecal anti_HuIJ,14. On 
Western blot analysis of the human neuronal protein extracts, the anti-Hu IgG of some 
patients primarily recognizes either the upper or the lower band of the Hu protein complex, 
These differences in reactivity of the anti-Hu antibodies may partially explain the clinical 
heterogeneity. Another possibility is that anti-Hu IgG subclasses are responsible for the 
clinical variety. In an earlier study no correlation was found between IgG subclass and 
clinical pres.entationl.5. This study, however, was carried out in a small number of patients. In 
order to find an explanation for the wide variety in clinical course and onset of the Hu-
syndrome, we examined the relationship betwcen clinical data and anti-Hu IgG subclasses. 
Patients and Methods 
Patient selection 
Ovcr a five years period more than 2500 sera of patients with a clinical SusplClOn of a 
paraneopiastic neurological syndrome were sent to our laboratory for the detection of anti-
neuronal antibodies (including anti-Hu,-Ri,-Yo). All sera were tested for anti-neuronal 
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antibodies using both the indirect immunofluorescence assay (IIF) and "'estern blot as 
described below. In total 30 patients were found positive for high titer anti-Hu antibodies (> 
1 :500 on IIF) and were selected for this study!6. 
The distribution of clinical signs and symptoms was based on (I) presenting symptoms, (2) 
spectnull of neurological disease, (3) course at onset, (4) time from onset of neurological 
symptoms to tumor diagnosis and (5) type of underlying malignancy. Furthermore, clinical 
symptoms were scored based on possible affected parts of the entire nervous system 
including sensory-, motor-, cerebral-, cerebellar-, brainstem- and autonomic dysfunction, 
when they were not caused by metastatic or iatrogenic causes. The clinical presence of 
nystagmus was scored separately. 
immunofluorescence and determination of IgG subclass 
Serum samples were drawn before anti-tumor therapy was initiated and stored at _80°C prior 
to testing. All tests were performed on one serum sample of each patient. Serological 
determinations were performed without prior knowledge of clinical data. 
As antigenic substrate human and rat cerebellar and cerebral cortex, liver and kidney were 
used. Human tissue was obtained at autopsy performed between 0-16 hours post mortem. 
Rat tissue was obtained immediately after decapitation. The indirect immunofluorescence 
assay was performed as described befores. Determination of IgG subclasses was performed 
as described below. Tissue was snap frozen in chilled isopentane and stored between _80°C 
and -120°C. Sections of 5 ~lIn were cut on a cryostate, air dried for 20 minutes at room 
temperature and fixed in cold acetone for 10 minutes. After rinsing sections one time in 
phosphate buffered saline (PBS)(pH 7.4) sections were incubated with 0.1% hydrogen 
peroxide/PBS to avoid endogenous peroxidase activity and subsequently for 20 minutes with 
PBS containing 5-10% of bovine serum albumin (BSA) in order to block non-specific bin-
ding. Next, sections were incubated with patient senun (1:100 PBS) or CSF (1:5 PBS) for 1 
hour at room temperature. After washing with PBS three times for five minutes sections 
were incubated with horseradish peroxidase (HRP) labeled rabbit anti-human pan-IgG-
F(ab)2 (1: 100)(DAKO, Glostrup, Dernnark) and a panel of HRP labeled mouse monoclonal 
antibodies against human JgG! to IgG, (1 :50) (Southern Biotechnology Associates, Inc. 
Birmingham, USA). After washing three times with PBS for 3 minutes bound IgG was 
visualized by developing the HRP with diaminobenzidine tetrahydrochloride (Sigma, 
St.Louis, USA). 
Weslern biOi 
Western blotting was essentially performed following method described by Towbin in 1979 
and slightly modified as described below17. As protein samples extracts of human and rat 
cerebellar cortical neurons and the HuD recombinant protein (obtained from H.M. Furneaux, 
Memorial Sloan-Kettering Hospital, New York, USA) were used. Protein samples were 
prepared by homogenizing frozen tissue pieces of 0.5 - 1.0 grams in a bullet homogenizer 
and dissolving the powder in PBS. After centrifugation at II.OOOg the supernatant was 
recovered and protein contents measured by an MBradford protein assay. Protein samples 
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Pat.no. MfF Age 
2 
3 
4 
5 
6 
7 
8 
9 
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II 
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29 
F 
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F 
M 
M 
F 
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M 
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F 
F 
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F 
F 
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62 
48 
59 
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65 
45 
60 
73 
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56 
59 
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Diagn. after 
onset of ncur 
symp\. in 
months 
6 
8 
3 
24 
3 
3 
24 
60 
6 
4 
o 
II 
6 
o 
78 
4 
2 
2 
4 
26 
20 
24 
II 
8 
2 
avg 11.8 
CB: cerebellar protein e,xlracl; HuD: BuD fusion protein; >1:600: ranging from 1:3200 to 1:128.000; n.k.: not known; 
n.t.f.: no tumor found; selc: small cell lung cancer; n-sclc: non small ceUlung cancer; p selc: probable small cell lung 
cancer, avg: average. Numbers at bottom indicate average or total number of posilh'cs per column. 
Clinical presentation and IgG subclasses in P E.lvUPSN 57 
Table I Clinical presentation and IgG subclasses in anti-Hu positive PEMlPSN (continued) 
Survival after 
onset of Presenting Total spectrum of neurological symptoms per patient 
neurol. symp\' Course neurological 
Pat.no. in months at onset symptoms sensory motor cerebral cerebel1ar brainstem autonomic 
still alive subacute sensor)' + + 
2 still alive subacute sensory + + + 
3 n.k. subacute motor + + 
4 6 subacute sensory + 
5 n.k. acute sensory + + 
6 n.k. acute cerebral + + 
7 36 chronic sensory + + 
8 still alive chronic sensory + + 
9 40 chronic motor + 
10 n.k. acute cerebral + 
" 
3 acute cerebellar + 
12 36 subacute autonomic + + + 
13 still aliye subacute sensory + 
14 n.k. subacute sensory + + + 
15 still alive subacute motor + 
16 still alive subacute sensory + + 
17 still alive subacute sensory + + 
18 1.5 acute cerebellar + + 
19 n.k. subacute sensory + + 
20 3.5 subacute sensory + + 
21 14 subacute cerebral + 
22 still aliye chronic motor + + + 
23 still aliye chronic sensory + + 
24 still aliye subacute sensory + + 
25 
" 
subacute cerebellar + + + 
26 10 subacute sensory + + + 
27 n.k. subacute cerebral + + 
28 24 acute sensory + + 
29 still alive subacute senso~ + + + 
20 13 7 9 4 5 
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were boiled in 1:5 Laemli's buffer (0.0625 M Tris hydrochloric acid (pH 6.8), 2% 
sodiumdodecylsulfate, 0.001% bromophenol blue and 5% 2-mercaptoethanol for 5 minutes. 
Protein samples were then separated by electrophoresis 011 a 10% SDS-polyacrylamidc gel. 
Gels were loaded with 20 ug of protein per weB or 150 ug per whole gel. After being trans-
ferred electrophoretically to Hybond nitrocellulose membrane (Amersham, Buckingham-
shire, United Kingdom), separate lanes were incubated with patient's serum in a I: 1000 
dilution. After washing, lanes were incubated with alkaline phosphatase labeled anti-human 
IgG F(ab), (DAKO). To visualize reactive bands, lanes were then incubated with developing 
substrate for 10 minutes. Molecular weight of reactive bands was estimated by comparing to 
a pre-stained protein standard (SeeBlueTh" Novex, San Diego, California). 
Results 
An overview of clinical features is given in table 1. All sera from the 29 patients with 
paraneoplastic neurological dysfunction showed characteristic anti-Hu staining pattern on 
immunofluorescence with bright staining of neuronal nuclei sparing the nucleolus and a 
diffuse fine granular staining of cytoplasm of all neurons in cerebellar and cerebral cortex. 
Titers ranged from I :800 to I :128.000 (table 1). All sera showed positive reactivity on 
\Vestern blots with the HuD recombinant protein. Four sera, all with titers less then I: 1600, 
did not show anti-Hu reactivity against the human cerebeHar cortex extract. Sixteen patients 
(55%) were female, age 45 to 73 (mean age 64.3) and 13 (45%) were men, ages 48 to 83 
(mean age 66.4). From 27 patients data were available on smoking habits and 21 patients 
(72.4%) smoked more than 5 cigarettes per day. 
Features relating to the tumor 
Fourteen patients (48%) had a SCLC including one patient with a double tumor (SCLC and 
non-SCLC). Nine of these patients had a histologically proven SCLC and five a cytological-
ly proven SCLC. Five patients (17%) had a probable SCLC, not histologically proven 
SCLC but the diagnosis was based on an X-ray or a CT-scan of the thorax. Four patients 
had a non-SCLC, including the one with the double tumor. Three patients had a breast 
cancer, of which one male. In the remaining 4 patients (14%) no tumor was found yet in 
spite of a follo\v up of 20 to 78 months. At the time the SCLC was diagnosed the tumor was 
limited to the chest in 13 (450/0) patients and metastases outside the chest were found in 6 
(21 %) patients. In 23 (79%) patients the neurological symptoms antedated the finding of the 
tumor. In 6 the symptoms coincided with the tumor diagnosis. Mean time from onset of 
neurological symptoms until diagnosis of the underlying tumor was 11.8 months ranging 
from ° to 6 years, including those patients in which no tumor had been found yet. 
Presenting symptoms 
The presenting neurological symptoms are summarized in figure 1. Sel1sOlY symptoms were 
the first complaint in 17 patients (59%), most of these complaints involved paresthesias or 
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dysaesthesias in the hands and feet. Four of these patients complained also about pain in 
hands or feet. Alotor weakness as the presenting symptom was seen in four patients (14%). 
One patient (no. 3) showed a proximal paresis of both legs with muscle wasting. Another 
patient (no. 9) had a clinical picture starting with loss of strength in both hands. 
In eight patients the clinical presentation was dominated by symptoms of disease outside the 
dorsal root ganglia or anterior horn cells. Three patients (10%) presented with complaints of 
cerebellar dysjimclion, including both axial and limb ataxia, eventually developing to a 
pancerebellar and multifocal neurologic dysfunction. Four patients (14%) presented with 
symptoms of limbic involvement including seizures, confusion and memory loss as signs of 
cortical dysfunction. One of these patients (no. 10) developed subsequently the picture of a 
full-blown encephalomyelitis including sensory neuronopathy, cerebellar ataxia and 
autonomic dysfuntion. Presentation by autonomic dysjimclion was only seen in patient no. 4 
(3%) and was characterized by a severe orthostatic hypotension. Symptoms of brail1stem 
dysjimctioll were not seen as the first presenting sign of PEMlPSN. 
Sensory Motor Cerebml Cerebellar Bminstem Autonomic 
Fig 1 Presenting symptoms in 29 patients with PEMlPSN (%). Open colunms represent 
data of the present study. Shadowed coiullms represent data from Dalmau et al. 1I 
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Spec/rum of neurological disease 
Figure 2 shows the areas of the nervous system involved that occurred during the disease. 
Seven patients (24%) showed signs and symptoms of unifocal involvement. All other 
patients developed multifocal neurologic dysfunction during the disease. Of the patients 
with unifocal involvement two patients showed cerebral dysfunction characterized by 
epileptic insults, together with confusion and memory loss, two patients motor neuron 
dysfunction characterized by muscle weakness and muscle wasting. In two patients the 
symptoms were limited to a pure sensory dysfunction and in one only cerebellar dysfunction 
was noticed. In the group of patients with multi focal involvement 14 patients had one other 
area involved. In seven patients three areas were involved. Sixteen patients had symptoms of 
a sensory neuronopathy accompanied by symptoms of involvement of other areas of the 
nervous system. The combination of sensory neuronopathy and motor weakness was seen 
eleven times. Other had cerebellar symptoms (5), cerebral/limbic symptoms (3), brainstem 
(1), or autonomic dysfunction (3). The combination of cerebellar- and brainstem dysfunc-
tion was seen three times (10%). Other combinations can be read from table I. During the 
disease in total 20 patients (69%) finally showed signs of sensOJY neuronopathy, 13 of 
motor neuron involvement (45%), 7 of limbic or cerebral cortical dysfimction (24%), 9 of 
cerebellar ataxia (31%), 4 of brainstem dysfimction (14%) and 5 of autonomic nerve 
dysfunction (17%). 
Secruory MO{or Cen:bral CecWellar Uralnslem AlIlonomic Total 
Fig 2 Number of involved areas of eNS in 29 patients with PEMlPSN (%). Shadowed 
parts represent patients with 1 area involved, open parts patients with 2 areas 
involved, and hatched parts patients with 3 or more areas involved. 
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Course at onset 
In 18 patients (62%) the onset of the neurological syndrome followed a subacute course 
with symptoms developing over a few days to weeks. For the majority there was a rather 
rapid progression in the first period of disease followed by a more slow progression 
followed by stabilization in the months following. Most patients with a subacute course had 
progressive complaints of sensory disturbances as presenting symptoms. 
A more acute course at onset was seen in six patients (20%). Two of these patients 
presented with seizures, two with rapidly progressing dysesthesia and pain and two others 
with an acute onset of gait ataxia. 
A more chronic progressive course of the neurological disorder was seen in five patients 
(17%), involving three patients with sensory complaints and two with motor neuron 
dysfunction. 
IgG sllbclasses 
Anti-Hu antibodies of IgG I subclass were present in 25 (86%) cases, IgG, in 14 (48%), IgG) 
in 7 (24%) and IgG, in 4 (14%) cases (table I). Seven patients showed IgG I reactivity only. 
o Two patients showed only IgG2 reactivity and one patient had only IgG-t reactivity. 
The combination of IgG] and IgG2 was seen in eight patients, IgG] and IgG) in five patients 
and two patients showed reactivity of IgG], IgG2 and IgG)' Two other patients had IgG], 
IgG, and IgG, reactivity. Only one patient showed IgG I and IgG, reactivity. For patient 
number 9 it was not possible to determine the anti~Hu IgG subclass(es). 
Cerebrospinal fluid was positive for anti-Hu antibodies in four of the six patients from 
whom it was available (data not shown). The anti~Hu antibodies in the CSF of three patients 
(no. 4,17,25) were of the same IgG subtype as in the serum, although IgGI could not be 
demonstrated in the CSF of patient number 4. Anti-Hll IgG, and IgG, were found in the 
CSF of patient number 13, while the serum showed IgG] reactivity only. 
Correlation beh,'een IgG subclasses and clinical presentation 
The only statistically significant correlation that could be found, indicated that a unifocal 
involvement was associated with the lack of IgG] antibodies. Three of the seven patients 
with only unifocal involvement had no IgG] antibodies, compared to lout of 21 patients 
with multifocal involvement (p=O.O I )). No further statistically significant correlation was 
found between the anti-Hu IgG subclass and items OIl which clinical presentation was scored 
when arranged in two by two contigency tabels using Pearson's chi2 or Fisher's two tailed 
exact test. 
Discussion 
In 1965 Henson and Urich introduced the term encephalomyelitis in patients with cancer 
who showed signs of damage in different parts of the nervous system]8. In post mortem 
studies they recognized the variable distribution of inflammatory sites in the central nervous 
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system or dorsal root ganglia that could occur alone or concomitantly. In 1982 they 
reviewed 69 patients with PEMlPSN and recognized that the dorsal root ganglion was the 
most frequently involved area of inflanuuation and SCLC the most common type of 
malignancyl9, 
Since the detection of the anti-Hu antibody in patients with a paraneopiastic neurological 
syndrome presenting with a variety of clinical signs of limbic encephalitis, sensory 
ncuronopathy, motor neuron dysfunction, cerebellar ataxia or brainstem dysfunction it was 
suggested that these symptoms may all be different manifestations of one common patho-
genic process. Consequently the term "Hu-syndrome" has been applied as a diagnostic entity 
to this group of symptoms next to the term PEMlPSN ll • 
There is only one larger series of 71 patients reported on the Hu-syndrorne ll , Other descrip-
tions can only be found in case-reports or series of less than 20 patients. 
Vle report a second large series 011 the clinical spectrum of 29 patients with PEMlPSN and 
studied the relation between anti-Hu IgG subclass and variability in clinical course and 
presentation. 
Patient selection and anti-flu detection 
Scra in our study were considered to be anti-Hu positive when both the results of IIF and 
Western blot were positive20• The sera of three patients did not react with the Hu complex in 
human cerebellar extract, but did react with the HuD recombinant protein. These observa-
tions illustrate the importance of using the recombinant protein in the detection of the anti-
Hu antibody2-I,22. Earlier studies showed the importance of using both immunohistochemistry 
and Western blot, which has been adopted in a recent consensus report on guidelines for the 
proper detection and interpretation of paraneoplastic anti-neuronal antibodies20, 
Tumor type 
In the majority of patients studied here the underlying tumor was SCLC (66%), a similar 
percentage to what others have found (77.5%)11, The tumor usually remains localized to the 
chest with limited metastatic spread, In our study. SCLC was limited to the chest in 13 
(45%) patients. Earlier reports found limited disease in 96% of PEMlPSN patients with 
SCLC at the time of diagnosis. They hypothesized that the anti-Hu immune response may 
be effective in tumor growth control. Our data do not support this hypothesis, and are in 
agreement with data for SCLC in anti-Hu negative patients (limited disease in 42%)23. 
However, some patients have been in complete remission for more than 6 years after 
diagnosis. 
We identified 4 (14%) patients in whom no tumor was found after a follow up of 20 to 78 
months. In some paticnts the tumor was identified only aftcr a long period of follow up. For 
exam pic, in patient number 7 the tumor was found two years after onset of symptoms. In 
our study as well as in that of Dalmau et a!. some tumors were only detccted at autopsyll, 
\Vc would advise regular screening of every patient with no tumor at presentation, as this 
may lead to the detection of the tumor up to several years later. 
Many other tumor types have been reported to be associated with PEMfPSN including: 
breast, ovarian. endometrial, gastric and testicular cancer, synovioma, Hodgkin's disease 
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and undifferentiated or anaplastic carcinoma of the bronclmsIl. Most of these cases, 
however, did not harbor the anti-Hu antibody. Tumors other than SCLC, found in anti-Hu 
positive PEMlPSN have been found to express the Hu antigen (prostate carcinoma, adrenal 
carcinoma, chondromyxosarcoma, adenocarcinoma of the lung and neuroblastoma) mostly 
in individual cases, Next to SCLC, four patients had non-SCLC, including one with a 
double tumor (SCLC and non-SCLC). Interestingly, we observed three patients with breast 
cancer and anti-Hu antibodies, Breast cancer has been reported before in patients with 
PEMlPSN, however, not in association with anti-Hu antibodies. \V11ether breast cancer can 
express the Hu antigen is not known. Another possibility may be that these patients had an 
as yet not identified SCLC next to breast cancer. 
Neurological findings 
In 23 patients (79%) neurological symptoms antedated and in 6 the symptoms coincided 
with tumor diagnosis, The rnean time from onset of neurological symptoms until diagnosis 
of the underlying tumor was 11.8 months ranging from 0 to 6 years. 
In our study, 7 patients (24%) showed unifocal involvement, 48% had two areas involved 
and in 24% three areas were involved. Dalman et al. found 20% with unifocal involvement, 
39% with two areas of involvement and 54% with multifocal involvement. There seems to 
be no major difference in the clinical spectrum between our series and that of Dalmau et al. 
(fig I)". 
IgG sl/be/asses 
Jean et al. described nine patients with anti-Hu antibodies subdivided in IgG subclasses. All 
patients had IgG J antibodies, 5 IgG" 4 IgG, and none had IgG,. All IgG bound to neurons 
was of the Ig01 subclass. They found no correlation between the specific IgG subclass and 
neurological symptoms. They found no clear evidence that anti-Hu of different IgG 
subclasses recognized different epitopes limited to different brain regions. In another study, 
IgG4 was, although in low titers, identified in serum of four patients15 • The frequent 
presence of IgG J and IgG, calmot simply be explained by the fact that IgG J and IgG, 
represent 65% and 23%, respectively, of the total amount of Ig0 in serum in general. The 
anti-Bu IgG1 and IgG2 are clearly present in excess compared to the normal distribution. 
The predominance of anti-Hu IgG, suggests that fixation of complement and antibody-
dependent cell-mediated cytotoxicity (ADCC) probably playa role in the immune response 
against the tumor and the nervous system. 
The reason for this remains unclear although one may speculate that IgG1 may pass the the 
blood brain barrier more easily. This may also explain why patients without IgG1 have more 
often multiple areas of 'the CNS involved as is indicated by the finding that patients with 
IgG1 have a statistically significant higher percentage of multifocal involvement. 
In a direct immunohistochemical autopsy study, Graus et al. did not identify natural killer 
(NK) cells or deposits of complement in the nervous system of a patient with PEMlPSN, 
indicating that the ADCC mediated by NK cells and complement mediated cytotoxicity 
plays no or only a minor causative role in the damaging of neurons24• However, small 
amounts of complement have been observed in a few areas of the nervous system of four 
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anti-Hu positive patientslS , IgG4• if present, may playa protective role by masking the 
epitopes to prevent binding of the pathogenic, complement binding IgG, 15. In our study the 
one patient that harboured JgG, antibodies had also JgG J antibodies. As he suffered from 
both sensory neuronopathy and cerebellar ataxia, tIllS suggests that IgG4, at least in his case, 
seems not to prevent damage of multiple areas of the eNS. 
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5 Serum from four patients with 
paraneoplastic encephalomyelitis/ 
sensory neuronopathy (PEM/PSN) identifies a 
novel 60-64 kD protein in neurons and 
small cell lung cancer* 
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Rotten/am, The Netherlands 
Abstmct 
Serum of four patients with paraneoplastic encephalomyelitis/sensory neuronopathy 
contained a novel anti-neuronal antibody, designated anti-St. Anti-St recognizes a 60-64 kD 
molecular weight cytoplasmic protein complex in neurons of cerebellar and cerebral cortex. 
Indirect immunofluorescence studies showed diffuse homogeneous cytoplasmic staining of 
allllcurons in cerebral and cerebellar cortex and in small cell lung cancer cell lines. 
In three of the four patients the underlying malignancy was a small cell lung cancer. In the 
fourth patient no tumor was detected. The anti-St antibody was not found in control sera, 
including sera of 52 patients with cancer with neurological complications of non-
paraneopiastic nature, 98 cancer patients without neurological complications, 51 patients 
with immune m.ediated neurological disease without cancer and 50 healthy controls. 
We conclude that next to the anti-Hu antibodies, anti-St seems another specific anti-neuronal 
antibody associated with paraneoplastic encephalomyelitis/sensory neuronopathy and small 
cell lung cancer. 
* Presented in abstract at the 47th Annltal meeting the American Academy of Nellrolog}: April 1995. 
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Introduction 
Patients with a clinically suspected paraneoplastic encephalomyelitis or sensory neuronopa-
thy (PEMlPSN) harbour anti-Hu antibodies in 38-50% of cases"'. This antibody was first 
described by Oraus ct al. in patients with sensory neuronopathy and small cel1 lung cancer 
(SCLC)'. Since then the detection of the anti-Hu antibody in patients with SCLC and 
encephalomyelitis, sensory neuronopathy or autonomic neuronopathy has lead to the 
suggestion that these clinical syndromes arc different manifestations of one underlying 
process7-9, 
Previous studies have shown that the neurological symptoms can antedate the detection of 
the underlying malignancy in 70-80% of cases with PEMlPSN by several months to 
years9,JO,lI, The detection of the anti-Hu antibody precedes the diagnosis of the tumor in 60% 
and serves as a specific diagnostic marker for the presence of SCLC I ,9. In one series of 71 
patients, 78% of anti-Hu positive cases harboured a SCLC9• In 10% other tumors were 
present and in 13% no tumor could be found, The presence of the anti-Hu antibody seems to 
counteract tumor progression and even spontaneous regression of SCLC has been reported12 , 
Only 4% of patients had metastasis outside the chest at time of diagnosis9• 
As in other paraneoplastic neurological syndromes (PNS), including paraneoplastic cere-
bellar degeneration (PCD) (associated with anti-yo antibodies and gynaecological can-
cers)13,14 and opsoclonus-myoclonus syndrome (associated with anti-Ri antibodies and breast 
cancer)15,16 a commonly stated hypothesis says that the immune response is initiated by 
expression of neuronal antigens by the tumor subsequently cross-reacting with similar 
antigens in the CNS 11.19, Darnell et al. have suggested that this immune response may be 
effective in tumor growth control of the underlying malignancy20, However, until now, 
neither in vivo nor in vitro experiments have lead to direct evidence for a pathogenic or 
immune modulating role of anti-Hu or other antibodies20•24 , 
In spite of the specific association between anti-Hu related PEMlPSN and SCLC, 38-50% of 
patients with a clinical picture of PEMlPSN do not harbour anti-Hu antibodiess. Some 
studies, mostly consisting of individual case-reports, indicate that other as yet not charac-
terized anti-neuronal antibodies can be found in some of these serologically negative PEM 
patients5,H.26, Others were unable to detect any other antibody reactivity in patients with 
PEM and SCLC'. These differences might be explained by the heterogeneity of patients and 
the possible nature of the antigen. It may well be that not all antigens can be detected by 
routine immunohistochemical or Western blot assays, Methods of fixation can greatly 
influence the antigenic epitopes and thus interfere with antibody detection25. 
In this paper we report four patients with PEM and SCLC in whom a novel anti-neuronal 
antibody against a 60-64kD neuronal antigen complex was detected by indirect immunofluo-
rescence (IIF) and Western blot. 
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Material and Methods 
Patient selection 
Over the past five years more than 2000 sera of patients from our institution and from 
physicians throughout The Netherlands and Belgium, with a clinical suspicion of a paraneo M 
plastic neurological syndrome were sent to our laboratory for the detection of antiRneuronal 
antibodies associated with PNS. 
Sera were screened for the presence of antiMneuronal antibodies by lIP. Anti-neuronal 
antibody detection was performed using the IIF and \Vestern blotting technique essentially as 
described before l1,28 and slightly modified as described here. Scra showing positive antibody 
reactivity on the IIF assay, regardless of the staining pattern, were tested for antibodies by 
Western blotting. 
As controls were used sera of 52 patients with cancer with neurological complications of 
l1on-paraneopiastic origin, 98 cancer patients without neurological complications, 71 patients 
with immune mediated neurological disease without cancer (multiple sclerosis, myasthenia 
gravis and chronic inflammatory demyelinating polyneuropathy) and 50 healthy controls. 
Anti-nell/vnal antibody testing 
Tissue substrates and seLe: As tissue-substrate, sections of human and rat central nervous 
system were used including cerebellar and cerebral cortex, dorsal root ganglia and spinal 
cord. Control tissue sections of liver and kidney and Hep-2 cells (Inova, St. Lonis, USA) 
were used. Normal human neuronal tissue was obtained at autopsy within 6 hours after 
death, through the Netherlands Brain Bank (Amsterdam) from individuals withont neurologi-
cal disease. Rat tissue was obtained immediately after decapitation. Both human and rat 
tissues-were snap frozen in chilled isopentane and stored between -80 DC and _l20De before 
use. Aceton fixed cytospins of the GLC8-SCLC cell-line were used for determination of 
antibody reactivity against SCLC on lIP. 
Immunofluorescence assay: Cytospins and sections of 5-7 J..tm were cut on a cryostate, air 
dried for 20 minutes at room temperature and fixed in cold acetone for 10 minutes. Tissue 
sections were incubated with 5% bovine serum albumin (BSA) in phosphate buffered saline, 
pH 7.4 (PBS) for one hour to block non-specific binding. Subsequently sections were 
incubated with patients sera in dilutions from I: 100 to I :6400 in PBS. After washing, 
sections were incubated with FITC-labeled anti-human IgG-F(ab), (1:40 PBS, DAKO, 
Glostrup, Denmark) for one hour. After washing sections were mounted with PBS/Glycerol 
(l :6) and read under a fluorescence microscope. 
Western bloffing: \Vestern blotting was essentially performed following methods as descri-
bed below·. Protein samples of cerebellar cortex and liver were prepared by homogenizing 
0.5-1.0 gram of frozen tissue in a bullet homogenizer and dissolving the resulting powder in 
PBS. After centrifugation at 11000 g for 10 min the supernatant was recovered and protein 
contents measured by an MBradford protein assay. Protein samples were boiled in 1:5 
Laemli's buffer (0.0625 M Tris-hydrochloric acid (pH 6.8), 2% sodium dodecyl sulfate, 
0.00 I % bromophenol blue and 5% 2-Jl-mercaptoethanol) for 5 minutes. Protein samples 
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were then separated by electrophoresis on a 10% SDS-polyacryJamide geL Gels were loaded 
with 20 fIg of protein per well or 150 fIg per whole gel. After being transferred 
electrophoretic ally to Hybond nitrocellulose membrane (Amcrsham, Buckinghamshire, 
United Kingdom), separate lanes were incubated with patient's serum in a I: 1000 dilution. 
After washing. Janes were incubated with alkaline phosphatase labeled anti-human IgG 
F(ab), (DAKO). 
To visualize reactive bands, lanes were then incubated with developing substrate (5-brorno-
4-chloro-3-indolyl-phosphate and nitroblue-tetrazolium (Bio-Rad, Hercules, California) in 
developing buffer (100mM TrisIHCI, 100mM NaCI, 5 mM MgCI, pH 9.5) for 10-30 
minutes. Molecular weight of reactive hands was estimated using a prestained protein sample 
(Bio-Rad) as reference. Reactivity was scored positive when distinct hands were visible in 
neuronal extracts and not seen on liver extracts. 
Control assays for ~)Istemic autoantibodies 
In order to exclude false positive reactivity or cross-reactivity, all sera showing reactivity in 
one of the assays were tested for the presence of systemic autoantibodies (ANA, ANCA, 
anti-SSA, anti-SSB, RNp, Sm, Sc170, Jol, IgM and IgA rheumatic factor, anti-mitochondri-
al, anti-parietal cell, anti-smooth muscle, anti-thyroglobulin and microsomal antibodies) 
using standardized routine assays as described before2~. Positive reference sera against ANA, 
ANCA, SS-A, SS-B, RNP, Sc170, Sm and mitochondria were tested in both IlF and Western 
blot assay in order to determine reactivity patterns of these antisera against neuronal sections 
and protein extracts. 
Results 
Of all patients, 55 showed a characteristic clinical diagnosis of PEMlPSN. In sera of 30 
patients anti-Hu antibodies were detected. In twelve anti-Hu positive patients small cell lung 
cancer was diagnosed at onset of neurological symptoms. In the anti-Btl negative group 68 
patients had SCLC. In four of these patients, of whom three had SCLC, an antibody was 
found against a 60-64 kD reactive protein complex on Western blot (fig I, appendix and 
table I). Clinical features of the anti-Hu positive patients are described elsewhere (see 
chapter 6). 
Anti-Sf reactivity 
Immullofluorescence: On IIF, the antibody yielded a t1int diffuse staining of the cytoplasm 
of all neurons on sections of cerebellar and cerebral cortex. Both Purkinje celis, granular 
layer cells and cerebral cortical neurons stained equally intensive in a homogeneous pattern, 
clearly different from anti-Yo cytoplasmic staining (figs 2a and 2b, appendix). The cyto-
plasm of dorsal root ganglia neurons (fig 2c, appendix) and motor neurons stained in an 
identical pattern. There was a low level of diffuse staining throughout the grey matter in 
sections of cerebellar and cerebral cortex. The antibody was of IgG isotype and present in 
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Table 1 Clinical and serological data in four patients harbouring antj~St antibodies 
Tumor Serological 
Patient no. diagnosis Isotype reactivity in 
M/F and Neurological in months and titer Ancillary IIF and 
age symptoms Course Tumor after onset ofAb investigations Western blot 
I. M 65 Cerebellar Subacute, SCLC 0 IgG CT nonnal Cytoplasmic, 
syndrome stabilized >1:800 CSF !lomla! all neurons; 
60-64 kD 
2. M64 Sensory Subacute, SCLC 6 IgG CT nonnal Cytoplasmic, 
neuronopathy slowly >1:800 CSF protein t all neurons; 
and encephalo- progressive IgG t 60-64 kD 
myelitis 
3. F 80 Sensory Slowly SCLC 12 IgG CTnomlal C)1opiasmic, 
neuronopathy progressive >1:3200 CSF 110nnal all neurons; 
and limbic 60-64 kD 
encephalitis 
4. F 69 Limbic ence- Subacute, no IgG CT nomIaI C}1oplasmic, 
phalitis slowly tumor >1:1600 CSF not done all neurons; 
progressive 60-64 kD 
liters from 1:800 to 1:3200 maximally whenlilrated in the IIF assay (Iable I). In two sera 
also anti-nuclear antibodies were present when tested on both neuronal and liver tissue and 
Ihe Hep-2 assay (patienl 3 and 4). Sera of palient I and 2 yielded no reaclivity on conirol 
tissue. This antibody reactivity was seen in none of the control sera. The serum of patient 1 
was tested on cytospin preparations of the SCLC-cell line GCL8 resulting in a fine granular 
cytoplasmic staining, indicating that the antigenic epitopes are present in SCLC also (fig 2d, 
appendix). 
Anti-St reactivity 
Western blots: Reactivity of anti-St antibody on Western blots of extracts of human and rat 
cerebellar and cerebral cortex is shown in fig 1, appendix. A protein complex of 60-64 kD 
was identified by all four sera. The complex consisted of four separate bands of which the 
lower sharp band showed strongest reactivity in all four sera. The middle band was stronger 
than Ihe upper and third band which yielded a weaker diffuse slaining. 
The protein complex in the rat cerebellar extracts comigrated with that in the human extracts 
but yielded a stronger (fig I, appendix) more diffuse reaclivity of Ihe upper and third band. 
The complex was not identified in control extracts of rat and human liver. No inlOlUnore-
activity against this complex was seen using normal human sera and sera of the control 
groups. 
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Description of clinical findings 
Case 1 
A 65-year-old man with mild diabetic retinopathy developed severe cerebellar ataxia over a 
two days period, resulting in impossibility of walking or of eating independently. He experi-
enced no dizzines or dysarthria. On neurological examination there was a horizontal 
nystagmus to the right. Strength ,vas normal and sensory examination revealed hypoaesthesia 
of the distal extremities with asymmetrically lowered tendon-reflexes in the upper extremi-
ties and loss of tendon-reflexes in the lower extremities. There were no signs of cognition 
defects. A CT scan of the brain revealed no abnormalities. CSF examination showed normal 
cell counts, protein level and IgG index without signs of malignant cells. Serum anti-Hu 
antibodies were negative. On evaluation a SCLC was found four weeks after onset of 
neurological symptoms. The patient had been smoking cigarettes for over 30 years. A 
presumptive diagnosis of paraneoplastic cerebellar syndrome was made. 
Case 2 
A 64-year-old man suffered from paraesthesias and burning feet, increasing over a period of 
two-three weeks. After six weeks he experienced weakness in his legs and difficulties in 
walking. He had problems with bowel movements and suffered from hiccups. He had a dry 
mouth. Complaints of double vision, slurred speech and difficulties swallowing developed 
two months later. On neurological examination we observed an alert, healthy looking patient 
with intact cognition. There was mild distal sensory loss with disturbed pin-prick sensation 
and two-points discrimination. A moderate weakness of the extremities with preserved 
tendon-reflexes was found. There was moderate limb ataxia. 
Examination of the CSF showed 'llild pleocytosis and increased IgG index. CT-scan of the 
brain and EEG showed no abnormalities. EMG examination revealed a mild axonal sensory 
polyneuropathy. Work-up for cancer resulted in a diagnosis of SCLC with multiple metasta-
ses in liver and mediastinum without malignant infiltration of the central nervous system. 
two months after onset of neurological symptoms. Anti-Hu antibodies in serum could not be 
detected. A presumptive diagnosis of paraneoplastic sensory neuronopathy and encepha-
lomyelitis with brainstem. autonomic and motor involvement was made. 
Case 3 
This patient was an SO-year-old female with an unremarkable history. She developed 
progressive sensory loss over a period of one year with mild signs of organic brain syn-
drome, including disorientation in time, place and loss of short memory and cognition. There 
was no loss of strength with preservation of tendon reflexes. Clear hypoaesthesia of the 
lower limbs was found with disturbed pin-prick sensation and loss of vibration sense. 
Further examination revealed a SCLC one year after onset of neurological symptoms. A 
presumptive diagnosis of paraneopastic encephalomyelitis/sensory neuronopathy was made. 
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Case 4 
A 69-year-old female with an otherwise unremarkable history developed signs of a severe 
organic brain syndrome over a six months period. There was severe loss of short memory 
functions and disorientation in time, place and person. Her relatives indicated that she could 
not be left alone since she would leave the gas turned on and ran out of the house leaving 
the doors open. 
Further neurological examination revealed no signs of motor or sensory involvement. There 
was a clear loss of cognition. Ancillary investigations showed normal findings on CT-scan 
of the brain and norm.al CSF findings. Extensive search for an occult tumor did not reveal 
any tumor. She smoked 10-15 cigarettes a day. A presumptive diagnosis of paraneopiastic 
limbic encephalitis was made. 
Discussion 
\Ve found a novel anti-neuronal antibody in four patients with a clinical picture of PEMlPSN 
of whom three harboured SCLC. The antibody was designated anti-St after the initials of the 
first patient. The anti-St antibody recognized a 60-64 kD cytoplasmic neuronal protein 
complex expressed in cerebellar, cerebral, dorsal root ganglion and motor neurons. At lIF 
the antibody recognized a diffusely expressed antigen which was present on virtually all 
neurons examined. 
The serum of one of the patients recognized a cytoplasmic antigen in a SCLC cell line, 
indicating that the antigen was expressed by SCLC cells. However, this is no definite proof 
that this is an identical antigen as expressed by neurons, also because the reactive antigen in 
SCLC seems to be expressed in a more granular way than in neurons. Nonetheless, our data 
suggest that the anti-St sera recognize neuroectodermal antigens distinct from those 
described previously2S. Since the anti-St antibody reactivity was neither found in sera of both 
normal and cancer groups nor in sera of patients with other neurological disease, this 
suggests that anti-St is a novel marker for PEMlPSN in patients who are anti-Hu antibody 
negative. 
The low frequency and the diffuse staining pattern seen on lIF using frozen aceton fixed 
tissue substrates, may be the reason why this antibody reactivity has not been recognized 
before. Also the diffuse type of lIP staining together with the presence of other non-organ 
specific autoantibodies may have interfered with IIF recognition of the anti-St antibody. 
Recently both organ- and non-organ-specific antibodies have been identified in patients with 
other PNS, suggesting a genetic susceptibility of these SCLC patients to develop autoim-
mune reactivity29. The importance of appropriate methods of tissue-fixation and preparation 
of protein samples for "'estern blots, in order to identify novel antibodies or antigens 
involved in PNS has been recognized2s.27, Recently PNS with novel anti-neuronal antibodies 
have been reported2S.27,30. 
Darnell et al. identified antibody reactivity (anti-Nd) in one patient with cerebellar degenera-
tion that reacted with a 150 kD protein expressed in Purkinje celis, cerebral neurons and 
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neuro-ectodermal tumors27, In their patient, however, no tumor could be detected. Antoine et 
al. identified antibody reactivity against 45, 60, 70 and 135 kD neuronal proteins in a patient 
with paraneoplastic encephalomyelitis, posterior uveitis and undifferentiated carcinoma. 
Nenmi et al. reported anti-neuronal cytoplasmic antibody reactivity against a 62 kD 
cytoplasmic neuronal protein in patients with chronic sensory neuropathy without cance~o. 
\Vhen compared to the St antibody, the serum of the patient described by Antoine et al. 
showed a comparable but not identical immunohistochemical reactivity. The reactive bands 
on Western blot were of different molecular weight (57, 68 and 135 kD towards 60-64 ill in 
our patients) and their patient suffered from PEM in the presence of undifferentiated 
carcinoma25 • The differences in antibody reactivity and molecular weights of reactive 
proteins may be due to differences in fixation methods (paraformaldehyde perfusion on 
paraffin sections versus aceton fixation on frozen sections). However, it seems more likely 
that this antibody recognized different neuronal antigens. The antibody described by Nemni 
et al. seems to recognize another neuronal antigen (personal communication) and is not 
associated with cancer. 
The clinical picture of the patients described by us largely resembles the clinical picture of 
anti-Hu positive PEMlPSN and shows a similar variation. However, the onset of neurologi-
cal symptoms in our four patients seems more protracted and less severe as compared to 
anti-Hu positive patients. 
One patient presented with cerebellar symptoms, two with sensory signs and one with mental 
changes. In anti-Hu positive PEM/PSN, 59% present with isolated sensory symptoms and 
21% with mental changes. Motor weakness is the presenting symptom in 14% and cerebellar 
symptoms in 13% of anti-Hu positive patients9• 
Except for patient no. I with a subacute cerebellar syndrome, the other three showed slowly 
progressive development of neurological symptoms over several months to one year. In anti-
Hu positive patients, presentation of neurological symptoms is usually acute to subacute, 
with severe symptoms developing over a period of one night to two weeks, followed by slow 
progression over the next months. However, recently more indolent courses of anti-Hu 
positive PSN have been reported with moderate sensory loss developing over one or two 
yearsJ1 ,)2 • 
Another difference of our patients as compared to anti-Hu positive PEMlPSN concerns the 
nature of the underlying tumor. In 83% of anti-Hu positive PEMlPSN, neurological 
symptoms appear before a tumor diagnosis has been made and progression of neurological 
symptoms is often more severe than tumor-progression. Dalmau et aI., Manley et al. and 
Delattre et al. have indicated that anti-Bu positive patients with SCLC have a better tumor 
survival than patients with SCLC without anti-Hu antibodies lO,19,33. Although the median 
survival of both groups was not different, 6&% anti-Hu positive patients had a tumor too 
small or localized to cause death, indicating that anti-Hu antibodies may be effective in 
tumor-growth control. 
In our patients progression of the tumor was the main cause of death. This suggests that the 
anti-St immune response may not be as effective in tumor-growth control as the anti-Hu 
inullune response, Obviously the number of patients with the anti-St antibody is small yet 
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and data on a possible role in the pathogenesis or in tUlllo[wgrowth control by the antibody or 
anti-St reactive 1:'cells are scarce, 
The pathogenic role of the anti-St antibody in the development of PNS remains to be 
established. This however, also holds for the other known paraneoplastic antibodies, like 
anti-Hu, anti-yo and anti-Rio As yet it has not been possible to demonstrate a definite 
pathogenic role for these antibodies, both in vivo and in vitro. A strict correlation between 
affected areas of the eNS in PNS patients and those neurons reactive with the associated 
anti-neuronal antibody is not always clear. 
From a neurological point of view the paraneoplastic antibodies have led to remarkable 
findings. The antigens identified by the paraneoplastic antibodies play key roles in the 
development and differentiation of neurons, Most of the analysed antigens have. RNA 
binding capacities. For the Hu antigen it has been suggested that it may be involved in 
oncogenesis. The Btl binds to Ihe AU-rich elemenls of mRNA of c-myc, c-fos and OM-CSF, 
all proteins that regulate cell proliferation)), These findings stress the importance of the 
nature of the identified antigens involved in PNS. They support the hypothesis th{lt antigens 
associated with autoimmune diseases are evolutionary conserved antigens playing key-roles 
in cell differentiation and maintenance)), 
Although the St antigen has only been partially characterized so far, further research on the 
exact structure of the St antigen is warranted and may lead to identification of another novel 
protein that is potentially important for neural and tumor development. 
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Abstract 
Background. Detection of anti-Hu, ·Yo, -Ri antibodies serves as highly specific diagnostic 
markers for paraneoplastic neurological syndromes. The sensitivity is limited, and this implies 
that many sera of patients with a paraneoplastic neurological syndrome remain antibody-
negative. Some studies have indicated that other as yet incompletely characterized antibodies 
may be found in patients with paraneoplastic neurological disease. We perfonned a systematical 
study to determine the nature and potential diagnostic value of newly identified anti~neuronal 
antibodies. 
A1etllOds. We examined sera from 1600 patients suspected of paraneoplastic neurological disease 
and a total of 221 sera from four control~groups on the presence of anti~neuronal specific 
antibodies. Sera were screened by an indirect immunofluorescence assay, \Vestern blots of 
neuronal protein extracts and in other routine autoantibody assays. 
Results. \Ve found autoantibodies in 18% (28711600) patients. Systemic autoantibodies were 
identified in 6.4% of sera tested and in 7.3% of patients a range of other autoantibodies, often of 
low titer. Anti~neuronal antibodies were detected in 67 (4.2%) of patients. Forty~six (2.8%) 
patients had one of the well known paraneoplastic antibodies. In 21 patients, 5 newly identified 
anti~neuronal antibodies could be identified. An anti-60-64 kD antibody staining neuronal 
cytoplasm, was detected in 4 patients with paraneoplastic disease of whom 3 suffered from 
small-cell lung carcinoma. An anti 55 kD antibody showed a nuclear neuronal staining pattern in 
4 neurological patients harboring a urogenital tumor. An anti-37 kD antibody reacting with all 
neuronal nuclei was identified in 7 patients with a variety of tumors and severe neurological 
complications. Of two other newly identified anti-neuronal antibodies, one (anti-21 0 kD) showed 
less consistent associated paraneoplastic features and of one (anti~40-200 kD) the nature of the 
antigen is uncertain. 
Conclusions. This study shows the spectrum of autoantibodies that may be encountered in 
paraneoplastic neurological disease. Systemic antibodies were found in a relatively high 
percentage. Apart from anti~Hu, we identified novel anti-neuronal antibodies associated with 
paraneoplastic disease. A specific anti~neuronal 60-64 kD antibody associated with paraneo~ 
plastic neurological disease in small cell lung cancer. A 55 kD antibody was found to be 
associated with urogenital cancers, and a 37 kD antibody with a variety of cancers. 
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Introduction 
Paraneoplastic neurological syndromes (PNS) consist of a variety of clinical neurological 
disorders that include: paraneoplastic encephalomyelitis (PEM), paraneoplastic sensory 
neuronopathy (PSN), paraneoplastic cerebellar degeneration (PCD), opsoclonus-myoclonus 
syndrome, and Lambert-Eaton myasthenic syndrome (LEMS)'"J. In 80% of PNS, the 
neurological symptoms antedate the detection of the underlying malignancy and frequently 
the progression of the tumor is slower than commonly seen in these patientsH , 
Although the etiology of most PNS is unknown, it may be explained by an autoimmune 
response against similar antigens or epitopes shared by the tumor and the nervous system. 
Specific anti-neuronal antibodies, reacting with both neuronal and tumor antigens, have been 
recognized (table 1)'·13. In the Hu-syndrome (PEMfPSN) and in LEMS, both associated with 
small cell lung cancer (SCLC), antibodies against the Hu antigen and voltage-gated calcium 
channels (VOCC) have been identified5,7,'-l. Another example is PCD associated with 
gynaecological tumors in which antibodies can be found against the cytoplasm of Purkinje 
cells, designated anti-YoI5,16. In the opsoclonus-myoclonus syndrome associated with breast 
cancer, anti-Ri antibodies have been identified ll , The presence of these anti-neuronal 
antibodies serves as a highly specific marker for a diagnosis of PNS and leads frequently to 
detection of the underlying tumorl7 • 
Next to their diagnostic value, PNS-associated antibodies have led to the detection of "onco-
neural ll antigens, which may play key roles in the regulation of gene expression or mRNA 
processing and thus in cell maintenance and proliferationI8•22 • 
Despite their specificity, the limited diagnostic sensitivity of the antibodies implies that 
many patients with PNS are antibody negative I'. In almost 50% ofPEMfPSN and SCLC, no 
anti-Hu antibodies can be identified. Some studies indicated that other as yet not well 
characterized antibodies can be found in sera of patients with PNS23-28• Others, however, 
were unable to detect a non-Hu antibody reactivity in PEMlPSN and SCLC29,30. \Ve 
performed a systematical study on sera of 1600 patients to determine the existence and 
nature of newly identifiable anti-neuronal antibodies in PNS. 
Patient and Methods 
Patient Selection 
Over the past five years more than 2500 sera of patients with a clinical suspicion of PNS 
were sent to our laboratory for the detection of anti-neuronal antibodies: anti-Bu, -Ri, -Yo 
and anti-Purkinje cell antibodies. From 1600 patients sufficient neurological and oncological 
data were available to be selected for this study. 
Suspicion on PNS was scored in three grades based on clinical data. Grade I: no suspicion; 
grade 2: possible PNS; and grade 3: clinically definite PNS. Patients had grade I when at the 
time of testing no tumor was diagnosed and neurological symptoms were not characteristic 
for PNS, or could well be explained by another cause. Grade I was also applied to patients 
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with a known tumor but in whom brain metastasis or therapy-induced neurological symp-
toms were present. Grade 2 was designated to patients suffering from a characteristic 
paraneoplastic neurological syndrome (e.g. encephalomyelitisllimbic encephalitis, sensory 
neuronopathy, sensory-motor neuropathy, cerebellar ataxia, bulbar encephalitis, opsoclonus-
myoclonus syndrome or a combination of these), in whom no tumor was known at the time 
of testing and for whom no other satisfatory cause could be given. Patients with character-
istic paraneoplastic neurological symptoms without other satisfactory explanation and with a 
known tumor at time of testing were scored as grade 3. All patients with either grade 2 or 3 
were selected for this study. Also all sera showing anti-neuronal specific antibody reactivity 
on the indirect immunofluorescence (lIF) assay were selected for this study, regardless of 
grade of suspicion. 
As controls (table 2 A), four groups were selected: sera of 52 patients with cancer with 
neurological complications (like brain metastasis or therapy-induced neurotoxicity) but no 
PNS, 98 cancer patients without neurological complications, 51 patients with other inunune-
mediated neurological disease (multiple sclerosis, myasthenia gravis) without cancer and 20 
healthy controls. 
Screening-assay 
Sera of all 1600 patients were screened for the presence of anti-neuronal antibodies by the 
IIF as described previouslyl7,JI and in short below. Sera of patients with grade 2 or 3, and 
those positive on the first IIF assay were tested for anti-neuronal antibodies by IIF assay and 
by Western blotting on neuronal protein extracts. 
Anti-neuronal antibody testing 
As tissue-substrates for the I1F assay sections of human and rat cerebral and cerebellar 
cortex were used. As control tissue sections of liver, muscle and kidney were used. Human 
tissue was obtained at autopsy performed between 0-16 hours post mortem. Rat tissue was 
obtained immediately after decapitation. Tissues were snap frozen in chilled isopentane and 
stored between -80°C and -120 DC. Sections of 5-7 pm were cut on a cryostate, air dried for 
20 minutes at room temperature and fixed in cold acetone for 10 minutes. After rinsing 
sections one time in phosphate buffered saline pH 7.4 (PBS), sections were incubated for 20 
minutes in PBS containing 5-10% of bovine serum. albumin (BSA) in order to block non-
specific binding. Sections were then incubated with patient serum in a 1: 1 00 dilution of a 
5% BSA solution ill PBS for I hour at room temperature. After washing with PBS three 
times for five minutes, sections were incubated with secondary anti-human IgG(Fab2) 
antibody (DAKO, Glostrup, Demnark) labeled with fluoresceinisothiocyallate (Fire) in a 
I :40 dilution for 1 hour. After washing three times for five minutes sections were mounted 
with mounting fluid consisting of a 9% glycerol solution in PBS and evaluated under a 
fluorescent microscope. Positivity was scored when a clear fluorescence pattern was seen on 
neuronal tissue but not on control tissue. Titer of positive sera was determined by serial 
dilution of patient's serum on rat cerebellar sections using the IIF assay. 
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Antibody 
Anti-Hu 
Anti-Yo 
Anti-PCA 
Anti-Ri 
Anti-CAR 
Anti-128kD 
Anti-VGCC 
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Possible antibody mediated parancoplastic neurological syndromes with incidence 
rates in The Netherlands calculated over a 5 years period (1990-1995)* 
Paraneoplastic Associated Antigen location 
neurological malignancy 
syndrome 
Encephalomyelitis Small cell lung cancer Nuclei of all neurons 
Sensory neuronopathy 
Cerebellar degeneration Ovarian Purkinje cell c)1opiasma 
Cerebellar de generation Hodgkin's lymphoma Purkinje cell cytoplasma 
Opsoclonus myoclonus Breast cancer All nuclei of eNS neurons 
Visual loss Small cell lung cancer Retinal neurons 
Stiff-man syndrome Breast cancer Synapses of eNS neurons 
Lambert-Eaton myasthenic Smail cell lung cancer Voltage gated calcium 
syndrome channels 
* Numbers are based on data from the Netherlands cancerregistty 1989, Cancer incidence and survival 1955-
1994 from the Eindhoven cancer registry. 
Hi?slern bIoI 
\Vestern blotting was essentially performed following the method described by Towbin et aL 
and slightly modified as described belo\y,,32. Protein samples of cerebral and cerebellar 
cortex, liver and muscle were prepared by homogenizing 0.5 - 1.0 grams of frozen tissue 
pieces in a bullet homogenizer and dissolving the powder in PBS. After centrifugation the 
supernatant was recovered and protein contents measured by an MBradford protein assay. 
Protein samples were boiled in 1:5 Laemli's buffer (0.0625 M Tris hydrochloric acid (pH 
6.8), 2% sodium dodecyl sulfate, 0.001 % bromophenol blue and 5% 2-mercaptoethanol for 
5 minutes. Protein samples were then separated by electrophoresis on a 10% SDS-polyacryl-
amide gel. Gels were loaded with 20 I-'g of protein per well or 150 llg per whole gel. After 
being transferred by liquid electrophoresis to Hybond nitrocellulose membrane (Amersham, 
Buckinghamshire, United Kingdom), separate lanes were incubated with patient's seniln in a 
I: t 000 dilution. After washing, lanes were incubated with alkaline phosphatase labeled anti-
human IgG (Fab2) antibody (DAKO). To visualize reactive bands, lanes were then incubated 
with developing substrate (5-bromo-4-chloro-3-indolyl-phosphate and nitroblue-tetrazolium 
(Bio-Rad, Herculus, California) in developing buffer (IOOmM Tris/HCI, 100mM NaCI, 5 
mM MgCI, pH 9.5) for 10-30 minutes. Molecular weight of reactive bands was estimated 
using a prestained protein sample (Bio-Rad) as reference. Reactivity was scored positive 
when distinct bands were visible in neuronal extracts and not seen on liver or muscle 
extracts. 
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Table 1 Possible antibody mediated parancoplastic neurological syndromes with incidence 
rates in The Netherlands calculated over a 5 years period (1990-1995)* (continued) 
Immunoblot 
381040 kD 
34 and 62 kD 
negative 
55 and 80 kD 
23 and48 kD 
128 kD 
?, 50 kD 
Total no. of associated 
tumors/year in The 
Netherlands 
1300 
1275 
375 
8000 
2500 
8000 
1300 
Total number of patients Total incidence rate of 
with PNS diagnosed/year PNS per lumor/year(%) 
7 0.53 
1.2 0.09 
0.6 0.16 
0.6 0.01 
0 0 
0 0 
n.k. n.k. 
+ The Netherlands central bureau of statistics 1993: Vademecum ofheallh statistics of The Netherlands 
Control assays for systemic autoantibodies 
In order to exclude false positive reactivity or cross-reactivity, all sera showing reactivity in 
one of the assays were tested for the presence of systemic autoantibodies (ANA, ANCA, 
anti-SSA, anti-SSB, RNP, Scl70, Sm, Jol, IgM and IgA rheumatic factor, anti-mitochon-
drial, anti-parietal cell, anti-smooth muscle, anti-thyroglobulin and microsomal antibodies 
using standardized assays31, IIF assays were performed on all sera using various substrates as 
antigenic source including rat liver, culture preparations of Hep-2 cells, Crithidia luciliae 
(DNA), rat kidney (mitochondria and brush border antigen), thyroid (thyroglobulin and 
microsomal fraction), stomach (parietal cells and smooth muscle)33.35. Antibodies to Sm, 
nRNP and ScI 70 were determined by immuno-precipitation reaction in agar geI36,37. 
Presence of anti-Ro/SS-A and anti-LaiSS-B antibodies were tested by an ELISA method 
using affinity purified antigens". Rheumatoid factor (IgM and IgA) was determined by an 
ELISA". Positive reference sera against ANA, ANCA, SS-A, SS-B, RNp, Scl70, Sm and 
mitochondria were tested on both IIF and \Vestern blot assays in order to determine reacti-
vity patterns of these antisera against neuronal sections and protein extracts. 
Results 
Selected patients 
Of 1600 patients, 514 scoring grade 2 or grade 3 or showing positive reactivity in the first 
IIF assay were selected for further study. A summary of the clinical features of these 514 
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Table 2 A Overview of control groups 
Controls No. 
Heallhy individuals 
Diseased controls: 
Multiple sclerosis 
Il.'lyasthenia gravis 
Primary Sjogren's syndrome 
Systemic lupus erythematosus 
Tumor controls: 
Small cclllung cancer 
Ovarian cancer 
Breast cancer 
Table 2 B Tumor type in 514 selected patients (grade 2 or 3 or positive for anti-neuronal antibodY) 
Tumor diagnosis 
Small cell lung cancer 
Non-small cell lung cancer 
Breast cancer 
Ovarian cancer 
Cervical cancer 
Prostate cancer 
Hodgkin's lymphoma 
Non-Hodgkin's lymphoma 
Other tumors 
No tumor found 
Table 2 C Paraneoplastic syndrome in relation to presence of tumor 
Neurological syndrome 
Sensory neuronopathy 
Sensori-motor neuropathy 
Motor neuropathy 
Cerebellar syndrome 
Opsoclonus myoclonus syndrome 
Organic brain syndrome 
Drain stem syndrome 
Otherwise or combinations of above 
Tumor 
+ 
36 
84 
26 
85 
37 
8 
98 
Total 375 
20 
20 
30 
45 
10 
55 
33 
10 
Total 223 
No. 
68 
74 
94 
20 
7 
23 
9 
16 
64 
139 
Total 514 
Tumor 
27 
28 
17 
39 
4 
9 
14 
Total 139 
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patients is presented in tables 2 Band 2 C. At the onset of neurological symptoms no tumor 
was known in 138 patients and 68 had SCLC, 74 non-SCLC, 20 ovarian cancer, 94 breast 
cancer, 7 endometrial carcinoma, 16 non~Hodgkin lymphoma, 9 Hodgkin's disease, 23 
prostate carcimoma and 64 patients had other primary tumors (table 2 B). Neurological 
symptoms consisted of 46 patients with organic brain syndrome, 63 with sensory polynM 
europathy/neuronopathy, 112 with sensori~motor polyneuropathy, 43 with motor neuron 
disease, 124 with cerebellar syndrome, 5 with opsoclonus myoclonus syndrome, 9 with 
bulbar encephalitis and 112 with other neurological signs or a combination of two or more 
of the above syndromes (table 2 C). 
Frequency of autoantibodies 
By IIF, Western blot and other autoantibody assays, we found autoantibodies in 17.9% 
(28711600) patients. A total of 117 patients had different non-neuronal specific autoantibod-
ies (see below). In assays for organ specific autoantibodies we found positivity in 103 of the 
735 sera of patients and controls tested in these assays. 
Anti-neuronal antibodies were found in 67 (4.2%) patients. Forty-six (2.9%) patients had 
one of the well-known paraneoplastic antibodies, including 35 anti~Hu antibodies, 6 anti~ Yo 
antibodies, 3 anti~Purkinje cell (anti-Tr) antibodies associated with Hodgkin's disease and 2 
anti~Ri antibodies. Antibodies against the cancer associated retinopathy (CAR) protein and 
the 128 kD protein associated with stiff-man syndrome were not found. Clinical data of 
patients positive for anti-Hu, -Yo, MTr and MRi are not included this report. 
Novel anli~l1etlronal antibodies 
Antibodies against 5 different not previously identified neuronal antigens were found in 21 
of 1600 (\.3%) patients (see below and table 3). An overview of different antibodies and 
clinical data is presented in table 4. 
Anti 60~64 kD: In 4 patients, an antibody against a 60~64 kD neuronal protein complex on 
Western blot were detected. This antibody showed cytoplasmic staining of all neurons. The 
antigen was not detected in other tissues (see Patient and Methods) by IIF or Western blot 
(fig. I, appendix). In three of these patients, two with sensory neuropathy and one with a 
cerebellar syndrome, SCLC was detected. In one patient with organic brain syndrome no 
tumor could be found (see also chapter 5). This antibody reactivity was not seen in any of 
the control sera. 
AI/Ii-55 kD: In 4 patients an antibody was detected that reacted with a 54-55 kD neuronal 
protein on \Vestern blot. On IIF a neuronal nuclear staining pattern was seen. \Veak reactiM 
vity was found in non-neuronal tissues (see Patients and Methods) in both IIF and Western 
blot (fig. 2, appendix). All 4 patients had a tumor of the genito-urinary system. Two patients 
had a sensory ncuronopathy and cervical carcinoma. Two patients suffered from a cerebellar 
syndrome of which one patient had ovarian cancer and the other bladder carcinoma. The 55 
kD antibody reactivity could not be detected in sera of the control groups. 
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Table 3 Overview of anti-neuronal antibodies identified in 1600 patients with suspected 
paraneopiastic neurological syndromes 
Anti-neuronal antibody 
Anti-Hu 
Anti-Yo 
Anti-Tr 
• Anli-Ri 
Anti-CAR 
Anti-mllphyphisin 
Anti 60-64 kD 
Anti 55 kD 
Anti 40-200 kD 
Anti 37 kD 
Anti 210 kD 
Total 
Other neuronal autoantibodies 
Systemic autoantibodies 
Total 
No of positives 
(% of 1600) 
35 (2.2) 
6 (0.4) 
3 (0.2) 
2 (0.1) 
o (0.0) 
0(0.0) 
4 (0.3) 
4 (0.3) 
3 (0.2) 
7 (0.4) 
3 (0.2) 
67 (4.2) 
117 (7.3) 
103 (6.4) 
220 (13.8) 
Most frequently associated 
neurological syndrome 
Encephalomyelitis 
Sensory neuronopalhy 
Cerebellar syndrome 
Cerebellar syndrome 
Opsoclonus myoclonus 
Cerebellar syndrome 
Sensory neuropathy 
Organic brain syndrome 
Cerebellar syndrome 
Sensory neuropathy 
Polyneuropathy 
Heterogeneous 
Sensory neuropathy 
Cerebellar syndrome 
Heterogeneous 
Heterogen~ous 
Most frequently 
associated tumor 
Small cell lung cancer 
Ovarian cancer 
Hodgkin's disease 
Breast cancer 
Small cell lung cancer 
Cancer of genito-urinary 
tract 
Lung cancer 
Heterogeneous 
Heterogeneous 
Heterogeneous 
Heterogeneous 
An/i-40-200 kD: An antibody reactive with a pan-neuronal cytoplasmic antigen was detected 
in three patients. On \Vestern blot these sera showed reactivity against an antigen which was 
homogeneously dislributed over the range of 40-200 kD on electrophoresis with the 
strongest reactivily in the upper 200 kD molecular weighl range (fig. 3, appendix). This 
antibody was not found in any of the control sera and did not react with other tissues (see 
Paterials and Methods). Two patients suffered from a polyneuropathy and the other showed 
signs compatible with limbic encephalitis. Two patients had adenocarcinoma of the lung and 
in one no tumor was found. 
An/i-37 kD: In 7 patients, an antibody against a 37 kD neuronal protein was found on 
Western blot. The antigen migrated just below the Hu complex and showed one sharp small 
band that could clearly be distinguished from the Hu complex. The serum of the patients did 
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not react with the HuD recombinant protein. The antibody reacted with all neuronal nuclei 
on lIF. No reactivity was seen on other tissllcs (see Patients and Methods) on both IIF and 
\Vestern blot (fig. 4, appendix). Three patients suffered from a polyneuropathy or sensory 
neuronopathy, one had a cerebellar syndrome. One patient had the clinical picture of bulbar 
encephalitis and one of limbic encephalitis. Three patients had lung cancer (one small-cell 
and two adenocarcinoma), one Hodgkin's disease and one patient had melanoma. In two 
patients 110 tumor was detected. Only in one of the sera from the control groups, this 
antibody was found in a patient with SCLC and without neurological signs. 
Allli-210 kD: In three patients, high-titer antibodies (all> 1:6400) against a 200-210 kD 
neuronal protein were observed. On IIF, a neurofilamentous staining pattern was seen with 
these sera (fig 5, appendix). No reactivity was present on other tissues (see Patients and 
Methods). Tllis antibody reactivity was seen in one patient of the control group who suffered 
from Miller-Fisher syndrome. Neurologically and oncoiogically, these three patients did not 
show common paraneoplastic characteristics. One patient had non-SCLC and suffered from 
sensory polyneuropathy and cerebellar ataxia. One patient had sensory neuronopathy without 
cancer. One patient had breast carcinoma, cerebellar ataxia and brain metastasis. This high-
titered anti-ncurofiiamentous antibody was not found in any of the controls. 
Other neuronal autoantibodies 
In 117 patients a range of other autoantibodies was found. Low titered «1:500) antibodies 
against neurofilaments NF-L, Hand M of 70, 150 and 200 kD molecular weight, respective-
ly, were seen in 58 (11%) patients (data not shown). No correlation was found between 
neurological and oncological data in this patient group. 
In 21 patients antibodies were found against a 40 kD antigen which was detectable on both 
neuronal and muscle protein extracts but not in the other tissue extracts (see Patients and 
Methods). This antibody reactivity was also detected in 6 sera from controls. This patient 
group was heterogeneous without correlation between the antibody, neurologicaJ symptoms 
and tumor. 
In 38 patients antibodies were identified against a 35-36 kD antigen, appearing just below 
the 37 kd and the 38-40 kD (Hu) antigen. This antigen was present in both the neuronal and 
the other tissue protein extracts. This antibody reactivity was seen in seven sera of the 
controls. No correlation was found between antibody, neurological symptoms or tumor. 
Other autoantibodies 
A variety of autoantibodies against other antigens was found in 103 (20%) of the 514 sera 
tested. Of these, 98 sera had anti-nuclear antibodies (ANF) in titers higher than I: 100 on 
Hep-2 cells. In 42 of these 98 sera, antibodies were found against SS-A, SS-B, RNP or Sm. 
Nine patients had antibodies against SS~A alone, seven patients had antibodies against both 
SS-A and SS-B. In 8 patients antibodies against SS-A and Sill or RNP were found and in 10 
patients against Sm or RNP only. Eight patients had antibodies against SS-B and RNP. 
Except for 3 patients, none had a known diagnosis of SLE or Sjogren's syndrome. All 
patients presented with neurological symptoms. In 69 (67%) of these patients, a tumor was 
known at the time of presentation of neurological symptoms. 
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Table 4 Five different anti-neuronal antibodies found in 1600 patients sllspected ofPNS 
No. M/F Age Thmor Neurological symptoms IIY-reactivity kD 
M 65 SCLC Sensory ncuronopathy, Neuronal cytoplasmic 60·64 
cerebellar syndrome 
2 M 64 SCLC Sensory neuronopathy Neuronal cytoplasmic 60·64 
3 F 80 SCLC Sensory neuronopathy Neuronal cytoplasmic 60-64 
4 F 69 n.l.d. Organic brain syndrome Neuronal cytoplasmic 60·64 
5 F 60 Cervical carcinoma Sensory neuronopathy Pan-neuronal cytoplasmic and 55 
nuclear 
6 M 80 Bladder carcinoma Cerebellar syndrome, Pan-neuronal cytoplasmic and 55 
bulbar encephalitis nuclear 
7 F 60 Ovarian cancer Cerebellar syndrome Pan-neuronal c)10plasmic and 55 
nuclear 
8 F 69 Cervical and breast Sensory ncuronopathy Pan-neuronal cytoplasmic and 55 
carcinoma nuclear 
9 M 80 n.t.d Polyneuropathy Pan-neuronal cytoplasmic 40-200 
10 M 66 Adenocarc.lung Polyneuropathy Pan-neuronal cytoplasmic 40-200 
II M 40 Adenocarc.lung Limbic encephalitis Pan-neuronal cytoplasmic 40-200 
12 M 69 Adenocarc. lung Polyneuropathy Anti-neuronal nuclear 37 
13 n.k. n.k. Adenocarc. lung Polyneuropathy Anti-neuronal nuclear 37 
14 F 25 Hodgkin's disease Cerebellar syndrome Anti-neuronal nuclear 37 
15 F 74 n.t.d. Bulbar encephalitis Anti-neuronal nuclear 37 
16 F 62 n.t.d. Limbic encephalitis Anti-neuronal nuclear 37 
17 F 37 h.-felanoma Sensory neuronopathy Anti-neuronal nuclear 37 
18 M 73 SCLC Cerebellar syndrome Anti-neuronal nuclear 37 
19 M 72 non-SCLC Sensory neuronopath.y, Neurofilamentous 210 
cerebellar syndrome 
20 F 61 Breast carcinoma Cerebellar syndrome, Neurofilamentous 210 
metastasis 
21 F 89 n.t.d. Sensory neuronopalhy Neurofilamentous 210 
M: male; F: female; n.k.: not known; IIF: indirect immunofluorescence; SCLC: small cell lung cancer; n.l.d.: no tumor 
detected; kD; molecular weight in kilodalton. 
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Discussion 
In this study, we found autoantibodies in 17,8 % of patients suspected of a PNS. Using 
appropriate controls and assays to exclude non-neuronal antibody reactivities, only 4.1 % of 
sera had anti-neuronal antibodies. Apart from the well-characterized paraneoplastic antibod-
ies, five novel anti-neuronal antibodies were identified. 
Previously, others have suggested the possibility that anti-neuronal antibodies might be 
associated with a number of neurological or psychiatric disorders. In one study, anti-
neuronal antibodies were found against proteins of various molecular weight in approxi-
mately 30% of patients, but no significant association with clinical symptoms was found~o. 
However, in this analysis the relationship between individual reactivity patterns of antibodies 
and patients was not studied, and there were no control assays on non-neuronal extracts. 
\Vhen sera from a random population are tested against a crude protein extract of neuronal 
or non-neuronal tissue on Western blots, many reactive bands can be found, especially when 
tested at low dilution4o,41. The frequency of autoantibodies rises with age and even at young 
age antibodies against many autoantigens can be detected in serum of normal healthy 
controls40.41. Therefore, the finding of autoantibodies has to be carefully interpreted, if using 
a sensitive technique as \Vestern blotting. In our study, only antibodies were considered 
positive with titers above 1 :500 and when in both IIF assays and \Vestern blotting a 
reactivity against non-neuronal antigens was excluded. Only the cloning or purification of 
corresponding antigens will lead to more direct detection of these antibodies. 
Frequency of antibodies and incidence of PNS 
In 67 (4.1%) of the patients examined, we found anti-neuronal antibodies, including 35 anti-
Hu antibodies, 6 anti-yo antibodies, 3 anti-Purkinje cell antibodies associated with 
Hodgkin's disease (anti-Tr) and 2 anti-Ri antibodies. Antibodies against the visual related 
protein and the 128 kD protein associated with stiff-man syndrome were not found. In 21 
patients (1.3%) other, novel anti-neuronal antibodies were identified. 
As we serve in The Netherlands as the only reference laboratory for determining paraneo-
plastic anti-neuronal antibodies, we presume that we receive material from virtually all 
patients suspected of PNS in The Netherlands. Approximately 2% had an immunologically 
confirmed diagnosis of PNS, in a popUlation of 3000 patients with a clinical suspicion of 
PNS grade I. The incidence of paraneoplastic neurological syndromes in The Netherlands 
thus does not reach above 0.1 %. For each syndrome, the incidence can be calculated (table 
I). For the Hu syndrome, the incidence would be 7 on a total of 1300 new SCLC cases per 
year or 0.53% of all new SCLC/year in The Netherlands. For anti-yo positive PCD, the 
incidence would be 1.2 cases on a total of 1275 newly diagnosed ovarian cancers/year in 
The Netherlands yielding an incidence of less than 0.09%. For anti-Tr and anti-Ri, the 
incidences are 0.16% in Hodgkin's disease and 0.01% in breast cancer patients (table I). 
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Novel antibodies 
\Ve identified 21 (1.3%) patients with other non-Hu, -Yo, -Ri, and -Tr anti-neuronal 
antibodies in a group of 1600 scra from patients with clinical suspicion of PNS. Five 
different types of antibodies were found that reacted specifically with a neuronal antigen in 
both IIF and Western blotting. 
Many previous studies, mostly case-reports, indicate that other as yet not characterized 
antibodies can be identified in patients with PEMlPSN or other PNS. One study reported 
antibodies to Purkinje and dorsal root ganglion cells reactive with a 62 and 110 kD protein 
in 3 patients with sensory neuronopathy without cancers. Another nOll-Yo antibody reacting 
with Purkinje cell cytoplasm has been described, identifying 65, 120 and 150 kD proteins in 
neurons and neuro-ectodermal tumor cells24 • Recently lacckle et al. reported the cloning of a 
novel antigen called Br in a patient with PSN and lung alveolar carcinoma42, An antibody 
against 45, 59 and 135 kD proteins in a patient with PEM, uveitis and undifferentiated 
carcinoma was reported by Antoine et al.28, They demonstrated that different findings may 
be explained by the techniques used and showed that not each antigen is resistant to routine 
immunofluorescence or \Vestern blot procedures. Methods of fixation can influence the 
antigenic epitopes to a large extent and thus interfere with antibody detection28• 
In control sera these antibodies could not be found23,42,43. However, no systematical study has 
previously been carried out to determine the actual existence or diagnostic value of these 
newly identified anti-neuronal antibodies in PNS. 
Although the relation between individual antibody and tumor type is not as direct as in other 
antibody-associated PNS, we think that our results suggest that each antibody identifies a 
subgroup of patients with PNS. The number of identified patients harbouring these antibod-
ies is small and the relation with neurological symptoms and tumor type may become more 
apparent when more patients are investigated. 
The criteria we used met the guidelines for the detection of relevant PNS antibodies, that 
have recently been defined44•4s • Nevertheless, patients with identical antibodies may have a 
variable neurological syndrome or more than one type of tumor. Different tumor types may 
express identical onco-neural antigens with corresponding anti-neuronal antibodies that may 
evoke different neurological syndromes. This phenomenon is not unique and is clearly 
apparent in the Bu-syndrome, in which a large variety of clinical presentations has been 
recognized and the Hu expression is not solely restricted to one tumor type4 •46 • 
Although the tumor type varies, for example in the group of patients with the 37 kD and 55 
kD reactive antibodies, it may well be that all tumors in one group express the same reactive 
antigen. Further study needs to clarify whether antigens recognized by the identified 
antibodies are present in the corresponding tumors. Nevertheless, our data indicate that the 
identified antibodies relate to patients with neurological syndromes associated with cancer, 
as they were not observed in sera of any of the control groups, although we only tested 20 
normal controls and 203 diseased controls. 
Allti-60-64 kD: In patients with 60-64 kD antibody, three of the four had a diagnosis of 
SCLC and in one 110 tumor was found. All had a clinical picture of central nervous system 
involvement similar to symptoms of a anti-Bu associated paraneoplastic encephalomyelitis. 
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The anti-60-64 kD antibody may therefore be a new marker of PEMIPSN associated with 
SCLC. 
Anti-55 kD: All patients harbouring serum reactivity against a 55 kD neuronal protein had 
cancers, that were derived from the Mullerian tract, which is ontogenetically closely related 
to the nervous system. This may indicate that an antigen expressed by the tumor induces an 
anti-55 kD inunune response. 
Ami-40-200 kD: Antibodies to the 40-200 kD antigen were found in two patients with 
adenocarcinoma of the lung and in one patient without tumor. The antigen detected by these 
sera is most likely not a protein, considering the behaviour of the antigen on \Vestern blots 
and the inullunoreactivity in lIF. The antigen may be of a lipid or mucoid structure or a 
large protein with positive degradation products on \\'estern blots. Further study has to 
reveal the nature of this antigen. 
Polyneuropathies as found in two of these patients are not characteristic for clas~ical PNS, 
although they may occur as a paraneoplastic syndrome. The third patient had a clinical 
picture of a limbic encephalitis, which is a well-known PNS. 
Ami-37 kD and 35-36 kD: In seven patients antibodies against a 37 kD neuronal protein 
were identified. Their sera did not react with the HuD recombinant protein indicating that 
the antigen is different from Hu. This group was clinically heterogeneous. Thus, although 
the data indicate that the -antigen is solely expressed by neurons, little can be said as yet on 
the clinical relevance of this antibody. 
The identification of antibodies against a 35-36 kD non-neuronal protein in 38 patients and 
controls underscores the importance of appropriate controls and the quality of techniques to 
detect and discriminate the antibodies. The Hu, the 37 kD antigen and the 35-36 kD antigen 
all comigrate closely on Western blots and are difficult to distinguish. Almost inevitably 
degradation products of proteolysis limit discrimination of these antigens. It is essential that 
electrophoresis gels are homogeneollsly polymerized and that during the preparation of 
protein extracts proteolysis is prevented by either proteolytic enzyme inhibitors or short 
processing times of the tissue materials. Parallel performing of IIF assays and eventually 
cloning of the antigens is necessary for unequivocal determination of antibody reactivities. 
Anti-2iD kD: Patients with sera recognizing the 210 kD neurofilamentous antigen had 
different neurological signs and various underlying tumors. Although their antibody titers 
were very high (all> I :6400), it is difficult to draw conclusions on whether this antibody is 
clinically relevant. Preliminary studies using monoclonal anti-neurofilament antibodies show 
that the antigen does not comigrate with the neurofilament proteins NF-L, H or M (data not 
shown). 
Other autoantibodies 
In the present study, we found autoantibodies in 20% (103 of 514) of the patients evaluated. 
One remarkable finding is that a relatively high percentage had antibodies against SS-A or 
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SSRB antigens associated with Sjogren's syndrome or SLE. However, this percentage may be 
biased by selection of patients. Only 514 patients from a total of 1600 were tested in assays 
for a variety of autoantibodies. Patients with Sjogren's syndrome may suffer from neurologi-
cal involvement in 10-25% of cases, and neurological symptoms may be the first manifesta-
tion of the disease'H, In that way, the finding of SS-A or SS-B antibodies in patients 
presenting with neurological symptoms may indicate an underlying Sjogren's syndrome or 
SLE. Besides, the neurological complications of Sjogren's syndrome have been associated 
with anti-neuronal antibodies.f7. In our study, only three of the 514 patients had a diagnosis 
of Sjogren's syndrome. 
Conclusions 
\Ve conclude that a number of novel antl·neuronal antibodies can be recognized in patients 
with PNS. Our study indicates that these antibodies identify hitherto unrecognized subsets of 
PNS. The anti-60-64 kD antibody may be a novel marker for a subgroup of patients with 
SCLC associated PEMlPSN. Anti-55 kD antibodies have been identified in PNS associated 
with urogenital malignancies. The abnormally reacting 40·200 kD antigen on \Vestern blots 
may indicate that not all antigens involved in PNS are proteins, but that other antigenic 
strlJctures may be involved as well. The relatively high percentage of systemic autoanti· 
bodies indicates that new neurological symptoms can well be the first presenting symptoms 
of a systemic cOIUlective tissue disorder. 
Expression and cloning of novel lIonco·neuralu antigens may reveal the nature and function 
of these proteins and may enable more reliable detection of corresponding antibodies. 
Understanding the molecular mechanisms by \'{hich neurons and tumor cells co· express 
shared antigens may help to reveal the pathogenesis that underly paraneoplastic syndromes 
of the nervous system. 
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Abstract 
The anti-neuronal antibodies found in some patients with paraneoplastic cerebellar degenera-
tion (reD) and Hodgkin's disease (HD) have not been sufficiently characterized to allow 
their appropriate identification among different laboratories. \Ve studied an antibody (called 
anti-Tr) found in five patients with HD-associated reD, that immunoreacted with the 
cytoplasm of Purkinje celJs of human and rat cerebellum. The molecular layer of rat 
cerebellum showed a characteristic, dotted pattern suggestive of immunoreactivity of 
dendritic spines of Purkinje cells. This dotted pattern was not produced by anti-Yo, or five 
different non anti-Yo anti-Purkinje cell antibodies from patients with neurologic disorders 
other than HD-associated peD. In the rat nervous system, anti-Tr immunoreactivity was also 
observed in multiple regions. Immunoblots of human Purkinje cells or mouse cerebellum 
were negative. Patients with cerebellar disorders without cancer (96), opsoclonus (14), recent 
infection with Epstein-Barr virus (16), HD without reD (30), or reD associated with other 
neoplasms (21) did not harbor anti-Tr antibodies. 
We conclude that the anti-Tr antibodies defined in this study are specific for HD-associated 
peD. Until the cloning of the Tr antigen(s), which will allow the unambiguous identification 
of these antibodies, the immunohistochemical staining pattern described in the rat cerebellum 
coupled with the absence of reactivity in the imrnunoblot may be used to identify anti-Tr 
antibodies. 
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Introduction 
Paraneoplastic cerebellar degeneration (peD) is characterized by the subacute development 
over weeks or months, of a severe pancerebellar syndrome. Postmortem study shows 
extensive loss of Purkinje cells with relative preservation of other cerebellar neurons. 
Inflammatory infiltrates in the deep cerebellar nuclei and brainstem are also identified in 
some patients. peD has mostly been reported in association with gynecologic tumors, breast 
and lung cancer, and Hodgkin's disease (HD)I. 
Except for the anti-Yo antibody, that is a marker of peD associated with ovarian or breast 
cancel,), no other antineuronal antibodies have been well characterized in patients with 
PCD4,5. A few patients with peD and HD harbor anti-neuronal antibodies, different from 
anti-Y06--IO. However, in none of the previous studies were these antibodies analyzed 
extensively enough to allow their correct identification among different laboratories, to 
differentiate them from anti-yo or other less well characterized antineuronal antibodiesll•15, 
and to demonstrate their specificity for PCD associated with HD. 
In the present study, we evaluated the immunohistochemical and immunoblot characteristics 
of an antineuronal antibody (that we called anti-Tr), found in the serum and cerebrospinal 
fluid (CSF) of five patients with HD-associated PCD. 
Methods 
Patients 
The most relevant clinical features of the five patients are summarized in table I. Four men 
developed a progressive subacute pancerebellar syndrome that left them disabled after one to 
four months. The fifth patient was a 14 year-old girl who developed a cerebellar syndrome 
and bilateral retrobulbar optic neuropathy two weeks after an episode of fever and tonsillitis. 
The neurologic deficit completely resolved over the ensuing two months after treatment with 
corticosteroids, I glday for 3 days followed by tapering doses during three months. All five 
patients had eSF pleocytosis and normal MRI scans of the head in the initial evaluation. HD 
appeared aner a median of 5 months (range: 0-12 months) following the diagnosis of PCD. 
In the last visit, the HD was in remission in all patients. However, patients 1 to 4 were 
disabled from the cerebellar dysfunction and the MRl showed cerebellar atrophy. Patient 5 
had a normal neurological examination but visual evoked potentials remained abnormal and 
there was a mild cerebellar atrophy in the MRI scan. 
Serum samples 
Serum was collected at the onset of peD or diagnosis of the HD, and after the treatment. 
CSF samples were also obtained at the onset of PCD in patients 2 and 3. As controls, we 
studied serum from 21 patients with PCD (15 associated with lung cancer and 6 with other 
solid tumors), 14 with opsoc1onus-myoclonus syndrome (8 paraneoplastic). 30 with newly 
diagnosed HD without neurologic disorders, 16 with recent Epstein-Barr virus (EBV) 
Anti-TI' antibodies ill peD and Hodgkin's disease 97 
infection, and 96 with different cerebellar disorders without cancer (8 with probable 
postinfectious cerebellitis). All sera were negative for anti-Bu, Yo, or Ri antibodies. The 
anti-Tr antibody reactivity of the five HD-PCD patients was compared with that of (I) 
anti-Yo antibodies; (2) five non anti-Yo anti-Purkinje cell antibodies from patients with 
different neurologic disorders (two with peD and solid hlIl10rS15 , two with non-
paraneopiastic cerebellar disorders and one with neuromyotonia); and (3) anti-glutamic acid 
decarboxylase (GAD) antibodies from a patient with stiff-man syndrome16• Samples were 
alliquoted and kept at -70'C until use. 
Table 1 Clinical features of paraneoplastic cerebellardegencration and Hodgkin's disease. 
Characteristics Palient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Age/Gender 72/Male 43Male 29IMaie 36/Male 14IFemaie 
Previous fe- "fiu-Iike" No No No Tonsillitis 
brile episode (2 weeks) (2 weeks) 
(time) 
Ataxia 
Truncal Severe Moderate Moderate Moderate Severe 
Limbs Mild Moderate Moderate Moderate Mild 
Nystagmus Horizontal Downbeat Horizontal Downbeat Downbeat 
Non cerebellar Extensor plantar No No No Retrobulbar 
signs responses optic neurop-
athy 
WBC/).l1 in 20 17 102 50 12 
CSF 
Initial MRI Nonnal Nonnal Nomlai Nonnal Nomlai 
Time (months) 7 5 2 0 12 
to HD diagno-
sis 
Type/stage NS/l A MC/Il A NS/lIl A LDIlIA NS/II A 
HD 
Treatment HD Chemotherapy Chemotherapy Chemotherapy Chemotherapy Radiotherapy 
Follow-up 52 48 12 72 38 
(months) 
HD/PCD NED/Stable NED/Stable NED/Stable NED/Stable NEDINED 
NS: Nodular sclerosis; Me: Mixed cellularity; LO: Lymphocytic depletion; NED: No evidence of disease. 
WBC/Ill: White blood cells per microliter; 
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TIssue samples 
Human brain samples were obtained at autopsy from patients without neurologic disorders, 
and HD lymph node samples from surgical pathology specimens. \Vistar rats were killed by 
decapitation and the brain and other organs were snap frozen in isopentane chilled in liquid 
nitrogen. Some rats were anesthetized and perfused with saline and with 4% 
paraformaldehyde in phosphate buffered saline (PBS) subsequently. After perfusion, brains 
were removed and frozen after further fixation with 4% paraformaldehyde for 4 hours, and 
cryoprotection with 20% sucrose in PBS overnight. In some experiments, brains were 
removed and immersed in the same fixative for 24 hours. Samples were stored in PBS at 
4"C until vibratome sections were obtained. 
For immunoblot analysis, human Purkinje neurons were purified as previously described l7• 
Fifteen BALBJc mice were killed by cervical dislocation and the cerebellum was isolated. 
The cortical gray matter was separated from the white matter, and homogenized in 
phospholysis buffer (1% Triton X-IOO, 0.1% sodium dodecyl sulfate (SDS), 120 mM 
sodium deoxycholate in PBS). 
Preparation of biotinylate{i IgG containing anli-1'r antibodies 
IgG was purified from serum of normal blood donors and patient 2 using a protein G 
column. Anti-Tr reactivity was confirmed by immunohistochemistry only in the IgG 
fraction. The purified IgG was diluted in PBS and reacted with biotin N-hydroxysuccinimide 
ester (Vector Labs, Birlinghame, USA) in dimethyl sulfoxide (DMSO)(lmgIIOmg of IgG) 
for 2 hours. The reaction was terminated by the addition of 10 mg glycine and the free 
biotin was removed by dialysis2• 
ImmunoJzistochemisfly 
Frozen sections of unfixed normal human brain and rat tissues were fixed with acetone for 
10 minutes, or 100% alcohol for 5 minutes at 4°C. After inhibition of endogenous peroxi-
dase with 0.3% hydrogen peroxide in PBS for 10 minutes, sections were sequentially 
incubated with 10% normal goat serum for 20 minutes, patient's serum (screening dilution 
I :500) for 3 hours at 3TC (tissue sections fixed with paraformaldehyde), or overnight at 
4·C, biotinylated goat anti-human IgG, kappa or labda specific, for 30 minutes, and the 
avidin biotin immunoperoxidase complex (Vector Labs) for 30 minutes. The reaction was 
developed with 0.05% diaminobenzidine with 0.01% hydrogen peroxide in PBS with 0.5% 
Triton X-100. Dilution of antibodies was done in PBS, or PBS with 0.1% Triton X-100 in 
the experiments using paraformaldehyde fixed sections. 
For a preliminary evaluation of the protein nature of the antigen recognized by anti-Tr 
antibodies, paraformaldehyde fixed frozen sections of rat cerebellum were pretreated, after 
suppression of the endogenous peroxidase, with 0.4% pepsin (Sigma, S1. Louis, USA) in 
Titrisol buffer (Merck, Darmstadt, Germany) for 10 minutes at 3TC. To ascertain if anti-Tr 
antibodies recognized carbohydrate epitopes, sections of rat cerebellum were deglycosilated 
by incubation in 10 mM periodic acid in 50 rnM sodium acetate (pH 4.5) for I hour at 25"C, 
washed in PBS, and incubated in 20 mM glycine in PBS for 1 hourl8• After these 
pretreatments, immunohistochemistry was proceeded as described above. 
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To study if antiMTr antibodies bound to samples of HD, frozen sections of pathological 
lymph nodes from 30 patients with !-ID were fixed in cold (4°C) acetone or 4% 
paraformaldehyde and sequentially incubated with 0.3% hydrogen peroxide, 10% normal 
human serum, biotinylated anti-Tr or control IgG (10 flg/ml) overnight at 4'C, and the 
Vectastain Elite ABC complex (Vector Labs). The substrate staining was developed with 
diaminobenzidine as described above. To evaluate the anti-Tr antibody binding to rat brain, 
serial sections of brain from perfused animals were cut at 5 ,..un in the vibratome. 
Free-floating sections were blocked with 3% normal goat serum and incubated at 4°C 
overnight with the serum diluted at I: 500 or biotinylated IgG (10 flg/ml). The sections were 
subsequently developed by the avidinMbiotin imillunoperoxidase teclmique described above. 
Serum and CSF anti-Tr antibody titers were defined as the reciprocal value of the highest 
dilution that showed positive staining on rat cerebellum. Titration of paired serum and CSF 
samples were done in the same experiment and repeated twice. To estim.ate the intrathecal 
synthesis of anti-Tr antibodies we used an antibody index defined by the formula: CSF titer 
x serum IgG / serum titer x CSF IgG. A value> 1.0 suggested intrathecal synthesis of the 
antibody19. 
Immllnoblottillg 
Protein extracts of human Purkinje cells (75 ).lg) or homogenates of mouse cerebellum (200 
f.lg) were separated in a 10% SDS polyacrylamide gel electrophoresis, and transferred to 
nitrocellulose filters 20 • The nitrocellulose filters were placed in a blocking solution 
containing 5% Carnation evaporated milk (Carnation Company, CA, USA) overnight at 4·C, 
then incubated with patients' sera (1:500) diluted in TBST buffer (1% bovine serum 
albumin, 10 mM Tris-HCI (pH 7.4), 0.9% NaCI, and 0.5% Triton X-100) for I hour at room 
temperature. Strips were then washed in 0.1 % TwcenM20, and incubated with sheep 
anti-human IgG diluted 1:20,000 in 0.1% Tween-20 for I hour at room temperature. After 
washing, strips were incubated with the chemiluminescence ECL detection reagents 
(Amersham, Buckinghamshire, United Kingdom) according to manufacturer's instructions, 
exposed to Kodak X-OMAT-AR film (Sigma, St. Louis, USA) for 5, 10, and 20 minutes. 
Results 
Specificity of al/li-1)' al/tibodies 
The sera of the five patients with anti-Tr antibodies stained both human and rat brain. The 
staining was obtained with anti-human IgG, kappa, or lambda, but not IgM. The 
inullunoreactivity observed with the biotinylated IgG anti-Tr antibodies from one of the 
patients was abolished when the tissue sections were preincubated with undiluted serum 
from the five patients with anti~Tr antibodies but not with normal human serum or serum 
containing high titers of anti-Yo antibodies. The titers of antiMTr antibodies ranged from 
I :8,000 to I :80,000 (median: I :20,000). Intrathecal synthesis was observed in the two 
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patients who had paired serum and CSF samples. The anti-Tr antibody titer dropped below 
I :500 immediately after treatment of the patients for their BD. 
Immunohistochemical staining patteI'll of anti-T!' antibody on human brain regions in 
comparison with Gnti-}v al1tibodies 
Anti-Tr antibodies reacted with the cytoplasm and proximal dendrites of Purkinje cells in 
human cerebellum. Unlike the immunoreactivity observed with anti-Yo antibodies, the 
basket and stellate neurons of the molecular layer were negative (data not shown). In rat 
cerebellum, the serum or biotinylated IgG anti-Tr antibodies strongly bound to the cyto-
plasm, with a coarse granular pattern, and dendrites of the Purkinje cells. Unlike anti-Yo 
immunoreactivity, basket and stellate neurons were negative but the molecular layer 
presented multiple positive small dots suggestive of immunoreactivity against dendritic 
spines of the Purkinje cells (Fig I, appendix). The dotted pattern in the molecular cell layer 
was similar to that observed with anti-GAD antibodies that label GABA-ergic nerve 
terminals. However, unlike anti-GAD, anti-Tr antibodies did not label nerve terminals 
around the Purkinje cell bodies and the dots were smaller and confined to the molecular cell 
layer (Fig I, appendix). 
The dotted staining pattern was observed after fixation with acetone, absolute alcohol, or 
paraformaldehyde. This pattern disappeared at higher dilutions while the cytoplasm of 
Purkinje cells still remained positive. Anti-Tr immunoreactivity was abolished by treatment 
with pepsin but not with periodic acid or delay of fixation with paraformaldehyde up to 16 
hours after death of the animal. rhe characteristic staining pattern was not seen with any of 
the control sera. Serum with anti-Yo, or non anti-Yo anti-Purkinje cell antibodies from 
patients with other neurologic disorders did not show the dotted staining pattern in the 
molecular layer of rat cerebellum (Fig I, appendix). 
In human brain sections, anti-Tr antibodies did not stain neurons of cerebral cortex, 
hippocampus, putamen, thalamus, mammillary bodies, lateral geniculate body, substantia 
nigra, dentate nucleus and dorsal root ganglia. Also no anti-Tr immunoreactivity was 
observed in the pathological lymph nodes from 30 patients with BD. 
Immunohistochemical staining pattern of anti-Tr antibody in the rat brain 
The anti-Tr antibody staining of the rat brain was evaluated in frozen and vibratome 
sections. In the rat, anti-Tr antibody staining was restricted to the nervous system. No 
staining was observed in liver, kidney, spleen, thymus, stomach, colon, adrenal cortex, and 
testis. Sensory neurons of the gasserian gangJia were faintly positive; a few showing strong 
reactivity. The satellite and SchWalm cells in the gasserian ganglia were negative. 
Identical results were obtained with whole serum or biotinylated IgG (table 2). In the 
cerebellum, the strongest staining was seen in the cytoplasm and proximal dendrites of 
Purkinje cells and in the molecular cell layer that showed the immunoreactive dots (Fig. 2B, 
appendix). A few Golgi cells of the granular cell layer were positive but neurons of the deep 
cerebellar nuclei, that are strongly positive with anti-Yo antibodies2! were faintly positive 
(Fig. 3A, appendix). Many neuronal groups in the thalamus, diencephalon and brainstem 
were immunoreactive but only weakly positive. Neurons of the piriform and entorhinal 
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cortex (Fig. 2A, appendix), lateral and basal amygdala, and isolated neurons in the basal 
ganglia, hilus of the dentate gyrus and plexiform layers of the hippocampus (Fig. 3B, 
appendix) and neocortex were strongly positive. In the neocortex, positive neurons were 
randomly distributed in the molecular layer and layers II and III, whereas large neocortical 
projection neurons were negative. The dotted pattern of the molecular layer of the 
cerebellum was not observed in other areas of the brain. Leptomeninges, glial and 
ependymal ceiJs, and choroid plexus were negative. 
Immullobiot studies 
Immunoblots of isolated Purkinje cells or mouse cerebellum homogenates under reducing 
and nonreducing conditions failed to identify a common band in the serum of the patients 
with anti-Tr antibodies. 
Table 2 Distribution of anti-Tr immunoreactivity in the rat nervous system 
Structure 
Neocortex 
Entorhinal cortex 
Hippocampus/dentate gyrus 
Striatum 
Thalamus 
Habenula 
Substantia nigra 
Red nucleus 
LocliS ceruleus 
Basis pontis 
Olivary nuclei 
Dentate nuclei 
Purkinje cells 
Granular cells 
Gasserian ganglia 
Non neuronal cells 
Discussion 
Intensity Comments 
++ Isolated cells, probably intemeurons 
++ 
++ 
++ 
+ 
++ 
+ 
+ 
+ 
++ 
+ 
+++ 
++ 
(see text) 
Neurons of layer II, isolated neurons in 
the other layers 
Isolated cells, probably intemeurons 
(see text) 
Isolated large-sized neurons 
Reticular thalamic nuclei 
Isolated neurons 
peD associated with HD presents clinical features different than that -associated with ovarian 
or breast cancer and anti-Yo antibodies. In HD-associated peD, men are more often affected 
than women. peD may occur in the setting of prolonged HD remission, and often improves 
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spontaneously, or after treatment with corticosteroids or the underlying HDJO. OUf patients 
with antiRTr antibodies, unlike those in the series of J-Iammack et aL IO with antlMPurkinje cell 
antibodies, had peD before the diagnosis of HD and in all hut one the clinical course was 
similar to that seen in patients with anti-Yo antibodies. In patient 5, the remitting cerebellar 
syndrome was associated with an optic neuropathy. The normal MRI reasonably excluded 
the possibility of postinfcctiolls encephalomyelitis. Optic neuropathy is not described in 
children with postinfectious cerebellar ataxia22,23 hut it has rarely been reported in patients 
with PCD24 or paraneoplastic encephalomyelitis25,26. Unlike patients with peD associated 
with gynecological cancer who almost always have anti-Yo antibodies3•27,28, anti-neuronal 
antibodies have been reported only in a few patients with HD-associated peD and never 
been well characterized6.\O. As Trotter et al. were the first to indicate the presence of anti-
Purkinje cell antibodies in the serum ofa 21 year-old woman with peD and HD6, we elected 
to name the antibodies examined in the current study, anti-Tr antibodies. 
Anti-Tr antibodies were not observed in peD associated with solid tumors, in patients with 
HD without neurologic symptoms, or in patients with cerebellar disorders other than peD. 
These data suggest that anti-Tr antibodies are in fact highly specific for lID-associated peD. 
Anti-Tr antibodies gave a sim.ilar pattern to that observed with anti-yo or other anti-Purkil~e 
cell antibodies in immunohistochemical studies on frozen human cerebellum. However, a 
more specific immunoreactivity was observed in rat cerebellum. Anti-Tr antibodies showed 
a characteristic dotted staining pattern of the molecular layer probably due to immuno-
reactivity with dendritic spines of the Purkinje cells. In a previous patient with 
HD-associated peD, Greenlee et al. S found an antibody that, although not specifically 
mentioned by the authors, also produced a dotted pattern in the molecular layers. Other 
anti-Purkinje cell antibodies, including anti-Yo, did not show this characteristic immunoreac-
tivity in the molecular layer of the rat cerebellum. In addition, anti-Tr antibodies, unlike 
anti-Yo, did not bind to the cytoplasm of stellate and basket neurons of the molecular layer, 
and did react very weakly with the dentate nucleus of the rat cerebellum21 . 
The abolition of the immunoreactivity by preincubation of the tissue sections with pepsin 
suggest the Tr antigen is a protein. Our failure to identify the neural antigens recognized by 
anti-Tr antibodies in immunoblots is in agreement with previous studiesJO• Unger et al.9 
studied the serum of a patient with anti-Purkinje cell antibodies and HD-associated peD. 
After affinity chromatography, the serum reacted against two bands of 43 kDa and 18 kDa, 
and three weak bands of 74 kDa, 56 kDa and 30 kDa. However, this finding should be 
confirmed with other antibody positive patients to conclusively demonstrate that these bands 
are characteristic. In the current study, the negative results in inununoblots of purified 
Purkinje cell extracts suggest that anti-Tr antibodies may be directed against conformational 
epitopes that are destroyed during processing rather than that the negative results are due to a 
low concentration of the antigen in the sample. 
Anti-Tr antibodies reacted with several neuronal types of the central and peripheral nervous 
system in the rat brain. Anti-Purkinje cell antibodies found in a previously reported patient 
with HD-associated peD did not stain neurons outside the rat cerebellums. The reasons for 
the discrepancy with our results are unclear, but could be due to the use of different 
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immunohistochemical procedures, antibody dilutions or, less likely, that the patients had 
different antibodies. 
The distribution of the anti-Tr immunoreactivity in the rat brain does not provide any clue 
about the possible functional role of the recognized antigen(s). Anti-Tr binding neurons do 
not belong to a particular functional group of the nervous system. In the cortex and 
hippocampus, the location and morphology of anti-Tr positive neurons is suggestive of local 
circuit rather than projective neurons, a similar pattern observed with antibodies against 
some calcium-binding proteins29• The anti-Tr staining in the cerebellum and brainstem was 
similar to the distribution of P-type calcium channel detected by a polyclonal rabbit 
antibody30, although the immunoJabeling of the hippocampus was clearly different from that 
shown in the present study31. 
The origin of anti-Tr antibodies in HD-associated PCD is unknown. HD patients present 
with dysfunction of T-cell mediated immune responses that leads to increased risk for viral 
infections32• In some patients, the onset of PCD is preceded by mild symptoms of a viral-like 
infection suggesting that the cerebellar syndrome, or the presence of anti-neuronal antibod-
ies, or both, could be the manifestation of postinfectiotls cerebellitis23• Antibodies against 
Purkinje cells were reported in a patient with cerebellitis following EBV infectionl2. In 
contrast, we were unable to find anti-Tr antibodies in six patients with post-infectiolls 
cerebellitis or in patients with recent EBV infection. Other findings that cast doubt on the 
possible infectious origin of the anti-Tr antibodies in our patients include the persistence of 
high titers of anti-Tr antibodies for many months until the HD was treated, and the decrease 
of the titer after treatment of the HD, suggesting that the neoplasm itself was the initial 
trigger of the antibody response. Our failure to detect anti-Tr immunoreactivity in HD tumor 
samples from patients without PCD does not rule out this possibility. Yo antigens are always 
present in the tumors of patients with PCD and anti-Yo antibodies2 but in only 20% of 
tumors from patients without PCDB. Future evaluation of Tr antigen expression by the 
tumor of HD-associated PCD patients with anti-Tr antibodies will help to resolve this issue. 
Conclusion 
We conclude that anti-Tr antibodies defined as in this study are characteristic for 
HD-associated PCD. Anti-Tr antibodies may be easily distinguished from other anti-Purkinje 
cell antibodies observed in patients with different neurologic disorders in inuuunohistochem-
ical studies of rat cerebellum. In addition, the distribution of the anti-Tr inul1unoreactivity in 
the rat brain may help in their identification. Until the cloning of the Tr antigen(s), which 
will allow the unambiguous diagnosis of anti-Tr antibodies, the immunohistochemical 
pattern described in tillS study coupled with the absence of reactivity in immunoblots of 
isolated Purkinje cells or mouse cerebellum homogenates should be used to identify the 
anti-Tr antibodies. 
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Introduction 
Paraneoplastic diseases of the central nervous system (PNS) consist of a variety of neurolog-
ical disorders including encephalomyelitis (limbic encephalitis, brainstem encephalitis and 
acute myelitis), sensory neuronopathy, subacute cerebellar degeneration, visual 
paraneoplastic syndrome, stiff-man syndrome and motor neuron disease l .), 
For the clinician, it is often difficult to arrive at a reliable diagnosis of the neurological 
syndrome and to detect the underlying tumor. Neurological signs and symptoms, although 
often stereotypic, are not specific. In two thirds of cases the underlying tumor is not 
discovered until after the first neurological symptoms4, Furthermore the neoplasm may be 
small and difficult to detece-7• 
PNS are frequently associated with semm autoantibodies reactive with neuronal antigens that 
are also present in the underlying tumor. These antibodies include (1) anti-Yo antibodies 
also called type I anti-Purkinje cell antibody (PCA-I), APCA-I or Type I antibody, (2) anti-
liu, also called type I anti-neuronal nuclear antibody (ANNA-I) or Type IIa antibody and 
(3) anti-Ri, also called type II anti-neuronal nuclear antibody (ANNA-2) or Type lIb 
antibody (table I). A clinical diagnosis of PNS is snpported by the finding of these specific 
anti-neuronal antibodies. The detection of these antibodies should also lead to a focused 
search for specific underlying neoplasms8-12• 
A major problem in comparing results obtained by different groups of investigators has been 
that individual laboratories have employed different laboratory techniques for detection of 
these antibodies. Although identification of these antibodies has rested on immunohisto-
chemistry and \\'estern blot analysis, not all laboratories have used \Vestern blot analysis to 
identify the molecular weight of detected antigens. Furthermore, material from a number of 
animal species has been used, methods of preparing substrates for \Vestern blot are not 
always spelled out and concentrations of serum and end-point staining have not always been 
defined. In some cases, this- has resulted in substantial differences in sensitivity and specifi-
city of these techniques for antibody detectionI2-17 • Some early publications and recent 
reports on several incompletely characterized novel anti-neuronal antibodies have compli-
cated this situation and make it even more difficult for the clinician to interpret the diagnos-
tic value of these antibodies 18_n. 
Approach to consensus 
In view of these uncertainties and the existing controversy between some research groups on 
the techniques for proper detection and on the terminology of anti-neuronal antibodies in 
paraneoplastic neurological disease, a workshop on this topic was organized during an 
international symposium on Paraneoplastic Neurological Disease, held on 22-23 October 
1994 in Rotterdam, The Netherlands. The primary aim of this workshop was to develop a 
consensus report that contained generally accepted guidelines in order to make laboratory 
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testing of anti-neuronal antibody detection more uniform and easily interpretable and to 
clarify the terminology. 
This paper reports on the work from II international research groups that formed a 
consensus group which discussed the terminology, methodology of detection and interpre-
tation of paraneoplastic anti-neuronal antibodies. 
Terminology 
Since the initial description of a paraneoplastic anti-neuronal antibody by \Vilkinson and 
Zeromski in 1965, different terminologies for paraneoplastic antibodies have been proposed 
by different groups working in this field23 • It is important to realize that during a relatively 
short period of time both denominations and methods of detection have been refined along 
with changes in improvement of techniques and disclosure of antibody characteristics. A 
brief survey on the terminology will be presented first. 
In 1982 an anti-Purkinje cell antibody was identified by Greenlee and later by Jaeckle et al. 
and Greenlee and Brashear in patients with paraneoplastic cerebellar degeneration and 
gynaecological malignancies8,JO,2-t,25. Neither group designated a specific name but described 
the antibody as an anti-Purkinje cell antibody. Vhrious names were designated later. The 
name anti-yo was introduced in 1990 for those anti-Purkinje cell antibodies reacting with 34 
and 62 kD proteins from isolated Purkinje cells on Western blot26• The abbreviations PCA Of 
PCab were used by Lennon et al. in 1989 using immunohistochemical criteria and were 
modified to PCA-l in 1994, based solely on inununohistochemical"criteriaI2•ls,16. The term 
APCA-l was introduced in 198921• 
The original description of possible anti-neuronal nuclear antibodies mainly emphasized the 
cytoplasmic staining by the antibody23. Graus et al. noted the nuclear reactivity and 
described reactivity with 37-40 kD molecular weight proteins on \Vestern blotting9,28. In 
1986, this antibody was designated anti-Hu (after the first patient in whom it was dis-
covered28. The anti-Ri antibody was first described in 1988 using both immunohistochemical 
and \Vestern blot characterization29 and its name was designated in 199111. The term ANNA 
was introduced by Lennon et a!. in 1989 and was modified to ANNA-I and ANNA-2 in 
1994 based on immunohistochemistry alone. Others identified differences in ANNA 
reactivity as anti-Hu and anti-Ri by additional testing on \Vestern blots12,ls,16. 
The term Type I for anti-Purkinje cell antibodies and Type II for the anti-neuronal nuclear 
antibody were designated in 1983, later in 1991 and further specified as Type IIa and Type 
IIb in 1993, based on the combination of inununohistochemistry and \\'estern blotting25,3()..)2. 
Although each of these investigators have made valuable contributions to current under-
standing of this area, it is clear that unequivocal definition and terminology is necessary in 
order to be able to compare results of different laboratories and to avoid confusion to the 
clinician. Obviously, the main point is not as much how these antibodies are being named as 
to formulate criteria on the proper methods of detection and classification of these antibod-
ies. 
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Methods of detection 
The nomenclatures with numerical designations likc ANNA 1 and 2, PCA-l or Type I, IIa 
and lIb (table 1) were originally given to those antibodies determined by immunohisto-
chemical assays 0111y I2,25,30.32, The terms anti-Hu, -Ri and -Yo are based on determination by 
both immunohistochemistry and \Vestern blotting ll ,26,33. Hence, strictly speaking, these termi-
nologies cannot he considered to be interchangeable. Nevertheless, all nomenclatures do 
intend to refer to equivalent antibodies and should therefore preferably be regarded as 
synonymous, as suggested in the December 1994 issue of Neurology 15,16,34,35. However, to 
do this identical methods and criteria should be used, which implies redefinition of the 
criteria in such a way that for proper detection of all three PNS-associated anti-neuronal 
antibodies both immunohistochemical and Western blot assays are required. The consensus 
group agrees that identification by immunohistochemistry alone, even when performed in 
experienced laboratories and according to previously given recommendations l5•16, cannot be 
considered as a sufficiently reliable test for the characterization of these antibodies. If on 
sole immunohistochemistry, anti-Purkinje cell cytoplasmic antibodies or anti-neuronal 
nuclear antibodies are detected, one should speak of anti-Purkinje cell antibody (APCA or 
PCA) or anti-neuronal nuclear antibody (ANNA), not further specified. In line with the 
recommendations of IINeurology'l we consider the anti-Yo antibody synonymous with 
APCA-l or PCA-l, anti-IIu synonymous with ANNA-l and anti-Ri synonymous with 
ANNA-2, providing that both inununohistochemical and \Vestern immunoblot assays are 
used. 
A specimen yielding no reactivity on immunohistochemistry is interpreted as negative for 
anti-neuronal antibodies, although \Vestern blot analysis may detect low titers of anti-Hu 
antibodies in sera of neurologically normal patients with small cell lung cancer using highly 
affinity-purified recombinant proteins. 
Some general guidelines on the appropriate methods together with technical details will be 
given here in order to provide non-controversial and accurate criteria for the definition of 
these antibodies. \Ve also expect that, by following these guidelines, identification of novel 
antibodies will become more easily comparable and interpretable. 
ImmUllohislochemisll), 
The first screening for the presence of anti-neuronal antibodies in serum or CSF consists of 
an immunohistochemical assay. Immunohistochemical screening can also detect other 
atypical (non-Yo, non-Hu or non-Ri) anti-neuronal antibodies. 
Patients' sera should be sent overnight and tested within 48 hours or can be stored at 4°C for 
several weeks. For longer delays samples should preferably be stored at -80 'c until tested. 
Human cerebellar and cerebral cortex are preferentially used as tissue substrates for 
immunohistochemistry. Occasionally, dorsal root ganglia, myenteric plexus, medulla, spinal 
cord and control tissues such as liver, muscle and kidney can be used for special interests, 
although on indirect immunohistochemistry some background staining may be found due to 
the presence of irrelevant IgG in systemic tissues. If obtaining human tissue is difficult, 
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alternatively mouse or rat tissue can be used for avidin biotin or peroxidase anti-peroxidase 
methods as these species express most human PNS antigens. However misleading results 
can be obtained when fluorescence staining is used in non-human tissueJ6• For novel 
antibody screening one should always employ human tissue and it may probably prove 
valuable to use non human tissue as well. 
Criteria for positive inununohistochemical identification of antibodies are presented in table 
1. It is possible to discriminate immunohistochemically between anti-Hu and anti-Ri by 
using peripheral neurons, for example myenteric plexus or dorsal root ganglion cells as 
substrate I5•37• In contrast to the Hu antigen, the Ri antigen is not expressed in these cells. 
Antibody titers should be determined by serial dilutional titration. In each series of tests, 
parallel control sections should include a section without use of primary serum, a section 
using a known positive serum and one with a known negative serum. The secondary 
antibody can be labeled with either fiuorescein-isothiocyanate (FITC), horse-radish 
peroxidase (HRP), alkaline-phosphatase (AP), biotin or other enzymes to visualize bound 
antibodies. Either polyclonal or monoclonal secondary antibodies against total human Ig or 
IgG may be chosen. Titers of antibodies depend on many factors among which are the purity 
of the antigen, concentration of the secondary antibody, time of incubation, quality of 
tissues, and type of secondary antibody. Dilution and diluent of the secondary antibody is of 
great importance in this respect. The secondary antibody should be diluted in the same 
medium used as blocking agent. Initial assays from the early groups used the FITC-Iabeled 
secondary antibody 8·10,38 which is easy to work with and reliable, Other frequently used 
techniques are avidin-biotin peroxidase and streptavidin-peroxidase methods 39, Different 
labeling techniques will often lead to difference in end-point staining. In general, 
inununoperoxidase and avidin-biotin methods give higher endpoint titers than indirect 
inununofluorescence. Therefore each laboratory should critically establish dilution and 
method of visualisation of secondary antibody, using appropriate positive and negative 
controls. 
Ideally, a set of positive reference control sera are assembled by exchange of various sera 
between experienced laboratories, 
End-point staining titers for positive identification of antibody should be determined using 
large series of controls and positive standards in order to prevent false positive detection. In 
most immunohistochemical assays using FITC labeled secondary end-point titers of> 1 :500 
can be regarded as positive, yielding high specificities, although in some patients lower titers 
can represent true positive reactivity 14. 
\Vith high serum IgG concentrations background staining can occasionally make the assay 
difficult to interpret. Isolation and direct labeling of senun IgG may eliminate background 
reactivity and may improve the quality of the assay39, 
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Table 1 
Name of anti· 
body 
Anti-Htl 
ANNA-I 
Type lIa 
Anti-Yo 
PCA-I 
Type I 
APCA-I 
Anti-Ri 
ANNA-2 
Type fib 
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Criteria for identification of paraneoplastic anti-neuronal antibodies 
First description of antibody 
Graus et al. 198628 
Lennon et al. 198912 
Greenlee et a!. 199132 
Furneaux et al. 199026 
Lennon ct al. 1994 IS 
Jaecklc ct al. 198525 
Greenlee et al. 198224 
Luqueetal.1991 11 
Lennenet al. 19941s 
Brashear a!. 199430 
Paraneoplastic NeUfolo-
gical Syndrome 
Encephalomyelitis, sen-
sory neuronopathy, 
autonomic neuropathy 
Subacute cerebellar syn-
drome, dysarthria and 
nystagmus 
OPSOCiOllllS, ataxia, nys-
tagmus dizziness, dysar-
thria 
Most frequently asso-
ciated tumors 
Small cell lung cancer, 
neuroblastoma; rarely 
non-small cell lung can-
cer, prostate cancer, 
seminoma 
Ovarian cancer, breast 
cancer, other 
gyneacological cancer 
Breast cancer (total 
number of patients de-
scribed still small), 
small cell lung cancer 
(one case) 
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Table 1 Criteria for identification of paraneoplastic anti~neuronal antibodies 
(continued) 
ImmUIlOhistoche8 
mical criteria for 
detectioll 
Strong staining of 
all CNS and PNS 
neuronal nuclei, 
sparing of nucleoli 
and weaker fine 
granular staining of 
cytoplasm. Negative 
on systemic tissues. 
Coarse granular 
staining of Purkinje 
cell cytoplasm and 
proximal axon and 
dendrites, negative 
nuclei. Negative on 
systemic tissues. 
Strong staining of 
all CNS but not of 
PNS neuronal nU 8 
clei with sparing of 
nucleoli and weaker 
fine granular stai 8 
ning of cytoplasm. 
Negative on syste-
mic tissues. 
Western blot criteria for 
detection 
35 8 40 kD reactive bands 
all extracts of isolated 
CNS neurons or (optio-
nal) reactivity with re-
combinant protein 
(HuD, HuC, He1-N1). 
62 kD band and 1110stly 
34 kD band on purified 
Purkinje cell extracts or 
(optional) reactivity with 
CDR 34 and CDR 62, 
p52/PCD 17 recombinant 
proteins. 
55 and 80 kD bands on 
neuronal proteins or (op-
tional) reactivity with 55 
kD recombinant protein 
Nova. 
COl11ments 
Anti-Hu: both imlllunohistochemistry and 
Western blot identification required. 
ANNA-t or Type lIa: il1llllunohistochemical~ 
Iy identical to allti-Hu, initial description 
lIsed no \\estern blot identification, but \\es-
tem blot identification now required for dia-
gnostic purposes. 
For Westem blot identification proteins from 
isolated eNS neurons are sufficiently reliable 
when 37-40 kD protein complex is identified. 
Use of recombinant proteins is optional (li-
censed in USA). 
Anti-Yo: both immunohistochemical and 
Westem blot required. 
APCA-I, PCA-t or Type-I: initial description 
used no Westem blot identification, but for 
diagnostic purposes now required. 
For Westem blot continnation proteins from 
isolated Purkinje cells reliable when 34 and 
62 kD bands are identified. 
Use of recombinant proteins is optional (li-
censed in USA). 
Anti-Ri: both immunohistochemical and 
Western blot identification required 
ANNA-2 or Type lIb: initial description used 
no Westem blot identification, but now requi-
red for diagnostic purposes. 
For Western blot identification proteins from 
isolated CNS neurons are sufficiently reliable 
when 55 and 80 kD band are identified. 
Use of recombinant protein Nova is optional 
(licensed in USA). 
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Western bIoI 
Essential and optional criteria for positive identification on \Vestern blot are described in 
table 1. Since the availability of recombinant antigens (HuD, HeIN-lIple21, HuC, Ri (Nova), 
CDR34, CDR62 and p521PCDl7, CZF) it may be useful, though not obligatory, to use these 
complementary to neuronal extracts40•46, One should realize, especially in the United States, 
that the commercial diagnostic use of the recombinant proteins HuD, Yo (CDR62) and 
Ri(Nova) is licensed by Genica (Boston, Mass. USA). 
\Vhen using neuronal proteins as antigenic substrate, an important factor for the diagnostic 
reliability of this technique is the nature and concentration of the protein extracts. Collected 
tissues should be processed as rapidly as possible (preferably within 6-8 hours, maximally 24 
Ius) post mortem. 
For anti-Hu detection on "'estern blots, a protein extract from isolated neurons or neuronal 
nuclei from normal human, rat Of murine cerebral or cerebellar cortex is used39. If available, 
the recombinant HuD protein can also be used. For recognition of anti-Yo and other anti-
Purkinje cell antibodies on Western blots, a protein extract of isolated human or murine 
Purkinje cells, separated on a sucrose/ficoll gradient, is used. Optionally the Yo-recombinant 
protein (CDR 62) or the p52 recombinant protein of Sakai can be used next to the Purkinje 
cell proteins 40,42. 
For identification of anti-Ri antibodies, the same guidelines as used for anti-llu antibodies 
are applicable. For the reliable detection of antl-Ri antibodies, \Vestern blotting on neuronal 
proteins is required. The Ri recombinant protein may also be used for proper recognition of 
anti-Ri antibodies. However, inununohistochemistry and \\'estern blot on neuronal proteins 
are sufficiently reliable for demonstrating the anti-Ri antibody. 
As a control antigenic substrate, protein extracts from human and murine liver, kidney and 
or muscle can be used. 
Diagnostic value 
Although no large eiinico-pathological studies are available to accurately establish sensitivity 
and specificity of these assays for detection of PNS-associated anti-neuronal antibodies, it is 
clear that their presence has high diagnostic value4,1I,14.25, However, in a minority of patients 
with characteristic PNS and high antibody titers no tumor could be found despite extensive 
evaluation,5,47. One presumes that in these cases the tumor is either too small to be detected 
or may have spontaneously regressed 4.5, On the other hand, failure to detect anti-yo, anti-
Hu or anti-Ri antibodies in patients with suspected paraneoplastic syndromes does not 
exclude a paraneoplastic neurological disease as it does not exclude an underlying malig-
nancy. 
If, following the guidelines above, anti-Yo (APCA-I), -Hu (ANNA-I) or -Ri (ANNA-2) 
antibody is identified, a sufficiently reliable diagnosis of PNS can be made in spite of the 
lack of proof of the presence of cancer. 
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Lastly, some cases with a clear clinical diagnosis of PNS are antibody-negative in the 
presence of cancer. \Vhether these patients harbour paraneoplastic antibodies that cannot be 
detected with presently available methods remains unclear. 
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Definition 
Paraneoplastic syndromes of the nervous system (PNS) are syndromes associated with 
cancer, without invasion of tumor cells into the nervous system. The incidence of PNS has 
been reported as high as 9% of new cases with cancer, but largely depends on the definition 
of PNS used to establish this incidence l , In its widest definition PNS include neurological 
syndromes secondary to metabolic changes, opportunistic infections or changes in 
haemostasis induced by cancer and an important group of cancer-associated syndromes 
without clear cause. For example metabolic encephalopathy can be induced by hypercal-
caemia secondary to osseous metastasis or by hyponatriaemia secondary to inappropriate 
secretion of antidiuretic hormone. Mucinous products from cancer cells can evoke chronic 
intravascular coagulation producing occlusion of small vessels in the nervous system or 
fibrin deposits on mitral heart-valves leading to embolic occlusion of large cerebral arteries, 
A classic example of opportunistic infection is progressive multifocal leucoencephalopathy 
caused by selective invasion of the papova (JC and SV-40) virus into oligodendrocytes, 
Opportunistic infections can be the direct consequence of cancer or its treatment, but can 
also be secondary to diseases not associated with cancer, like diabetes mellitus, or acquired 
immunodeficiency syndrome or be the consequence of immunosuppressive therapy in 
patients with autoimmune disorders or organ transplants2•3, 
Therefore it would be more accurate to restrict the term paraneoplastic disorders of the 
nervous system for those syndromes which are uniquely associated with cancer. If defined in 
that way the first description of a true paraneoplastic syndrome was published in 1888 by 
Oppenheim4, Later, in 1938, the Dutchmen Brouwer and Biemond pointed at the possible 
relationship between the occurrence of cerebellar degeneration and carcinomas. The associa-
tion of encephalomyelitis with carcinoma was noted by Henson, Hoffman and Urich in 
19656 • Abnormalities of the peripheral nervous system in cancer were first recognized by 
Denny-Brown in 1948J and later by Henson, Russell and \Vilkinson in 19548• From then on, 
it became clear that a number of specific paraneoplastic syndromes could be associated with 
cancer, each having its own characteristic clinical presentation, sometimes associated with 
certain types of cancer and specific neuropathological findings. A common and important 
feature of these syndromes is that at the beginning of neurological symptoms, patients 
usually have no apparent cancer, 
Henson and Urich in 1982 were the first to give a definition of PNS: l!A paraneoplastic 
syndrome is a degenerative disease of the nervous system that is associated with the presence 
of cancer but not caused by the direct effect of the tumor, its metastasis or therapyl!2, 
By now we know that the "truel! PNS can affect any portion of the nervous system from the 
cerebellar cortex through the brainstem and spinal cord to peripheral nerves, neuromuscular 
junction or muscle. Clinical manifestations can reflect pathologic damage to a single specific 
structure in the nervous system (e.g. degeneration of Purkinje cells in isolated paraneoplastic 
cerebellar degeneration (peD)) or can reflect damage to multiple areas of the nervous 
system simultaneously, as in paraneoplastic encephalomyelitis (PEM). In other florid PNS, 
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for instance in some patients with paraneopiastic opsoclonus-myoclonus syndrome, no 
pathological damage is found at all. 
Regarding the recent insights in clinical course and possible pathogenesis of the various 
forms of PNS the original definition of Henson and Urich does not fulfil its purpose 
sufficiently. Also it is better to distinguish lltrue" PNS, i.c. is possibly immune-mediated, 
from other "paraneoplastic" neurological complications of cancer as mentioned in table 1. A 
better definition would be: "A paraneopiastic syndrome is an inflammatory disease of the 
nervous system that occurs in the presence of a hnuor, but is not caused by the direct effect 
of the tumor, its metastasis or therapy, and characterized by the finding of autoantibodies 
that react with a neuronal antigen, which similar antigen or antigenic epitope is also 
expressed on the underlying hlmor. ll 
In the future this definition might be simplified by stating that PNS are true autoimmune 
diseases caused by the presence of an ectopically expressed neuronal antigen on a tumor 
which induces an autoimmune response against the nervous system, resulting in neurological 
disease. This is until now only true for the PNS of the peripheral nervous system like the 
Lambert-Eaton myasthenic syndrome and myasthenia gravis, which can be regarded as PNS 
of the motor-endplate. 
Incidence 
Several studies have addressed the incidence of PNS. Results of these studies depend on the 
definition of the syndrome and on how strictly other catlses of neurologic dysfunction are 
excluded. For example a paraneoplastic sensory neuronopathy ocCUrs in less than I % of 
patients with small cell lung cancer (SCLC), but a combined sensori-motor polyneuropathy 
occurs in almost 40% of patients with SCLC and is likely to be related to weight loss and 
nutritional stahls3.9. iO• 
Another example on the different frequencies is found in patients with cerebellar degenera-
tion. Croft and Wilkinson found only 2 of 319 patients with lung cancer suffering from 
cerebellar ataxia and only 3 of 1476 patients with any type of cancers. Wessel et al. found 13 
of 50 patients with lung cancer showing cerebellar signs when analysed by posturographic 
analysisll (table I). These conflicting reports make it difficult to estimate the incidence of 
true paraneoplastic syndromes. In general it can be said that the clinically significant PNS 
(i.e. that can be diagnosed by the demonstration of anti-neuronal antibodies) occur in less 
than 1 % of patients with cancer. In chapter 6 we estimated the frequencies and incidence of 
PNS in The Netherlands. We found anti-neuronal specific antibodies in 67 (4.1%) of the 
1600 examined patients, including 35 anti-Bu antibodies, 6 anti~ Yo antibodies, 3 anti~ 
Purkinje cell antibodies (anti-Tr) associated with Hodgkin's disease and 2 anti-Ri antibodies. 
Antibodies against the CAR-protein and the 128 kD protein associated with stiff-man 
syndrome were not found. In 21 patients (1.3%) other, novel anti-neuronal specific anti-
bodies were identified. 
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In The Netherlands we represent the only reference laboratory for the detection of 
paraneopiastic anti~lleuronal antibodies and we presume that we receive material from 
virtually all patients suspected of PNS. Given this assumption, in a population of 3000 
patients with a clinical suspicion on PNS, approximately 2% had an immunologically 
confirmed diagnosis of PNS. 
The overall incidence of PNS in patients with cancer in The Netherlands thus is not higher 
than 0.1%. For each syndrome separately the incidence can be calculated (table 1 and see 
cbapter 6). For the Hu syndrome the incidence would be 7 on a total of 1300 new SCLC 
cases per year or 0.53% of all newly diagnosed SCLC patients in The Netherlands. Incidence 
of anti-Yo positive peD would be 1.2 cases on a total of 1275 newly diagnosed ovarian can-
cers/year in The Netherlands yielding an incidence of less than 0.1%. For the anti-Tr and 
anti-Ri antibody associated PNS, incidence rates are 0.16% and 0.01% in Hodgkin's disease 
and breast cancer patients, respectively. 
Importance 
Although PNS are rare, their recognition is important for several reasons. First, in 80% of 
cases the neurological symptoms precede the diagnosis of the underlying cancerJ2. In these 
cases, diagnosis of PNS wiJI direct the search for an underlying malignancy and may lead to 
early detection of the tumor. Second, since no effective treatment is known for most PNS, it 
is important to distinguish true PNS from other neurological complications of cancer, that 
might be treatablelJ. Third, the hypothesis of the cross-reactive anti-tumor immune response 
and the discovery of the antibodies and their antigens provide a unique model to study the 
interaction of cancer, immunological mechanisms and the nervous system13• The identifica-
tion of novel proteins, playing key roles in the development and maintanance of neurons, 
may in future prove to benefit studies on regeneration of neurons and thus be applicable in 
therapeutic strategies14•17• 
The elucidation of the exact pathogenic mechanism may be more feasible in PNS than in for 
instance multiple sclerosis, because of the isolated and cloned antigens. ParalJel mechanisms 
may play a role in the pathogenesis of multiple sclerosis and other immune mediated 
diseases, which occur more frequently. In this way shldies on the pathogenesis of PNS may 
show its benefit in another way. 
Direct use of the identification of novel anti-neuronallanti-tumor specific antibodies may be 
found in the application of adoptive immune-therapy and inunune imaging. Toxin or tracer 
labeled monoclonal antibodies or antigen specific cytotoxic T-cells may be examples of such 
applications. First studies using radioactively labeled anti-Hu monoclonal antibodies to 
detect early stages of SCLC or micrometastases are currently ongoing and first steps to study 
the cytotoxicity of Hu specific cytotoxic T-cells on SCLC are taken. 
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Table 1 Frequency of paraneoplastic syndromes in several studies 
No. of patients Percentage of pa-
with cancer Type of Type of exam i- tients with cancer 
examined cancer nation Neurologic diagnosis and neurologic signs Ref. 
1465 Any Clinical Neuromyopathy 6.6 9 
1465 Any Clinical Cerebellar ataxia 0.2 9 
150 SCLC Clinical, EMG LEMS 2.0 18 
150 SCLC Clinical Weakness 44.0 18 
171 Any Sensory, clinical Sensory neuropathy 12.0 10 
50 Lung Postural testing Cerebellar ataxia 26.0 II 
100 Lung Muscle biopsy Neuromuscular 33.0 19 
641 SCLC Clinical, EMG LEMS 0.3 20 
3843 Lung Clinical Encephalomyelitis 0.36 2 
3843 Lung Clinical Peripheral neuropathy 0.7 2 
908 Ovary Clinical Cerebellar degenera- 0.1 21 
lion 
EMG = electromyogram; LEMS = Lambert-Eaton myasthenic syndrome; SCLC = small-cell lung cancer 
Source: J.B. Posner. Neurologic complications of cancet Contemporary neurology series, vol. 45, p.355. F.A. 
Davis Company, Philadelphia, USA, 1995. 
Pathogenesis 
The pathogenesis of most PNS is unknown, but several mechanisms have been put forward. 
Oppenheim proposed that neurological complications of cancer might be caused by a toxic 
substance released by the tUl11or4• \\'e now know that tumors indeed can secrete substances 
like cytokines or hormones that interfere with central nervous system (CNS) function22 • 
Cachexia, fatigability, asthenia and general weakness can affect up to 50% of patients with 
cancer during some stage of their disease. 
Another mechanism was proposed by Delllly-Brown, when he probably described the first 
case of a pure paraneoplastic dorsal root ganglionitis. He suggested competition for a vital 
nutrient, in this case pantothenic acid? Deprivation of pantothenic acid in swine gives rise to 
identical features as found in dorsal ganglionitis?, 
A third pathogenic mechanism may be an opportunistic viral infection involving the CNS. 
Progressive multifocal leucencephalopathy, which was originally classified as a 
paraneoplastic neurological disease, is such an exampleD. Opportunistic viral infections 
mainly playa role in patients immuneMcompromised by tumors such as malignant lymphoma 
or by chemotherapy. However, no viral particles have been isolated from affected brain 
regions of PNS patients. 
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A fourth pathogenic mechanism, discussed in more detail below, is that of PNS being an 
immune mediated disease. In the last to years, this hypothesis has gained support by the 
results of many studies demonstrating the involvement of both the humoral and cellular 
immune system. However, when thinking about the pathogenesis of PNS we have to realize 
that each separate syndrome might have a different pathogenesis. 
For example, in peD the antibodies react selectively with Purkinje cells possibly resulting in 
degeneration of these cellsH . Interestingly hardly any lymphocytic infiltrates are found in the 
cerebellum of PCD2.f.26. 
On the other hand, in paraneoplastic encephalomyelitis/sensory neurollopathy (PEMlPSN) 
the antibody seems to react with all neurons and yet clinically and pathologically only 
distinct areas are affected. Dorsal root ganglia and the limbic region are most frequently 
involved and infiltrates with CD8+ lymphocytes are found27• 
The situation in anti-Ri paraneoplastic opsoclonus myoclonus and in anti-Yo positive 
paraneoplastic cerebellar degeneration is also different from the anti-Hu syndrome. The 
antigens (Ri and Yo) are only expressed by tumors (e.g. breast and ovarian carcinoma) of 
patients with PNS and not by tumors of patients without PNS. This is in contrast to the 
expression of the Hu antigen associated with PEMlPSN, which is expressed in virtually each 
SCLC. 
Autoantibodies and al1ti-newvl1al antibodies 
The question can be raised whether the anti-neuronal antibodies are true autoantibodies 
when compared to the autoantibodies associated with other autoimmune diseases. Several 
aspects need to be addressed to answer tlus question. 
In the normal individual there is evidence of autoimmunity in the B-cell repertoire. Normal 
donor serum often contains autoantibodies which increase in titer during infections, 
immunization and pregnancy52. In addition, activated or EBV-transformed B-cells as well as 
human lymphocyte hybridomas may also secrete autoantibodies in vitroS3 • 
In one group of autoimmune diseases (i.e. systemic autoimmune diseases) the autoantibodies 
bind to key intracellular proteins or to nucleic acids involved in the regulation of transcrip-
tion and translation, DNA replication, cell division and RNA processing and the antibodies 
are usually non-organ specific5~. Examples are systemic lupus, scleroderma, Sjogren's 
syndrome, mixed connective tissue disease and polyw and dermatomyositis5-1. However, in 
neither of these diseases a direct pathogenic role of the antibody has been proven. On the 
other side of the spectnllTI of autoimmune diseases are those diseases in which autoanti-
bodies are directed against membrane proteins (e.g. ISH receptor) or cell specific products 
(e.g. thyroglobulin), like thyrotoxicosis and Hashimoto's thyroiditis. In this group of 
diseases evidence does exists that the antibodies, that are usually organwspecific, are directly 
involved in the pathogenetic mechanisms causing disease55• 
\Vllether PNS belong to the group of autoimmune diseases can be discussed. Paraneoplastic 
antibodies clearly react with "self' antigens. In this way the antiwneuronal antibodies should 
be regarded as true autoantibodies. From the side of the tumor, however, they may be 
regarded as effective anti-tumor antibodies raised to defend the body against the harming 
tumor cells. 
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One parallel between PNS and the known autoimmune diseases can be drawn. Compared to 
the nature of the antigens the PNS of the CNS clearly belong to the gronp of generalized 
autoimmune diseases. The paraneoplastic antibodies are aU directed against intracellular 
antigens, which probably play key roles in cell development and maintanance. On the other 
hand, it can be reasoned that PNS of the peripheral nervous system, e.g. LEMS and 
myasthenia gravis, belong to the other end of the spectrum of autoinunune disease. LEMS 
and myasthenia gravis show parallel features with for instance thyrotoxicosis with respect to 
the nature of antigen (membrane bound voltage-gated calcium channel and acetyl-choline 
receptor versus membrane-bound TSH receptor). In these diseases there is more evidence on 
the pathogenic role of antibodies than in PNS of the CNS. 
Major difference, however, is that autoantibodies against nuclear antigens, e.g. ANA such as 
anti-SS-A, anti-SS-B or anti-DNA can also be found in individuals without symptoms of 
disease (chapter 3). This is definitely not true for the PNS. PNS associated antibodies are 
solely found in patients with cliuically definite PNS. 
Another difference between PNS and other autoimmune diseases is that in PNS, no HLA-
class association has been found yet56. However, our finding of a high frequency of systemic 
autoantibodies in patients with PNS suggests that a genetic susceptibility to develop autoim-
mune phenomena may be a prerequisite to develop PNS (chapter 3). 
Immune palJlOgenesis 
There is circumstantial evidence that a humoral, and recently also a cellular autoinmmne 
response, may be involved in the generation of PNS. However, it is uncertain whether 
autoantibodies or cellular cytotoxicity are pathogenic or represent an epiphenomenon of the 
disease process. 
The idea that paraneoplastic neurological syndromes might have an autoimmune basis 
originates from neuropathologic findings of lymphocytic parenchymal infiltrates, without a 
causative infectious agent 6.7. \Vilkinson raised the question of a humoral immune patho-
genesis when describing the first anti-brain antibodies in serum of patients with carcinoma-
tous sensory neuronopathy 28. 
Further support for an autoimmune pathogenesis was provided by the finding of a patho~ 
genic antibody to voltage-gated calcium channels (VGCC) in paraneoplas!ic Lambert-Eaton 
myasthenic syndrome (LEMS)20.29, and the demonstration of the serum and CSF autoanti-
bodies in PNS patients that are reactive with antigens in both the underlying neoplasm and 
in the central nervous system neuronsJQ..-JJ. 
Evidence for an autoimmune genesis is convincing in LEMSH. Both active and passive 
immunisation experiments have demonstrated the role of anti-VOCC antibodies in the 
development of LEMS. For other PNS, the finding of specific antibodies only suggests a 
similar pathogenic role of the antibody. However, neither in vivo nor in vitro studies have 
been able to demonstrate a direct pathogenic role for anti-neuronal antibodies in other 
PNS35.39. One crucial difference between LEMS and PNS of the central nervous system 
seems the nature of the antigen against which the antibodies are directed, being a membrane-
bound ion-channel in LEMS towards nuclear or intracytoplasmic proteins in PEMlPSN and 
PCD. Binding of anti-VOCC antibodies to the calcium channel has been shown to block the 
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influx of calcium29, whereas little is known about the effect of the binding of antiwHu or anti-
Yo and other antibodies to their corresponding antigens. If binding of the antibodies to the 
paraneoplastic antigens does not influence their function, this might explain the failure of the 
passive and active immunization experiments in PNS. Furthermore, in contrast to LEMS, the 
in vivo accessibility of the Hu and Yo antigens for antibodies is clearly different (intracyto-
plasmic versus membrane bound) and has been disputed lately40. 
The paraneoplastic antibodies, if produced in response to antigenic stimulation by a tumor in 
the periphery, must first gain access to the eNS. Intraperitoneal injections of large quantities 
of rabbit IgG in rats with intact blood~brain barrier has resulted in retrograde axoplasmic 
transport to spinal cord, medullary Illotor neurons and Purkinje neurons2J. However, 
quantitative analysis of anti-Hu and anti-Yo antibody in the cerebrospinal fluid of PNS 
patients has also shown evidence of intrathecal anti-Hu IgG synthesis. Once in the CSF, it 
appears that PNS antibodies can reach their target; intraventricularly injected IgG in rats or 
guinea pigs localizes within Purkinje cells. Pathologic examination of CNS tissues and 
tumors of patients with PEM has revealed IgG bound to nuclei of neurons and tumor cells12• 
However, immunohistochemical localization of anti-Hu IgG has shown only limited 
correlation with clinical symptoms and regions of major tissue injuryll.41-42. Immunoglobulin 
depositions within neuronal tissues are primarily of the IgG] and IgGJ subclasses. The 
finding of IgG deposition within neurons in a biopsy taken from a patient with PNS suggests 
that antibody gains intracellular entry prior to death26• However, the recent finding of anti-
Hu IgG in post mortem specimens of HuD immunized mice and of patients with PEMlPSN 
has been disputed by data suggesting that the apparent uptake of anti-Hu IgO by neurons in 
vivo may be an artifact and possibly due to postmortem perivascular diffusion of anti-Hu 
IgG and tissue processing methods~o. If this is true, these findings have wide implications on 
the thinking about the role of anti-I-Iu in the pathogenesis of PEMlPSN and support the 
notice that anti-Htl (and other paraneoplastic) antibodies are merely an epiphenomenon of an 
as yet unknown pathogenic process. 
Anti-Hu antibodies in the pathogenesis of PE},UPSN 
Several findings indicate that anti-Hu associated PEMlPSN may result from either a humoral 
or a cellular immune response against one or more of the Hu antigens. One study showed 
that the anti~Hu antibody produces lysis of rat cerebellar granular neurons in vitro, which 
could be enhanced by the addition of complemene7• Others, however, were not able to 
reproduce these results43 . Other findings supporting a pathogenic role for the anti-Hu 
antibodies include (a) the strong correlation between the presence of high titers of anti-Hu 
antibodies in CSF and semm and the development of PEMlPSN in patients with SCLC or 
neuroblastoma, (b) intrathecal synthesis and deposits of anti-Hu antibodies in the CNS4\ and 
(c) the highly restricted expression of Hu antigens by the nervous system and the tumor". 
This restricted extraneuronal expression of Hu antigens suggests that the aberrant or ectopic 
expression of these proteins may trigger the immune mechanisms involved in PEMlPSN. 
The possibility of a mutation of the HuD gene from SCLC cell lines has been mentioned" as 
a cause for this trigger, but Sekido et al. and Dalmau et al. (unpublished data) were unable to 
confirm earlier reported mutations45. 
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Attempts at modeling anti-Hu PEM/PSN in animals until now have included (a) passive 
transfer of anti-Hu senun and IgG, and (b) immunization with recombinant HuD~o. Although 
animals developed high titers of anti-Hu antibodies with a similar pattern of epitope recogni-
tion, they did not develop clinical or pathological symptoms of PEMlPSN. These findings, 
along with the nature of the inflammatory infiltrates in the nervous system of patients with 
PEMlPSN, suggest that a cell-mediated cytotoxic response may be involved in the 
disorder7.~6. This is supported by the correlation found between expression of HuD 
coexpressed with major histocompatibility complex (.MHC) class I proteins on the tumor and 
development of anti-Hu associated PEMlPSN~7, indicating that T-cells are able to recognize 
the Bu antigen on the tumor. 
Other studies (chapter 4) examined the IgG subclasses of the anti-I-Ill antibodies in serum, 
CSF and nervous system ofPEMlPSN patients~8. These studies revealed predominantly IgGl 
and IgG3 subclasses of anti-Hu IgG with only weak complement activation in the affected 
areas of the CNS and no infiltration of natural killer (NK) cells, suggesting tllat complement 
mediated cytotoxicity and cytotoxicity mediated by NK cells do not playa major role in 
PEMlPSN. Severely damaged regions of the CNS contained infiltrates rich of EBMll+ cells 
(monocytes/macrophages) in the perivascular spaces". The ability of IgGI and IgG3 to bind 
Fe receptors may playa role in the recruitment of these cells. 
The inflammatory infiltrates primarily consist of CD4+ T-cells and CDI9+ B-cells in the 
perivascular spaces, while infiltrating lymphocytes are primarily CD8+ T_cells'6.27.~8. 
However, it remains to be established if these cytotoxic T-cells are Hu specific. Monocytes 
and macrophages have also been demonstrated within the interstitium~8. Other authors have 
reported some antibody-secreting cells27. 
Taken together these data suggest that the anti-Hu associated PEtvllPSN is a complex 
disorder in which both humoral and cell mediated mechanisms may play a role. The 
reactivity of IgG anti-neuronal antibodies to the cell-surface of neurons and in vitro studies 
using tissue cultures suggest that internalization of anti-Hu IgG is possible. Internalization of 
anti-Hu IgG may result ill inhibition of the fuuction of the Hu protein which, by homology 
with the Drosophila proteins Sex-lethal and Elav, appears to have a crucial role in establish-
ing and maintaining the neuronal phenotype l6. This inhibition may then result in irreversible 
cell damage and neuronal death. In addition, the analysis of the inflammatory infiltrates 
suggests a role of cell-mediated cytotoxicity in the pathogenesis of the disorder. Therefore, 
further studies on the pathogenesis of PEMlPSN and efforts to develop an animal model of 
PE1vVPSN should also be directed towards a cellular immune response against HuD. 
Allli-Yo alllibodies ill peD alld olher PNS 
As for the anti-Hu antibody, the pathogenic role for the anti-Yo antibodies in PCD has not 
been established. There is only circumstantial evidence like (a) a strict correlation between 
the presence of anti-Yo antibody and PCD", (b) the demonstration of uptake of antibodies 
by Purki,ue cells", (c) the demonstration of intrathecal synthesis of antibodies, and (d) the 
restricted antigen expression by Purkinje cells and tumor cells49. The expression of Yo is 
even more restricted than Hu, since only ovarian cancer of patients with PCD and anti-yo 
antibodies seem to express the antigen. This, however, has recently been disputed since the 
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the Yo-antigen seems also to be expressed intracytoplasmically in ovarian cancer cells of 
nOIl-PeD patients 50, 
Graus et al have reported negative results foHowing passive transfer of anti-Yo JgG to 
guinea pigs35 • Also intraventricular injection of anti-yo IgG did not produce cell damage, 
although uptake of IgG by Purkinje cells could be demonstrated. Even injection of anti-Yo 
IgG together with complement failed to induce any damage38,39,51. Neither peripherally 
recruited mononuclear cells, nor lymphocytes recruited from the CSF from a peD patient 
injected into the peritoneum or brain of SCID mice caused ataxia or Purkinje cell 108s38, 
Mice immunized with recombinant Yo produced high titers of anti-Yo antibody during a 3 
month period but no signs of disease39 • 
Explanations for the failure to produce disease in animals are numerous. Differences 
between human and rodent Yo protein and immunological make up of the host have to be 
taken into account. 
Still it can be reasoned that the anti-Yo antibody plays a pathogenic role in loss of Purkinje 
cells. The Yo antigen possesses a leucine-zipper motive, a DNA-binding sequence, that may 
influence the regulation of gene transcription. Binding of anti-yo to the protein might 
influence the function of the protein and affect cell metabolism and survival. 
In contrast to the findings in patients with PEMlPSN, the lack of finding of lymphocytic 
infiltrates in cerebellum of patients with PCD supports the hypothesis of direct antibody 
mediated cytotoxicity24,26.49• 
No studies are currently available providing data on possible pathogenic mechanisms in 
other PNS (e.g. anti-ill associated opsoclonus, PCD in Hodgkin's disease). 
Self tolerallce 
In recent years it has been postulated that self tolerance usually results from deletion and 
suppression of potentially reactive T-cell clones during intrathymic maturation. Acquired 
self tolerance may also result if the antigen fails to associate with MHC class II antigens or 
is expressed at such low levels that generation of self reactive T-cells does not occur. 
Furthermore excessive amounts of exogenous antigen may induce tolerance of B-cells and 
CD8+ T-suppressor cells. How the immune tolerance breaks down in PNS is largely 
unknown and may vary from disease to disease. In most autoimmune diseases, however, 
genetic factors next to enviromental influences playa role. 
\Vith regard to the antigens of the CNS, one theory is that neuron-specific proteins are not 
presented to the immune system during the establishment of immune tolerance. The 
implication is that the expression of neuron-specific proteins in tumor tissue (that expresses 
MHC antigens) may result in a profound inmlUne reaction. This is an even more interesting 
model for PNS if we realize that SCLC normally does not express MHC abundantly but 
SCLC cells in patients whith anti-Hu antibodies harbours relatively high MHC expression. In 
this study, 17 of 20 tumors from seropositive patients expressed both Hu and MHC class I 
proteins, but only 4 of 30 tumors from seronegative patients expressed both proteins47, 
Another intriguing question remains whether during the ontogeny self-reactive T or B celts 
were produced against antigens that are normally restricted to an immune privileged site as 
the CNS. This could explain why aberant expression of the antigen on a tumor then would 
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induce such a fulminant immune respons. Recently it has been suggested that peripherally 
activated or memory T~cells randomly wander to and from the CNS through the blood~brain 
barrier. Only those cells recognizing their antigen will be activated and proliferate resulting 
in inflammation. This model would perfectly fit the hypothesis on the pathogenesis of PNS. 
PNS therefore provide a unique model to study neuro-immune inflammation also because 
some of the antigens are well characterized. It is therefore of great interest to focus future 
research on cellular cytotoxicity to see if the PNS specific cytotoxic cells exists. Extrapola~ 
Hon of findings to other immune~mediated neurological diseases like multiple sclerosis 
further warrants this research. 
Clinical variation 
A wide variety of clinical presentations can be encountered in the Hu~syndrome as illustrated 
in chapter 4. As yet it is unknown why only certain arcas of the CNS are involved and 
others spared. It may be that the Hu antigen, although expressed by all neurons, only plays a 
functional role in the dorsal root ganglion and limbic area. Also differences in fine specifici~ 
ty or affinity to the Htl antigen of anti-Hu antibodies in individual patients may playa role 
in variability of clinical symptoms. There are no data on differences in affinity of anti-Hu 
JgG. The finding that anti-Hu sera obtained from patients with PEMlPSN, but with different 
neurological symptoms, react with all Hu antigens (HuD, HuC, Hel-NI) indicates that none 
of these proteins in particular can be causative of specific neurological symptoms. Also 
differences in IgG subclasses of anti-Hu antibodies have been shown not to play crucial role 
in determining differences in clinical course of PEMlPSN. 
Diagnosis 
PNS are found in patients with occult or active cancer or with cancer in remission after 
treatment. As in most PNS patients, the cancer is subclinical and undetected at presentation. 
In patients with undiagnosed cancer the diagnosis can easily be made when neurological 
symptoms present as one of the classical paraneoplastic syndromes. Still other possible 
neurological discases should be excluded. A CT or MRI scan to exclude metastasis and CSF 
examination should be carried out. Rigorous evaluation for systemic cancer, especially when 
one of the anti-neuronal antibodies is found in serum or CSF. is necessary. These antibodies 
can direct the search for the underlying tumor. 
In general several clinical features suggest a paraneoplastic origin of the neurological 
symptoms: 
1. The onset of disease is usually subacute with development of signs in days to some 
weeks and occa'sionally months after which stabilization follows. Acute onset with a 
relapsing-remitting course is less likely to be paraneoplastic. 
2. Most PNS cause severe neurological disability. Recently a more indolent, slowly 
progressive type of PNS has been described. 
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3. CSF examination reveals mostly mild lymphocytic pleocytosis, elevated protein 
concentration and oligoclonaI bands. 
4. Imaging procedures, like MRI and CT scan of the brain, usuaIJy reveal no abnor-
mality. In peD some cerebellar atrophy may be encountered. 
5. Usually at the onset of the disease one area of the eNS is mainly affected, resulting 
in a typical clinical presentation. 
As indicated throughout this study, detection of the various antibodies is of great help in 
making the diagnosis of PNS with a specificity of almost 100% and both prompts and 
directs the search for an underlying tumor. Specific actions that are recommended to he 
taken when a distinct antibody is found are summarized in table 2. 
Table 2 Anti-neuronal antibodies and guidelines for tumor detection 
Syndrome 
PEM/PSN 
Cerebellar 
Opsoclonus myoclonus 
Visual loss 
Stiff-man 
Molar neuron disease 
Test for 
Anti-Hu 
Anti-Yo 
Anti-I-Iu 
Anti-Ri 
Anti-CAR 
Anti-128kD 
No tests available 
Diagnostic value of antibodies 
Action if positive 
Look for SCLC: chest X-ray, CT scan, frequent 
follow-up 
Look for gynaecological malignancy: abdomi-
nal echogram, laparoscopy, mammogram, 
adnex extirpation, frequent follow-up 
Look for SCLC 
Look for breast cancer: mammography. Ifnega-
tive look for SCLC 
Look for SCLC 
Look for breast cancer If negative look for 
anti-GAD 
Look for lymphoma or paraproteinemia 
Although many studies have established that anti-neuronal antibodies are highly specific for 
PNS and associated tumors, hardly any systematic study has been performed reporting the 
actual diagnostic value of these antibodies. One major problem (see chapter 1 or 2) in such a 
study is the gold standard to make a definite diagnosis of PNS in calculating the sensitivity 
and specificity for ,the diagnosis of PNS. In order to overcome this problem one can use a set 
of clinical definitions to provide reliable diagnostic criteria. Consequently one will find 
different values in different studies when different criteria arc used or criteria are differently 
interpreted. It is therefore important to try to standardize methods of detection in order to 
make studies from different laboratories comparable. Also the population under study will 
influence the outcome of diagnostic sensitivity. The more rigourous the criteria used for 
making a clinical diagnosis of PNS in such a study, the higher sensitivity of antibody 
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detection will be. However, it seems feasable that even when it would be possible to perform 
such a study using the gold standard of post mortem confirmation of the diagnosis of PNS, 
sensitivity would still be relatively low. Probably not all anti-neuronal antibodies can be 
identified yet, using currently available and applied methods (see also chapters 5, 6 and 7). 
Also it is very well possible that not all PNS are associated with the presence of anti-
neuronal antibodies. 
The criteria for the detection of paraneoplastic anti-neuronal antibodies as diagnostic tool 
and the technical methods for laboratory assay are described in chapter 8. These criteria are 
the result of a consensus meeting held in 1994 in Rotterdam, from 11 international research 
groups which discussed the terminology, methodology and proper interpretation of 
paraneoplastic anti-neuronal antibodies. 
Novel PNS antibodies 
In spite of the specific association between anti-Hu antibodies, PEMlPSN and SCLC, 38-
50% of patients whith a clinical picture of PEMfPSN do not harbour anti-Hu antibodies. 
Some studies, mostly case-reports, indicate that other as yet not characterized anti-neuronal 
antibodies can be found in some of the anti-Hu negative PEMlPSN patients. Others have not 
been able to detect other antibody reactivities in patients with PEM and SCLC. The different 
findings in these studies may be explained by the low frequency of antibodies against novel 
antigens, the heterogeneity of patients and the techniques used to detect the antibodies. It is 
probable that not all antigens can be detected by routine IIF or \Vestern blot assays. Methods 
of fixation can largely influence the conformation of the antigens and thus interfere with 
antibody detection. It is therefore important to try to identify novel anti-neuronal antibody 
reactivities in PNS and to establish a correlation with the neurological and oncological 
symptoms. 
In chapters 5, 6 and 7 several novel anti-neuronal antibodies are described in relation to the 
neurological symptoms and the underlying tumor. Although the exact diagnostic value of 
some of these antibodies is not precisely known, as indicated in chapter 5, we think that the 
discovery of these novel antibodies and their antigens will help to identify new subgroups of 
PNS, and thus help to clarify the clinical pictures of patients with a yet undefined type of 
PNS. 
In chapter 6 we report four patients with PEM and SCLC in whom a novel anti-neuronal 
antibody against a 60-64kD neuronal antigen complex was detected by IIF and Western blot. 
In chapter 7 the anti-neuronal antibodies found in some patients with PCD and Hodgkin's 
disease (HD) are reported. The antibody, designated anti-Tr, found in five patients with 
HD-associated PCD, bound with the cytoplasm of Purkinje cells of human and rat cerebel-
lum. The molecular layer of rat cerebellum showed a characteristic dotted pattern suggestive 
of reactivity with dendritic spines of Purkinje cells. This dotted pattern was not produced by 
anti-Yo, or five different anti-Purkinje cell antibodies from patients with neurologic 
disorders other than HD-associated PCD. They are sufficiently characterized to allow 
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appropriate identification in different laboratories and discriminate the anti-Tr from the anti-
Yo reactivity. In this chapter we conclude that anti-Tr antibodies, as defined in this study. 
appear to be specific for HD-associated reD. Until the Tr antigen(s) are cloned, which will 
allow the unambiguous identification of these antibodies, the IIF pattern in rat cerebellum in 
combination with the absence of reactivity in the immullobiot assay may be used to identify 
anti-Tr antibodies. 
Treatment 
In general, treatment of PNS has been unrewarding and most patients suffer from severe 
neurological disability. Most therapies tried forms of immune-modulation, like plasmaphere-
sis, corticosteroids or intravenous immune-globulin, and were evaluated in the antihody-
associated syndromes. \Vith the exception of LEMS, in which plasmapheresis is clearly 
effective, and the paraneoplastic opsoclonus-myoclonus syndrome in children, in which 
removal of the tumor may be of benefit, results have been disappointing. One valid 
explanation for the failure of therapy is that rapid onset of disease has resulted in irreversible 
destruction of neurons at the time therapy is started. In most cases the interval between onset 
of neurological symptoms to the definite diagnosis of PNS and start of therapy is more than 
one month up until several years. However, when considering a therapeutic strategy, we 
have to bear in mind that the model of inunune-mediated pathogenesis of the PNS has not 
been proven. The hypothesis that the antibodies are only an epiphenomenon of a different 
non-immune pathogenic mechanism leading to neuronal damage may be another explanation 
why immune-modulatory therapies are not effective in PNS. 
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Summary 
Patients with cancer develop neurological symptoms in the course of their disease in morc 
than 40% of cases. The neurological symptoms may be caused by either metastatic spread of 
the tumor, by metabolic complications, by direct or indirect side-effects of anti-tumor 
therapy or by a paraneoplastic mechanism. The paraneoplastic syndromes of the nervous 
system (PNS) are those syndromes that are associated with cancer, but not caused by direct 
invasion of tumor cells in the nervous system and not caused by cancer therapy. Defined in 
this way, PNS occur in less than I % of patients with cancer. The PNS consists of a number 
of characteristic clinical syndromes that can involve the peripheral or central nervous system. 
The PNS of the central nervous system form a separate group of syndromes that can 
clinically be divided in encephalomyelitis, sensory neuronopathy, subacute cerebellar 
degeneration, opsoclonus myoclonus syndrome, visual degeneration and stiff-man syndrome. 
These syndromes are all considered to be induced by an immune-mediated mechanism. The 
central hypothesis rests on the assumption that a neuronal antigen is expressed by the tumor 
which is usually of neum-ectodermal origin. The antigen is expressed in such way that 
imm.une tolerance for the antigen is broken and a fulminant humoral andlor cellular· immune 
response is induced against this tumor and particularly against the neuronal antigen. This 
misdirection of the immune reaction against the antigen in the nervous system then causes 
the neuronal damage and thus clinical symptoms. Following this hypothesis, each syndrome 
would be associated with a specific immune reaction, which can be demonstrated by the 
presence of a specific anti-neuronal autoantibody. 
Another characteristic feature <'f these syndromes is that in more than two-third of cases the 
neurological symptoms precede the detection of the tumor. 
Thus detection and characterization of specific anti-neuronal antibodies is important, since 
they can be used as diagnostic markers for the presence of a paraneoplastic syndrome. The 
specificity of the presence of these antibodies approaches 100% indicating that a reliable 
diagnosis of PNS can be made including the presence of a tumor. On the other hand, a 
negative assay does not rule out that the neurological symptoms have a paraneoplastic origin. 
It is therefore of major importance that these antibodies can be detected and identified in a 
reliable way in order to justify an extensive and sometimes invasive search for the underly-
ing tumor. 
In patients with PNS, the antibodies, or better the humoral and cellular immune response, 
seem to control the underlying tumor as compared to patients with similar tumors without 
these antibodies. In this way the autoimmune response may benefit the patient through 
impairment of the tumor growth. However, recent studies indicate that the overall survival of 
patients with PNS and cancer equals the survival of patients with a similar cancer but 
without PNS, primarily because PNS patients frequently die of the neurological complica-
tion. 
The major focus of this study concerned the detection of the different anti-neuronal antibod-
ies including the comparison and reliability of teclmiques, the diagnostic value of the 
antibodies, and the description of some newly discovered anti-neuronal antibodies. 
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In chapter 1 a detailed overview is given of different PNS, with a focus on the immune~ 
diagnosis of these syndromes. 
Chaptcr 2 reports on a study, in which the diagnostic value of the presence of two of these 
antibodies (anti~Hu and anti~Yo) is determined, using the indirect immunofluorescence assay 
only. Chapter 3 shows that PNS patients harbour not only anti~neuronal antibodies but in a 
large percentage other organ~ and non-organ specific autoantibodies. This may indicate that 
patients with PNS have a genetic predisposition to develop autoimmune phenomena. This 
predisposition, together with the presence of a tumor may be a prerequisite to develop PNS. 
A series of 29 patients with the most frequently appearing PNS, the encephalomyeli-
tis/sensory neuronopathy, is described in chaptcr 4. The wide variety in clinical presentation 
is described in relation to the different IgG subclasses of anti-Hu antibodies. 
In chapters 5, 6 and 7 several novel anti-neuronal antibodies are described in relation to 
neurological syndromes and underlying tumor. Although the true diagnostic value of some 
of these antibodies is not precisely known, we think that the discovery of these novel 
antibodies and their associated antigens will help to identify new subgroups of PNS and thus 
clarify some clinical pictures of PNS. 
Since the presence of systemic autoantibodies interferes with a reliable identification of anti-
neuronal specific antibodies in an indirect immunofluorescence assay, the finding of 
systemic autoantibodies in more than 50% of PNS patients has pointed out that the indirect 
immunofluorescence assay alone is not a reliable method of detection of these antibodies. 
Chapter 8 extensively describes the criteria for the detection of anti-neuronal antibodies as a 
diagnostic tool for the neurologist and gives the basic technical rules for the laboratory 
assay. This chapter is the result of an international consensus meeting held in 1994 in Rotter-
dam, with 11 research groups that discussed the terminology, methodology and interpretation 
of paraneoplastic anti-neuronal antibodies. 
Another important aspect of the PNS is found in the nature of the antigen. Although this 
study does not focus on this aspect, the analysis of involved antigens has thus far shown that 
they may play key roles in cell-regulatory processes of neurons and in pathogenesis of 
tumors. The gene coding for the Hu antigen has been shown to be closely related to other 
onco-genes as c-myc and c-fos and is now called an onco-neural gene. These findings led to 
speCUlations that PNS antigens and antibodies may be used in the future for immune-
imaging of malignancies and even for adaptive inllnuno~therapy. When applied in this way, 
the finding of specific antibodies and antigens in very rare, severe and often untreatable 
diseases, provides a unique model for cancer, and warrants further research. 
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Samenvatting 
Meer dan 40% van de patienten met kanker ontwikkclen neurologische symptomen in de loop 
van hun ziektc. Deze neurologische symptomen kunnen zowel worden veroorzaakt door tumof-
metastasen, metabole complicaties, directe of indirecte bijwerkingen van de anti-tumor therapie. 
als door cen parancoplastisch mechanisme. Paraneoplastische syndromen van het ZCllllwstelscl 
zijn syndromen die zijn geassocieerd met kanker, maar niet worden veroorzaakt door invasic van 
tumorcellen in het zcnuwstelse! of door tUlllortherapie. 
Op deze manier gedefinieerde syndromen worden in minder dan I % van aile kankerpatienten 
gezien. Paraneoplastische syndromen vormen een groep karakteristieke klinische syndromen, 
waarbij zowcl het perifere als het centrale zenuwstelsel betrokken kan zijn. 
De paralleoplastische syndromen van het centraal zenuwstelsel vormen een aparte groep die 
klinisch kan worden onderverdeeld in encephalomyelitis, scnsorische neurollopathie, subacute 
cerebellaire degeneratie, OpSOclOIlUS myoclonus syndroom, retina degeneratie en hct "stiff-man" 
syndroom. De hypothese is dat al deze syndroll1cn een immuungemedieerde pathogenese hebben. 
De basis voor deze hypothese wordt gevormd door de bcvinding dat de tumor, meestal een 
cctodermale tumor, een neuronaal antigen tot expressie brengt, zodanig dat de immuuntolerantie 
voor dit antigen wordt doorbroken en een fulminante humorale en/of cellulaire afweerreactie 
wordt opgewekt tegen de tumor en in het bijzonder tegen het neuronale antigecn. Deze primair 
tegen de tumor gcrichte afweerreactie kruisreageert met het zenllwstclsel, waardoor neuronale 
schade met klinische verschijnselen ontstaat. \blgens deze hypothese is elk paraneoplastisch 
syndroom geassocieerd met een spccifieke immuunreaktie, die kan worden aangetoond door de 
aanwezigheid van karakteristieke anti-neuron ale antilichamen. 
Een ander kellmerk van deze syndromen is, dat in mecr dan twecderde van de gevallen de 
neurologische symptomen voorafgaan aan de ontdekking van de tumor. Het is om die reden zo 
belallgrijk de specifieke anti-neuronale antilichamen op te sporen en te karakteriseren aangezien 
ze kunnen dicnen als diagnostische merker voor een paraneopiastisch syndroom en voor de 
aanwezigheid van een bepaald type tumor. De specificiteit van deze antilichamen is bijna 100%. 
Aan de andere kant sluit de afwezigheid van deze antilichamen een parancoplastisch syndroom 
niet uit. Het is van groot belang dat deze antilichamen betrouwbaar kunnen worden 
ge'ldentificeerd, alvorens een uitgebreid en soms invasief onderzoek naar de aanwezigheid van 
een bepaalde tumor kan worden gedaan. 
Vit vergelijking van patienten met identieke tumoren, met en zonder anti-ncllronale antilicha-
men, lijkt de immuunrespons een groeiremmend effect te hebbell op de tumor. Als zodanig zou 
vanuit oncologisch gezichtsveld deze auto-immuunreactie voor dc patient gunstig kunnen zijn. 
Recent ondcrzoek daarcntegen laat zien dat de overleving van kankerpatienten met of zonder 
paraneoplastisch syndroom niet verschilt, voornamelijk omdat patientcn met een 
paraneoplastisch syndroom doorgaans overlijdcn aan de neurologische complicaties. 
Het in dit proefschrift beschreven onderzoek spit.st zich toe op het aantonen van verschillende 
antilichamen, de hiervoor gebruikte technieken, de betrouwbaarheid van deze technieken en de 
voorspellende waarde van de aanwezigheid van deze antilichamen. \borts worden enkele nieuw 
ontdekte anti-neuronale antilichamen beschreven. 
In hoofdstuk I wordt een gedetailleerd overzicht gegeven van dc verschillende paraneoplastische 
syndromen, gericht op de immunodiagnose. Hoofdstuk 2 bcschrijft een van de eerste studies, 
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waarin de diagnostische waarde van twee anti~neuronale antilichamen (anti~Hu en anti~Yo) 
wordt aantgctoond. In hoofdstuk 3 wordt beschreven dat paticntcn met een paraneoplastisch 
syndroom niet aileen anti~ncuronalc antilichamen maken, maar dat zij in een haag percentage 
tevens andere allto-antilichamen hebben die niet gericht zijn tegen neuronale antigenen. Dit kan 
betekenen dat patienten met een paraneoplastisch syndroom een genetische predispasitie hebben 
voor het krijgen van allta-immuunziekten. Misschien is deze predispositie een voorwaarde voor 
het ontwikkelen van een paraneoplastisch syndroam bij aanwezigheid van een tumar. 
In haofdstllk 4 worden 29 patienten beschreven met de meest bekende verschijningsvarm van 
de paraneoplastische syndromen, te weten de encephalomyelitis/sensorische nellronopathie. 
Onderzocht werd of de gevarieerde klinische presentatie van dit syndroom kon worden 
gecorreleerd met de verschillende IgG subklassen van de met encephalitis geassocieerde anti~HlI 
antilichamen. 
In de hoofdstukken 5, 6 en 7 worden enkele nieuwe anti-l1curonale antilichamen beschreven in 
relatie tot de klinisch neuralogische symptomcl1 en de anderliggende tumor. De diagnastische 
waarde van sommige van deze antilichamen is niet precies bekend. Echter, de verdere 
karakterisatie van deze nieuwe antilichamen en het antigeen waartegen zij gericht zijn, zal 
waarschijnlijk bijdragen tot de 'identificatie van enkele nieuwe subgroepen paraneoplastische 
syndromen. Op deze manier kall beter inzicht worden gekregen in het klinisch bceld van 
patienten met een paraneoplastisch syndrool11 dat zich niet als een van de bekende, 
karakteristieke paraneoplastische syndromen presenteert. 
Daar de aanwezigheid van andere auta-antilichamen interfereert met een betrouwbare bepaling, 
heeft het vinden van niet~neuronale auto-antiliehamen in meer dan 50% van de paraneoplastische 
syndroom patienten, dllidelijk gemaakt dat het gebruik van aileen indirecte immunoftllorescentie 
technieken niet altijd even betrauwbaar is voor het aantonen van anti~neuronale antilichamen. In 
hoafdstllk 8 worden uitgebreid de criteria beschreven waaraan het aantanen van anti~neuronale 
antilichamen als diagnostische test voor de l1ellrolagisch specialist dient te voldoen. Tevens 
worden de technische details van de laboratoriumbepalingen nader toegelicht. Hoofdstuk 8 is het 
resultaat van de consensus bijeenkomst gehollden in 1994 te Rotterdam, waar 11 internatiollale 
onderzoeksgrocpen discussieerdell over de terminologie, methodolagie en interpretatie van anti-
neuronale antilichamen bij paraneoplastische syndromel1. 
Een ander belangrijk aspect van paraneopiastische sYl1dromen vormt de aard van het antigecn 
waartegen de antilichamen gericht zijn. Hoewel dit proefschrift zich hierop niet specifiek ricin, 
is het vermeldenswaard dat analyse van de hetrokken antigenen heeft aangetoond dat deze 
antigenen een sleutelrol spelen in de ceireglilatie van neuronen en van tumorceilen. Met name 
het Hu antigeen blijkt nallw verwant te zijn aan oncogenen als c-myc en c~fos en wordt derhalve 
oak weI een onconeuro gen genoemd. Deze bevindingen hebben tat de speculatieve verwachting 
geleid dat paraneoplastische antigenen en de daartegen gerichte antilichamen in de toekomst 
gebruikt kunnell worden voor "immuno-imagingll van maligniteiten cn misschien zelfs cen ral 
kunnen vervullen in immunotherapie. Dc aanwezigheid van specifieke antilichamen en hun 
antigenen bij zeldzame, vaak onbehandelbare aandoeningen, vonnt een uniek model voor 
toekomstig kanker onderzoek. Onderzoek hiemaar is dus zeer de moeite waard. 
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List of Abbreviations 
ADCC 
ANA 
ANF 
ANNA 
ANSA 
AP 
APCA 
BSA 
CAR 
CDR 
CNS 
CSF 
CT 
DNA 
EEG 
EMG 
ENA 
FITC 
GABA 
GAD 
HD 
Hep 
HRP 
Hu 
IIF 
Ig 
kD 
LEMS 
Nd 
OMS 
PBS 
PCA 
peab 
PCD 
PEM 
PNS 
PSN 
Ri 
RNA 
RNP 
SCLC 
SDS 
SLE 
St 
Tr 
VGCC 
WBC/IIL 
Yo 
antibody dependent cell~mediated cytotoxicity 
anti-nuclear antibody 
anti-nuclear factor 
anti-neuronal nuclear antibody 
anti-neuronal specific antibody 
alkaline phosphatase 
anti-Purkinjc cell antibodies 
bovine serum albumin 
cancer associated retinopathy 
cerebellar degeneration related 
central nervous system 
cerebrospinal fluid 
computerized tomography 
deoxyribonucleic acid 
electroencephalogram 
electromyogram 
extractable nuclear antigen 
fluorescein isothiocyanate 
gamma-aminobutaric acid 
glutamic acid decarboxylase 
Hodgkin's disease 
human epithelial pharyngeoma 
horseraddish peroxidase 
antigen called after the first patient's initials 
indirect immunofluoresence 
immunoglobulin 
kilo dalton 
Lambert-Eaton myasthenic syndrome 
antigen called after the first patient's initials 
opsoclonus myoclonus syndrome 
phosphate buffered saline 
Purkinje cell antibody 
Purkinje cell antibody 
paraneoplastic cerebellar degeneration 
paraneoplastic encephalomyelitis 
paraneopiastic syndromes 
paraneoplasticsensory neuronopathy 
antigen called after the first patient's initials 
ribonucleic acid 
ribonuclear protein 
small cell lung cancer 
sodiumdodecylsulfatc 
systemic lupus erythematosus 
antigen called after the first patient's initials 
antigen called after name of author who first reported the antibody 
voltage-gated calcium channel 
white blood cell count per microliter 
antigen called after the first patient's initials 
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Figures 
Chapter 2 Figure 1 
Indirect immunofluorescence (dilution 1: 1 00) of nuclei of granular and Purkinje cells with 
sparing of nuclei (100 xl. 
Chapter 2 Figure 2 
Indirect immunofluorescence (dilution 1: 1 00) of nuclei of granular and Purkinje cells with 
sparing of nuclei (400 xl. 
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80 
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Western immunoblot showing reactivity against rat cerebellar and liver protein extracts. Clearly visible is the 
60-64 kD neuronal reactive protein complex in cerebellar extracts (lanes 2,3,4 and 7 incubated with serum of 
patient no. 1 to 4) not seen in liver extracts. Also visible is the 52 kD reactive band in lanes 2,3 and 4 in both 
cerebellar and liver extracts indicating the presence of a systemic auto-antibody (ANA). Lane 1 shows 
reactivity of normal healthy control serum. Lanes 5 and 6 are incubated with serum of patients with SCLC 
without neurological complications. Lanes marked C show reactivity of several sera known to have antibodies 
against neuronal and liver proteins and is used as control to indicate relative molecular weights (numbers in 
centre of figure), 
Chapter 5 Figure 2a Chapter 5 Figure 2b 
Chapter 5 Figure 2c Chapter 5 Figure 2d 
Chapter 5 Figure 2 
Figure 2a and 2b: Indirect immunofluorescence with anti-S1 reactivity (patient 4, 1 :500 dilution, 400 x 
magnification) showing cytoplasmic staining of Purkinje and granular layer cells compared to coarse 
granular staining of Purkinje cells as seen in figure 2b (anti-Yo positive patient, 1:500,400 x magnifica-
tion). 
Figure 2c: The anti-St reactivity seen on human dorsal root ganglion cells showing clear speckled cyto-
plasmic staining (patient 4, 1 :500 dilution, 400 x magnification). 
Figure 2d: Cytoplasmic staining of a smal cell lung carcinoma cell line with the anti-St anti-serum of 
patient 4 (1 :100 dilution, 100 x magnification). 
Chapter 6 Figure I a 
Western immunoblot of rat cerebellar and liver protein extracts incubated with serum of Donnal healthy 
controls (lane 1,2 and 3), serum of patient 4 (lane 4) and selllm of a patient with SCLC without neurolo-
gical symptoms (lane 5). Lane 6 and lane marked C are incubated with anti-Hu positive serum. Lane 7 is 
incubated with selllm of a patient with sensory neuropathy without cancer. Clearly visible is the 60-64 kD 
protein complex not seen in liver protein extract or with control sera. Lane I shows reactivity against a 
liver protein not seen in neuronal extract with serum of nOlTI1al healty control. 
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Chapter 6 Figure 1 a 
Chapter 6 Figure 2a 
Western immunoblot of rat cerebellar and liver protein extracts showing a clear 55 kD reactive band in lane 
4 incubated with serum of patient 6. This serum also showed reactivity against a 80 kD mitochondrial 
protein also seen in liver. Lane 3 incubated with anti-Hu positive scrum. Lanes marked C are incubated 
with sera harbouring various anti-neuronal an liver antibodies and are used as marker to indicate relative 
molecular weights (numbers in center of text). 
Chapter 6 Figure 3a 
Western irnmunoblot of rat cerebellar and liver protein extracts showing reactivity against a 40-200 kD 
neuronal antigen when incubated with serum of patient 13. Lane 1 incubated with serum of normal healthy 
control. Lane 2 incubated with serum of anti-Hu positive patient. Lanes 4-8 incubated with different sera 
from control groups. Lanes marked C (all rat cerebellar extract) are incubated with several sera harbouring 
various anti-neuronal antibodies used as marker to indicate relative molecular weights (numbers in center 
offigure). 
Chapter 6 Figure 4a 
Westem immunoblot of rat cerebellar and muscle protein extract. Lanes I to 6 all show anti-37 leD anti-
neuronal reactivity not seen in control sera (lane 7) and only in 2 sera on muscle extract showing clearly 
weaker reactivity. Reactivity was not seen on liver extracts. Lanes marked C (all rat cerebellar extracts) are 
incubated with sera harbouring various anti-neuronal antibodies and used as marker to indicate relative 
molecular weights (numbers in center of figure). 
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Chapter 6 Figure Sa 
Chapter 6 Figure Sa 
Western immunoblot of rat cerebellar and muscle protein extracts. Lanes 3 and 5 show anti-2IO kD anti-
neuronal specific reactivity not seen in control seral (lane 1,2 and 4). Lanes marked C (all rat cerebellar 
extracts) are incubated with several sera harbouring various anti-neuronal antibodies used as marker for 
relative molecular weights (numbers in center of figure). 
Chapter 6 Figure 1 b 
Indirect immunofluorescence on frozen rat cerebellar section (Sum) with anti-60-64 kD reactivity (patient 4, 
1 :500 dilution, 400 x magnification) showing ditTuse cytoplasmic staining of both Purkinje and granular 
layer cells. 
Chapter 6 Figure 2b 
Indirect immunofluorescence on frozen rat cerebellar section (5 urn) with anti-55 kD reactivity (patient 5, 
1,500 dilution, 400 x magnification) showing clear speckled nuclear staining of virtually all neurons. 
Chapter 6 Figure 3b 
Indirect immunot1uorescence on frozen rat cerebellar section (Sum) with anti-40-200 kD reactivity (patient 
12, 1 :500 dilution, 400 x magnification) showing diffuse homogeneous staining of cerebellum. 
Chapter 6 Figure 4b 
Indirect immunofluorescence on frozen rat cerebellar section (Sum) with anti-37 kD reactivity (patient 20, 
I :500 dilution, 400 x magnification) showing bright nuclear staining of neurons not seen on systemic tissue. 
Chapter 6 Figure 5b 
Indirect immunot1uorescence on frozen rat cerebellar section (Sum) with anti-210 kD reactivity (patient 61, 
1:500 dilution, 400 x magnification) showing filamentous staining of astrocytes in molecular layer. 
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Chapter 7 Figure 1 
Anti-Tr (A), Anti-GAD (B), and anti-Yo (C) innnunoreactivity in rat cerebellum. Both anti-Tr 
and anti-Yo antibodies irnrnunoreact with the cytoplasm of Purkinje cells. Anti-Tr antibodies 
show a dotted staining in the molecular layer suggestive of immunoreactivity of dendritic spines 
of the Purkinje cells. Compare the dot pattern with that of anti-GAD antibodies (B) that label 
GABA-ergic nerve terminals. Basket and stellate neurons are anti-Tr negative but anti-Yo 
positive. A and B slightly counterstained with hematoxylin. Bar = 10 ~m for panels A and B; 
bar ~ 15 flm for panel C. 
Chapter 7 Figure la Chapter 7 Figure 1 c 
Chapter 7 Figure 1 b 
Chapter 7 Figures 2 and 3 
Anti~ Tr immunoreactivity in vibratome sections of rat cerebellum incubated with biotinyla-
ted anti-Tr IgG. Strong anti-Tr immunoreactivity is observed in Purkinjc cells. The 
molecular layer shows the fine dotted pattern (2B). Neurons of the dentate nucleus are only 
weakly positive (3A). Anti-Tf immunoreactivity in vibratome sections of the rat entorhinal 
cortex (2A) and hippocampus (3B). Anti-Tr positive cells are present in layer II and 
scattered in the inner layers. Isolated Tr-immunoreactive non-pyramidal neurons are located 
in the stratum oriens, stratum pyramidale and stratum radiutum. 
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